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Abstract
Ovarian cancer is the most common cause of death from gynecological malignancies in
women in the UK and China. This is related to its late presentation that results in an
extremely poor prognosis. Previous studies have demonstrated that disruption of
multiple genetic loci is associated with carcinogenesis. Loss of heterozygosity (LOH) on
a chromosome can suggest the presence of a tumour suppressor gene (TSG) at that
locus. LOH at chromosome 1 lq between D11 SI894 and D1 IS 1309 occurs frequently in
ovarian and colorectal cancer and is associated with progression and poor prognosis in
ovarian cancer. Therefore, there may be important TSGs involved in the progression of
ovarian cancer on this region. The Barx2 gene, a homeobox transcription factor, is
located within this minimal region and expressed at the site of epithelio-mesenchymal in
developing mouse. It has also been identified as a regulator of cell-adhesion molecules
(CAMs). Therefore, Barx2 is worthy of consideration as a candidate tumour suppressor
gene.
Previous LOH studies have demonstrated that LOH at chromosome 11 q between
D11S1894 and D11S1309 occurs frequently in ovarian and colorectal cancer (using
same polymorphic markers and got same results in ovarian and colorectal cancer in our
lab). Because there was shortage of ovarian tumour/blood pairs samples in that time, in
order to further refine the TSG region at chromosome 1 lq between D11S1894 and
D11S1390 (4.5Mb) and also confirm location of Barx2, 14 polymorphic loci were
investigated using microsatellite analysis in colorectal cancer tumour/blood pairs. Of 39
colorectal cancer specimens, 28(71.18%) demonstrated LOH at one or more marker, 10
(25.6%) demonstrated LOH at all marker and 18 (46.2%) had partial LOH. Three
distinct LOH regions were detected, between GATA72A01 and D11S4131 (less
200Kb), between D11S912 and D11S4150 (less 200Kb), and between D11S1320 and
D11S4085 (2Mb), suggesting possible sites for TSG. There was no correlation with
clinicopathological features. This LOH data not only confirmed the previous studies but
also narrowed further this minimum region from 4.5Mb to less 200Kb and 2 Mb. This
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study has therefore more precisely defined the regions of chromosome 1 lq likely to
contain TSG.
The Barx2 gene is located within this minimal region. In this study, we present evidence
from in vitro expression studies that, following transfection, human Barx2 inhibits
matrigel invasion in the ovarian cancer cell lines OAW42 and OVCAR3. OAW42, a
Barx2 non-expressing cell line, following transfection, was also inhibited for migration
in response to a collagen IV signal and adhesion to collagen IV. In two sequential cell
line series derived from patients with ovarian cancer pre- and post-platinum
chemotherapy, the Barx2 gene was downregulated following treatment. Transfection of
the Barx2 gene into a platinum resistant cell line, PEOl cDDP that is derived from
PEOl by in-vitro cisplatin exposure and has downregulated expression of Barx2,
showed that Barx2 reversed cisplatin resistance. We also show that Barx2 expression
levels are lower in clear cell/endometrioid ovarian adenocarcinoma histological variants
that are less likely to respond to cisplatin. But we were unable to detect evidence of
somatic methylation or inactivating mutations in the coding region of Barx2 gene in
ovarian cancer. Our data suggested that the Barx2 gene is a candidate suppressor of
tumour progression, and a modulator of cisplatin resistance in ovarian cancer.
Furthermore, this represents the first report of Barx2 gene expression associated with
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1.1 Epithelial Ovarian Cancer :Causation and Distribution
Ovarian cancer is the most lethal of gynaecological malignancies, and the seventh
most common cancer in women worldwide, after breast, cervix, colon/rectum,
stomach, corpus uteri, and lung cancers. Each year, an estimated 5,000 women in the
UK. are diagnosed with ovarian cancer. During any given year, approximately 4,200
cases in the UK die from this disease. In the UK, it is the fifth commonest cause of
cancer death in women (Chang J, et al. 1994.). Approximately 1 woman in 70 will
develop ovarian cancer, and 1 women in 100 will die from it. In China, the mortality
rate of ovarian cancer was 0.67/100,000 per year during 1990's. Compared with
1970's, it has increased nearly five folds and is the sixth commonest cause of cancer
death in Chinese women (Lee ND, et al. 1997). This high mortality rate is due to
presentation at an advanced stage of the disease as symptoms of the disease are
insidious in onset and non-specific in nature. Over 75% of women with the ovarian
cancer have tumour spread beyond the pelvis at the time of diagnosis and this is the
reason why the overall five-year survival rate is very poor alive; only about 25% to
30%.
The incidence rate of ovarian cancer is age-related, it is uncommon in women younger
than the age of 40 years, after which incidence rates increase sharply until the eighth
decade of life, then decrease slightly. The age-specific incidence rates increase from 2
to 3 cases per 100,000 in the third decade to 59 cases per 100,000 in the eighth
decade (Adami HO, et al. 1994). There is a difference in incidence rates of ovarian
cancer in different geographical areas. There is a particularly high incidence in
Scandinavia, followed by Northern Europe and North America. Despite being
industrialised, Japan has a particularly low incidence of the ovarian cancer; however,
the incidence increases sharply in Japanese migrants to America and in their
daughters, suggesting profound environmental components to aetiology (Herrinton LJ
et al.l 994). However, there has been little change in the incidence rate of ovarian
cancer during the last three decades. In high-risk countries such as the United States,
there is only a slight increase especially in the older age groups. A trend of increasing
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incidence has been reported in previously low-risk countries (Daly M and Obrams G.
1998). There is also a difference in incidence rates of ovarian cancer in different ethnic
groups. In USA, it is significantly higher among white and Hawaiian women,
intermediate among African-American, Hispanic, and Asian-American women.
Presumably, this reflects differences in distribution of risk factors, From 1986-1990,
the incidence rate among whites was 50% higher than among African-American,
observed in both premenopausal and postmenopausal women (Ries LAG, et
al. 1997). Both white and African-Americans women have a similar age pattern of
incidence, and the known risk factors appear to operate similarly in both groups.
Although analytical epidemiological studies have examined a number of potential risk
factors for ovarian cancer, the causative factors that lead to ovarian cancer are still
unclear. According to many epidemiological investigations, the aetiology of ovarian
cancer mainly includes the following:
1) The continuous uninterrupted cell division and regeneration of ovarian
epithelium with each ovulation provides opportunity for mutation and malignant
transformation. Empirical evidence exists to show the explanation is likely to be
correct.
Multiparity, lactation, and the oral contraceptive (OC) use all decrease a woman's
risk for ovarian cancer. In data combined from 12 United States case-control studies
of epithelial ovarian cancer, the estimated risk of developing ovarian cancer before age
65 for the total population is 0.8%. Among women with no family history of ovarian
cancer, the lifetime risk varies from 0.6% among those with three or more term
pregnancies and 4 or more years of OC use, to 3.4% among nulliparas with no OC
use (Hartge P, et al. 1994). In a large prospective study, parity was the only
reproductive factor that had a substantial independent association with ovarian
cancer; parous women had a 45 % decrease in ovarian cancer risk relative to
nulliparous women, regardless of age at first birth; each birth was associated with a
16% decrease in risk (Hankinson SE, et al. 1995). Other investigation also confirms
this trend. Adami et al noted that each additional birth decreases a woman's ovarian
cancer risk by between 14% and 22% (Adami HO, et al. 1994). But the other case-
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control studies showed those incomplete pregnancies, due either to a spontaneous or
induced abortion, either decreases risk slightly or are not associated with ovarian
cancer risk in either nulliparous or parous women (Chen MT, et al. 1996). Increased
ovarian cancer risk among nulliparas could reflect an association between ovarian
cancer and infertility. The pooled analysis of studies of ovarian cancer has shown an
increase in risk among women who had used fertility drugs with an odds ratio of 4.0
among women with low malignant potential tumours and 2.8 among women with
invasive ovarian cancer, with the highest odds ratio (27.0) for nulliparas with
infertility drug use (Harris R, et al. 1992). In another study, infertile women who had
taken clomiphene for 12 or more ovulatory cycles were at greater risk of ovarian
cancer than infertile women who had taken it for less than 1 year or not at all
(Rossing MA, et al. 1994). There is evidence that women with a history of lactation
had a lower risk of ovarian cancer than who had not breast-fed. Lactation is known to
suppress ovulation in most women. Whittemore et al reported that ovarian cancer
risk decreases almost 1% for each month of lactation. The protective effect is
strongest in the months immediately after delivery, when ovulation is most likely to
be suppressed (Whittemore AS, et al. 1988). Another epidemiological study also
reported that pregnancies with lactation appear to be slightly more protective than
pregnancies without; The average months of lactation per pregnancy was strongly
inversely associated with ovarian cancer risk (Risch HA, et al. 1994).
2) Pituitary gonadotropin stimulation can lead to malignant transformation;
The use of OCs appears to decrease a woman's risk of ovarian cancer by 30% to
60%. In the Oxford Family Planning Association cohort study, the relative risk of
ovarian cancer for OC users was 0.4; in comparison with never users (Vessey MP, et
al. 1995). The results from analysis of the cancer and steroid hormone study
suggested that 5 years of OC use by nulliparous women can reduce their ovarian
cancer risk to that of parous women, and that 10 years of OC use by women with a
positive family history can reduce their risk to a level below that of women with a
negative family history (Gross TP, et al. 1994). With regard the mechanism by which
OCs reduce risk of ovarian cancer, the data suggested that OCs suppress
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gonadotrophins and in turn, the ovary produces less androgens, estrogens, and
progesterone (Daly M and Obrams G. 1998). Furthermore, the high gonadotrophic
milieu of the post-mcnopausal state may confer addition risk (Cramer DW, et at.
1983). But recent findings do not support the hypothesis that gonadotrophin
stimulation is an aetiological factor in ovarian cancer. A case-control study of serum
gonadotrophins and steroid hormones has shown that women with low serum
gonadotrophin levels are at increased risk of ovarian cancer, as are women with high
androgen levels. Specifically, higher androstenedione and dehydroepiandrostenedione
(DHEA) levels are associated with increased risk. The risk of ovarian cancer increases
with increasing levels of these hormones (Helzlsouer KJ, et al. 1995). Some
researchers think that it may be also important to consider that the levels of steroids
in follicular fluid and the ovarian epithelial microenvironment may be more important
in ovarian cancer pathogenesis than are serum hormone levels (Daly M and Obrams
G. 1998).
Although the relationship between exogenous estrogens and development of human
ovarian cancer is still unclear, many studies have suggested that ovarian cancer is
hormone sensitive and that oestrogens, progesterone and their specific intracellular
receptor expression are associated with histopathological subtypes and prognosis of
ovarian cancer. The actions of these hormones are mediated by specific intracellular
receptors that function as hormone-inducible nuclear transcription factors with
context-specific, often conflicting effects on proliferation and differentiation of target
tissues (O'Malley BW, et al. 1990). Investigations of the relationship between the
oestrogens, progesterone and their specific intracellular receptor expression and
human ovarian cancer have shown; (a), Oestradiol induced PR expression has been
demonstrated in ovarian cancer cell lines, which express ER (Langdon SP, et al. 1994).
(b); there is difference in PR expression in different histopathological subtypes of
epithelial ovarian cancer. Endometrioid ovarian carcinoma contains relatively more PR
than other histopathological subtypes (Slotman BJ, et al. 1988), and PR positivity is
associated with well differentiated ovarian cancer in premenopausal women
(Munstedt K, et al, 2000) (c); Ovarian cancer has been reported to respond to
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antioestrogens in about 10%-20% of cases and to progestins with an average of 36%,
within a range between 0% to 60%(Slotman BJ, et al, 1988). (d); Tumour PR content
has prognostic significance in ovarian cancer (Hempling RE, et al. 1990), But the
evidence for association of tumour ER content with prognosis is conflicting (Eissa S,
et al. 1995; Sevelda P, et al. 1990).
3) The ovary is exposed to carcinogens that can travel to the ovary via the vagina and
fallopian tubes.
Case-control and record linkage studies have shown decreased risks of ovarian cancer
after tubal ligation and/or hysterectomy (Kreiger N, et al. 1997). A case-control study
of ovarian cancer in India, that has a high rate of childbearing and early age at first
pregnancy and where tubal ligation is widely practiced, showed that the only
significant factor to influence ovarian cancer risk was tubal ligation, with an odds ratio
of 0.25(Nandakumar A, et al. 1995). Another case-control study showed a significant
odds ratio of 0.5 for ovarian cancer after hysterectomy (Risch HA, et al.1994).
Therefore the hypothesis is consistent with the idea that surgery prevents exogenous
agents from entering the peritoneal cavity and reduces the risk of ovarian cancer.
The use of cosmetic talc in dusting the perineum, in feminine hygiene sprays or on
sanitary napkins, condoms or diaphragms has been suggested as a possible risk factor
for ovarian cancer. In a case-control study, a significant odds ratio of 1.5 was
reported for use of talc, with higher risks in those women who applied it directly to
the body, on a daily basis, or for more than 10 years (Harlow BL, et al. 1992).
Investigations of women undergoing laparoscopy have suggested that the majority of
women have retrograde menstruation (Olive DL and Schwarz LB. 1993). Some data
also indicated that talc may be transported by retrograde menstruation through the
fallopian tubes to the ovary (Wehner AP. 1994). In view of the fact, talc is
contaminated with significant amounts of asbestos; several workers investigated and
reported an increased risk of ovarian cancer in women asbestos workers (Heller DS,
et al. 1996). Furthermore, asbestos fibre can be found in the ovaries of majority of
women with household asbestos exposure, and that fiber burdens were higher in
those with exposure histories (Heeler DS, et al. 1996).
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4) Hereditary factors:
Case-control studies have demonstrated the importance of a family history of ovarian
cancer and a family history of other cancers on the risk for ovarian cancer. The risk of
ovarian cancer and other cancer was assessed in first-degree relatives of patient with
ovarian cancer from an analysis of 391 pedigree. This analysis showed that overall
there was a significant increase in the risk of ovarian cancer (4.5-fold). The risks were
14.2-fold, 5.2-fold and 3.7-fold for relatives of patients diagnosed before 45, between
45 and 55 and after the age of 55, respectively (Houlston RS, et al. 1993). A meta¬
analysis of family history and risk of ovarian cancer has shown that family histories
of ovarian, uterine, breast, and pancreatic cancer were significantly associated with
increased risk of ovarian cancer. The relative risk of ovarian cancer was 4.31 for
women with a first-degree relative with ovarian cancer, 2.12 for women with an
affected second-degree relative, and 1.48 for women with an affected third-degree
relative (Kerber RA and Slattery ML. 1995).
5) Other factor:
Galactose metabolism has been proposed as a risk factor for ovarian cancer based on
data that galactose is toxic to oocytes, but the result of epidemiological investigation
are still conflicting (Cramer DW, et al. 1994;Risch HA, et al. 1994; Hcrrinton LJ, et
al. 1996).
Initial evidence that consumption of animal fat is associated with an increased risk of
ovarian cancer (Cramer DW, et al. 1984) was followed with a large case-control study
into diet and ovarian cancer risk. This study suggested every lOg of ingested
saturated fat per day increased ovarian cancer risk by 20%, whereas the same
ingested weight of vegetable fibre reduced ovarian cancer risk by 37%(Risch HA, et
al, 1994).
In a record-linkage study of women employed in hairdressing, a small increased risk
for ovarian cancer incidence was reported. The increase was significant with a
standardised incidence ratio of 1,88(Boffetta P, et al. 1994). This finding may be of
further interest because hair dyes contain known mutagens.
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1.2 Epithelial Ovarian Cancer: Biology and Pathophysiology
1.2.1 Development ofovarian surface epithelium in embryology
In the embryo, the ovarian surface epithelium originates in the coelomic epithelium
that overlies the gonadal ridge. Therefore, it is of mcosdermal origin, and
developmentally closely related to the underlying stromal fibroblasts. Coelomic
epithelial cells penetrate into the fetal ovary and contribute to the development of
granulos cells. Furthermore, the gonadal ridge lies near the regions where invaginations
of the coelomic epithelium give rise to the mesonephros and the ovarian rete, and to
the Mullerian ducts which are the primordial cells for the epithelia of the Fallopian
tubes, uterus, and endocervix. Thus, the embryonic coelomic epithelium in the
urogenital region is competent to develop along many different pathways. Common
epithelial tumours of the ovary arise from the ovarian surface epithelium, and exhibit
a range of histological structures which have appearances similar to other Mullerian
derived structures; i.e. serous differentiation (similar to fallopian tube epithelium),
endometrioid differentiation (uterine body endometrium), and mucinous
differentiation (endocervical epithelium). Ovarian malignant tumour, usually arise
from the ovarian surface epithelium. There are anatomical reasons why the ovarian
surface epithelium may have an increased tendency to neoplasia. Firstly, the ovarian
surface epithelium, in contrast to the peritoneal mesothelium, is in close proximity to
the paracrine influence of adjacent ovarian tissue and receptors for many of the
hormones and growth factors produced by the ovary in the course of ovum
maturation and release are present in surface epithelial cells but not in adjacent
peritoneal mesothelium. Surface epithelial cells are often found entrapped in the
ovarian cortex and this potentially places the cells under increased mitotic pressure
(Hamilton TC. 1992; Salazar H, et al. 1996). Additionally, it may be significant that
the surface epithelium in contrast to other adult coelomic epithelial derivatives shows
delayed differentiation as manifest by its ability after transformation to differentiate
along several pathways. This retention of pluripotentiality may be accompanied by
greater proliferative capability with reduced induction of apoptotic death pathways
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and therefore perhaps enhanced susceptibility to neoplastic transformation
(Auersperg N, et al. 1998).
1.2.2 pathology
1.2.2.1 Benign tumours
Benign tumours are almost always serous or mucinous, and generally arise in women
between the age of 20 and 60 years (Russel P and farnsworth A. 1997) The tumours
are frequently large, sometimes in 15-30 cm dimension. Benign serous tumours are
more commonly bilateral, but benign mucinous tumour are almost always unilateral.
Benign epithelial tumours are typically cystic, hence the term "cystadenoma" e.g.,
serous or mucinous cystadenoma. The essential cytological features of them are a
single layer of columnar cells, which line the cysts, lack of cellular atypia, a normal
nucleocytoplasmic ratio, few mitoses, and no evidence of either microinvasion or
invasion into the underlying stroma. Papillae, if present, consist of a fibrovascular
core covered by a single layer of mature, tall, columnar epithelium identical to that of
the cyst lining. A prominent fibrous component can be present, giving a grossly solid
or papillary appearance to areas. In serous tumours, the fluid within the cyst is
watery. The serous epithelium is well differentiated, and forms a regular single layer
of cuboidal cells with centrally placed nuclei lying on loose stroma. Whereas in
mucinous tumours, the cysts are multilocular containing a gelatinous mucinous
secretion. The epithelium consists of tall columnar epithelial cells with basal nucle.
1.2.2.2 Borderline tumours (tumours of low malignant potential, LMP)
Tumours of LMP have an excellent prognosis, despite peculiar histologic features
suggestive of cancer (Bamhill DK, et al. 1995). The histologic features used to
diagnose borderline tumours include; (1), epithelial papillae (especially in serous
tumours), with detachment of atypical cell clusters as single or small groups of cells,
(2), cellular stratification (especially in mucinous tumours), (3), increased mitotic
activity, and (4), nuclear atypia (increased nuclear/cytoplasmic ratio,
hyperchromatism, and prominent nucleoli).
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1.2.2.3 Malignant tumours (invasive carcinoma)
Malignant ovarian tumours often present as solid masses, usually with areas of
necrosis and haemorrhage. By the time a carcinoma is found, it has often already
spread beyond the ovary and seeded the peritoneum.
The histological hallmarks of malignant tissue are the same as for borderline tumours,
with cellular atypia, a high nucleocytoplasmic ratio, and frequent mitoses. There is,
however, destructive invasion of the underlying stroma by the malignant
adenocarcinoma cells. As part of histopathological diagnosis, an attempt at estimating
the degree of differentiation of ovarian adenocarinomas should be made (Baak JP, et
al, 1987). Grade 1 tumours have fine, well-developed papillae nearly throughout with
little cellular atypia and relatively few mitoses. Grade 2 tumours disclose areas where
sheets of tissue may form greater cellular atypia and mitoses. Grade 3 tumours
exhibit large sheets of undifferentiated cells. The mitotic rate and number of atypical
mitoses increase progressively in the various grades. Tumours can also entirely lose
their histogenic features leaving an undifferentiated adenocarinoma.
High correlation has been observed between the stage and grade of tumour. Nearly
90% of tumours that extends to the pelvic peritoneum, omentum, or beyond (Stages
II B to IV) are grades 2 and 3. In contrast, 72% of tumours confined to the ovaries or
the surfaces of the reproductive organ (Stages I to IIA) are grade 1. Both stage and
grade were identified as an independent prognostic variable in the multivariate model
(Bichel P, et al. 1989; Shimizu Y, et al. 1998).
Serous adenocarcinoma accounts for just under half of all epithelial ovarian cancers
and usually display obvious invasion. The tumour may appear as large sheets of cells
growing autonomously without stromal support or as broad-to-fine clusters of cells
related to papillae that irregularly dissect through the stroma.
Mucinous adenocarcinoma accounts for only 5-10 % of all epithelial ovarian cancers.
The tumours present as sheets of cells, often in a cribriform pattern, or as tumour
cells dissecting into the stroma. As they become less well differentiated, the cells
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often lose their intracytoplasmic mucinous component, and therefore may be difficult
to distinguish from serous and endometrioid carcinoma.
Endometrioid carcinomas account for a relatively small proportion (15 %). They
resemble adenocarcinomas of the endometrium, and are usually less cystic than
serous and mucinous adenocarcinomas. In a quarter of case endometrioid
adenocarcinomas may co-exist with endometrial carcinoma, and have identical
histology. They can also co-exist with, or arise on, a previous site of endometriosis
(Heaps JM, et al. 1990).
Clear cell carcinomas are uncommon, just about 6% of epithelial ovarian cancers. It is
characterised by both clear and "hobnail" cells. The clear appearance of the
cytoplasm is due to the dissolution of glycogen as the tissue specimen is prepared for
microscopic examination. The hobnailed cells are bulbous nuclei that protrude into
the lumen well beyond the apparent cytoplasmic limits of the cell. The clear-cells are
usually found in sheets of cells that have the appearance of a solid growth. The
hobnailed cells and sometimes flat cells are encountered more commonly in a pattern
of growth characterized by tubules and cysts.
Undifferentiated epithelial ovarian cancers account for about 3 % of the total, and
tend to behave in aggressive fashion (Canzonier V, et al. 1995).
1.3 Epithelial Ovarian Cancer: Clinical Management and
Prevention
1.3.1 Screeningfor ovarian cancer
Available potential screening techniques have included pelvic examination, ultrasound
examination, CA 125 and other tumour markers, and combined modality approaches.
Successful screening should result in a decrease in site-specific morbidity and
mortality of the screened population from a disease.
The detection of an asymptomatic pelvic mass on routine physical examination may
identify an ovarian cancer before abdominal dissemination, but there are no data on
the frequency with which ovarian cancer is detected in asymptomatic women on the
basis of an annual pelvic examination.
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Ultrasound examination has been used widely for screening for ovarian cancer.
However, transabdominal ultrasonography is not sufficiently specific to be useful as
a routine screening procedure. A prospective study showed that the odds that
abnormal transabdominal ultrasonography could identify the presence of primary
ovarian cancer were only one in 67 (Campbell S, et al. 1994). Transvaginal
ultrasonography has been proposed as a more specific alternative to abdominal
sonography as a screening test because of increased resolution capable of detecting
minimal morphologic changes in the ovary (DePriest PD, et al. 1993). On other hand,
coupling colour flow imaging with transvaginal ultrasonographymay may further
improve the accuracy of sonography and reduce the unacceptably high rate of false-
positive results (Karlan BY, et al.1994).
Prospective studies have shown that serum CA-125 levels are sufficiently sensitive
to identify patients with early-stage disease. However, as previously noted, false-
positive test results have been reported in a number of non-malignant gynaecologic
condition, such as peritonitis, pancreatitis, and so on (Olt GJ, et al. 1990). Due to the
high false-positive rate relative to the low incidence of epithelial ovarian cancer, a
single CA-125 assay is not useful in screening for ovarian cancer.
Multimodal screening has been proposed as a useful tool to screening ovarian cancer
because any technique alone could not be sufficiently sensitive to identify early-stage
disease. A scheme of multimodal screening has been used to screen ovarian cancer and
resulted in 99.9% specificity, with sensitivity of 78.6% at 1 year and 57.9% at 2
year. Serum CA-125 was first screened, if it was greater than or equal to 30U/ml,
women underwent abdominal ultrasonography, followed by a laparotomy for an
ovarian abnormality (Jacobs I, et al. 1993).
1.3.2 Prognostic factors in ovarian cancer
Prognostic factors in ovarian cancer include many features, surgical, pathological,
biological, etc. Multivariate statistical methods have been used to analyse prognostic
factors, which are truly independent in themselves rather than simply reflecting
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association with other prognostic factors. Such analyses suggest that there are several
general independent prognostic factors and described below.
1) Surgical prognostic factors;
The 5-year survival of patients with epithelial ovarian cancer is directly related to the
Internation Federation of Obstetric and Gynecology (FIGO) stage (seeTable 1-2).
Patients with stage I and stage II ovarian cancer have a significantly better outcome
than those with stage III or stage IV tumours. Within each stage, however, there are
often marked differences in patient survival and subcategorization of stage provides
useful prognostic information; capsular invasion, surface excrescence, tumour
rupture, ascites, positive peritoneal cytology and degree of peritoneal cytology
(Makar AP, et all995; Ahmed FY, et al. 1996). The volume of residual disease
following cytoreductive surgery is also directly correlated with survival. Patients who
have been optimally cyoreduced have a better prognosis than those undergoing less
than optimum resection. In retrospective analyses of the importance of residual
volume on survival, the size of the largest residual mass (< 2cm, or >2cm in size), and
not the total number of lesions, has emerged as the primary factor correlating with
prognosis (Hunter RW, et al. 1992). But one study has been demonstrated that the
number of residual masses may be an important prognostic factor as well (Heintz
AP, etal. 1988).
1) pathological prognostic factors;
In general, patients with mucinous adenocarcinomas have an overall better survival in
comparison to endometrioid or serous adenocarcinomas in same stage and histologic
grade (Ansell SM, et al. 1993). Clear cell carcinomas are commonly found to be stage
I at diagnosis. There is some controversy regarding their prognostic significance, but
there are data to suggest that they have a more aggressive natural history (O'Brien
ME, et al. 1993). There are also reports that suggest clear cell tumours are more likely
to be resistant to platinum-based chemotherapy (Goff BA, et al. 1996).
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The histologic grade of the tumour is a particularly important prognostic factor in
patients with early-stage disease. Stage I patients with well or moderately well
differentiated tumours have a greater than 70 %-80 % 5-year survival when treated
with surgery alone (Young RC, et al. 1990). In advanced-stage patients treated with
cisplatin-based chemotherapy, most studies have failed to demonstrate a significant
correlation between histologic grade and survival (Friedlander ML. 1998).
On the other hand, flow cytometric analysis of tumoral DNA content can indicate the
presence of an euploid tumour populations and is a significant adverse independent
prognostic factor (Friedlander ML, et al. 1988).
Although CA125 levels are increased in 75% to 90% of patients with ovarian cancer
and have a well established role in following the response to treatment and detecting
relapse (Nagele F, et al. 1995), the relationship between CA125 and survival is still
ambiguous. The preoperative CA125 level of patients with advanced ovarian cancer
does not correlate well with survival, but the decrease of CA125 during the first three
cycles of treatment is an important predictor of outcome (Yedema CA, et al.1993).
1) biological prognostic factors;
There is growing understanding of the molecular events associated with the
development and progression of ovarian cancer and they have led to numerous
reports on the prognostic impact of molecular markers. These molecular markers
frquently can be categorized as abnormalities in oncogene products (such as HER-
2/neu, p20), tumour suppressor genes (p53, pi6, pRB), and measures of dmg
sensitivity (Pgp, LRP, MPR, GST, BAX) (Bookman MA, et al.l996; Eisenhauer
EA, et al. 1999) In addition, there have been a series of reports about markers of
proliferation (DNA index, KJ-67 index, proliferating cell nuclear antigen), DNA
repair (leukocyte platinum, DNA excision repair, helicasep complexes), serum
cytokine levels (CSF-1, IL-6 ), and factors associated with tumour invasion and
metastases (NM23) (Friedlander ML. 1998). Despite the large number of reports
describing putative prognostic factors, they are not currently used in the routine
selection of treatment for patients with either early-stage or advanced-stage disease.
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Recently, some studies have demonstrated that p53, HER-2/neu and EGFR are
independent prognostic factors (Eisenhaucr EA, et al. 1999).
1.3.3 Clinical staging and primary cytoreductive surgery
Adequate and complete surgical intervention is mandatory primary therapy for
ovarian carcinoma, permitting precise staging, accurate diagnosis, and optimal
debulking of the tumour (taking out as much of the cancer as possible).
Many clinical studies underscore the importance of a comprehensive surgical staging
procedure (Table 1-1) (Boente MP, et al. 1998). Accurate staging is crucial as it
determines subsequent therapy, which will contribute to outcome. The widely used
FIGO staging system is presented in Table 1-2.
Table 1-1 Comprehensive Staging Laparotomy for Suspected Early
Ovarian Carcinoma
Vertical incision that allows adequate visualization and palpation of structures in
the upper abdomen and retroperitoneum
Peritoneal washings (pelvis, parabolic gutters, hemidiaphragms)
Inspection/palpation of all peritoneal and mesenteric surfaces
Biopsy of any lesions or adhesions
Total abdominal hysterectomy and bilateral salpingo-oophorectomy
Infracolic omentectomy
Random peritoneal biopsies (bladder, pouch of Donglas, bilateral pelvic
peritoneum, paracolic gutters hemidiaphragms )




Table 1-2 Carcinoma of the Ovary: FIGO Nomenclature (1998)
Stage I Growth limited to the ovaries.
IA Growth limited to one ovary; no ascites present containing malignant
cells. No tumour on the external surfaces; capsule.
IB Growth limited to both ovaries; no ascites present containing
malignant cells. No tumour on the external surfaces; capsule.
IC Tumour either Stage IA or IB, but with tumour on surface of one or
both ovaries, or with capsule rupture, or with ascites present
containing malignant cells, or with positive peritoneal washings
Stage II Growth involving one or both ovaries with pelvic extension
IIA Extension and/or metastases to the uterus and/or tubes
IIB Extension to other pelvic tissues
IIC Tumour either stage IIA or IIB, but with tumour on surface of one or
both ovaries; or with capsule rupture, or with ascites present
containing malignant cells, or with positive peritoneal washings
Stage III Tumour involving one or both ovaries with histologically confirmed
peritoneal implants outside the pelvis and/or positive retroperitoneal
or inguinal nodes. Superficial liver metastasis equals Stage III.
Tumour is limited to the true pelvis, but with histologically proven
malignant extension to small bowel or omentum.
IIIA Tumour grossly limited to the true pelvis, with negative nodes, but
with histologically confirmed microscopic seeding of abdominal
peritoneal surfaces, or histologically proven extension to small
bowel or mesentery.
IIIB Tumour of one or both ovaries with histologically confirmed
implants, peritoneal metastasis of abdominal peritoneal surfaces,
not exceeding 2 cm in diameter; nodes are negative.
IIIC Peritoneal metastasis beyond the pelvis >2 cm in diameter and/or
positive retroperitoneal or inguinal nodes.
Stage IV Growth involving one or both ovaries with distant metastases, if
pleural effusion is present, there must be positive cytology to allot
a case to Stage IV. Parenchymal liver metastasis equals Stage IV.
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If there is obvious evidence of tumour spread, debulking of residual tumour masses to
under 2 cm maximum diameter should be undertaken as there is evidence that this
results in better response and survival with subsequent chemo- or other therapy.
This is thought to be due to the following: a), the resection of large bulky masses
removes the portions of tumour and it will be of benefit for increasing the
chemosensitivity of residual tumour nodules (Hoskins WJ. 1991). b), the
Gomperzian model suggests that cytoreduction causes a high percentage of resting
tumour cells to migrate into the pool of actively dividing cells with a consequent
increase in chemotherapy sensitivity (DeVita VT, et al. 1993). c), after removal of
large tumour masses, leaving fewer cancer cells would be more easily eradicated by
postoperative chemotherapy (Hoskins WJ.1993).
1.3.4 Chemotherapy
Ovarian cancer is a fairly chemosensitive tumour, and chemotherapeutic agents from a
wide variety of different classes have shown activity (McGuire WP, et al. 1998). The
best effect of chemotherapy are likely to be achieved after optimal tumour
cytoreduction, using combination regimens for chemotherapy. The platinum
compounds remain the most active agents in ovarian cancer and are the cornerstone of
combination regimens. In the past decade a series of novel compounds were identified
to be clinically active in recurrent ovarian cancer. Currently the standard of care for
most patients with ovarian cancer consists of combination of paclitaxel and
carboplatin (Ozols RF, et al. 1997).
1.3.4.1 Platinum compounds
Platinum analogues function as cytotoxic drugs by binding to amino or hydroxyl
groups of nucleoside bases and forcing DNA intra-strand and inter-strand crosslinks.
This DNA crosslinking results in interference with replication/repair mechanisms.
The Gynecologic Oncology Group (GOG) performed the largest comparative trial of
a cisplatin-containing regimen versus a non-cisplatin-containing regimen. The results
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showed that the complete response rate for the platinum-containing regimen was 51
%, compared to 26 % for non-cisplatin-containing regimens, and the cisplatin-
containing regimen was superior with regard to response duration, progression-free
interval, and overall survival (Omura G, et al. 1986).
Carboplatin is a second-generation platinum compound which was less nephrotoxic,
neurotoxic, and emetogenic than was cisplatin (Canetta R, et al. 1988). There have
been many radomized trials comparing single-agent caboplatin with cisplatin or in
combination regimens in patient with ovarian cancer (Go RS and Adjei AA. 1999).
Most of these results showed equivalent efficacy and two meta-analyses also showed
that there was no significant differences in survival, with 5-year survival rates of 15
% and 19 % for cisplatin and carboplatin, respectively (Aabo K, et al. 1998; Stewart
LA, et al. 1992).
1,3.4.2 Paclitaxel
Paclitaxel is the prototype drug of a new class of agents. The cytotoxicity of
paclitaxel is due to its unique effects on microtubles. Paclitaxel can bind preferentially
to the beta subunit of tubulin, leading to stable polymerized microtubles that inhibit
the dynamic reorganization of the microtuble network. Paclitaxel arrests cell in G2/M
(Dumontet C, et al. 1999).
Paclitaxel was reported to have significant activity in advanced ovarian cancer (Kohn
EC, et al. 1994; Eisenhauer EA, et al.1994). A series of clinical trial exploring the
activity of paclitaxel as a single agent or in combination with platinum compounds
was followed by prospective randomized trials comparing cisplatin plus paclitaxed
versus cisplatin plus cyclophospamide (Rowinsky EK and Donehower RC. 1995;
McGuire WP, et al. 1996; Eisenhauer EA, et al. 1994). The Gynecologic Oncology
Group (GOG) protocol 111 and Ovarian Cancer (OV) protocol 10 showed that
complete response rate of cisplatin plus paclitaxed were 51 % and 50 % comparing
with 31 % and 36 % of cisplatin plus cyclophospamide respectively. Overall
response rate of cisplatin plus paclitaxed were 73 % and 77 % versus 60 % and 66 %
of cisplatin plus cyclophospamide respectively. The median progression-free
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survival (month) of cisplatin plus paclitaxed were 18 month and 16 month comparing
with 13 and 12 months for cisplatin plus cyclophospamide respectively; median
overall survival (month) of cisplatin plus paclitaxed were 38 months and 35 months
comparing with 24 and 25 months of cisplatin plus cyclophospamide respectively
(McGuire WP, et al. 1996; Sturt G, et al. 1998). In addition, three randomised trial of
carboplatin plus paclitaxel vs cisplatin plus paclitaxel showed equivalent responing
rates and reduced toxicity (Go RS and Adjei AA. 1999). Based on the superior
therapeutic index, paclitaxel plus another platinum compound, carboplatin, has been
considered the standard of care for treatment of patients with ovarian cancer (Neijt
JP, et al. 1997; Ozols RF .1999)
1.3.4.3 Second -line chemotherapy
The optimum treatment of patients who have recurrent disease remains a major
management problem in ovarian cancer. Although most patients with ovarian cancer
can achieve a clinical CR after completion of cytoreductive surgery followed by
placlitaxel plus a platinum compound, most of them still recur with disease and fail to
respond to initial chemotherapy. A series of new agents have been shown to have
activity in the second-line treatment of patients with recurrent ovarian cancer
including Topotecan and liposomal doxorubicin. Patients with drug-sensitive tumour
have a high re-respond to drugs that have been used in their initial induction regimen.
The re-respond for rctreatment with a platinum compound, and presumably
paclitaxel, is a direct function of the length of the disease-free interval. The exception
may be those patients who have had an extremely long disease-free interval, perhaps
greater than 1 to 2 years, in whom combination chemothrepy may be the preferred
treatment at the time of recurrence. Most patients with recurrent drug-sensitive
disease are usually treated with either paclitaxel or platinum compound then crossed
over to the other durg as necessary. Retreatment with these two agents in recurrent
drug-sensitive tumour has not been show to be superior to using some of the newer
agents to be diseaseed as the the first chemotherapy option for recurrent disease. It
has also been shown that a higher response-rate will be obtained with most second-
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line agents in drug-sensitive patients compared with drug-resistant patients. There are
summarised by McGuire and Ozols (see Table 1-3) (McGuire WP and Ozols RF.
1998).
Table 1-3 New Active Agents in Recurrent Ovarian Cancer
Agent Response (%) Comment
Prior treatment did not
include paclitaxel
Paclitaxel 19 to 40 Multiple studies
Topotecan 14 to 23 Lower response rates in
platinum-resistant patients
Vinorelibine 22 Duration of response > 19
weeks
Gemcitabine 29 Activity in platinum-
resistant patients
Docetaxel 40 Neutropenia and fluid
retention common
Prior treatment with paclitaxel
and patinum
Lipospomal doxorubicin 26 Median survival 11 months
Oral etoposide 27 to 35 Higher response rate in
platinum-sensitive patients
1.3.4.4 Drug resistance
Acquired drug resistance is the major factor that limits the effectiveness of
chemotherapy in patients with advanced ovarian cancer. Patients with recurrent
disease after an initial response to chemotherapy rarely, if ever, are cured with
chemotherapy. In part, this is related to the broad cross-resistance that develops
toward antineoplastic agents from different pharmacologic classes. On the other hand,
about 20 % to 25 % of patients have intrinsically drug-resistant tumour at the time of
diagnosis and never respond to any chemotherapy regimen.
The biochemical and molecular mechanism associated with drug resistance in ovarian
cancer have been extensively studied. But the mechanism of multidurg resistance
remains unclear. Many investigations have demonstrated that resistance to alkylating
agent and platinum is multi-factorial (Lehnert M. 1996), and includes;
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a) Altered drug transport and decreasing drug accumulation in cancer cell. Increased
expression of the human MDR1 gene product, P-glycoprotein (P-gp) is one
mechanism in multidurg resistance. P-gp is an ATP-dependent drug efflux pump that
confers resistance to wide variety of naturally derived dmgs such as vinca and
taxanes, but not platinum drugs (Germann UA. 1996). Overexpression of MDR1
mRNA or P-gp has been observed in a variety of tumours and has also been found to
be an indicator of poor prognosis in patients treated with chemotherapy (Goldstein
L. 1996). In ovarian cancer, the role of MDR1 expression is still conflicting
(Holzmayer TA, et al.1992; Kavallaris M, et all996; Zhu L, et al. 1997).
LRP, a vault protein, also is associated with multidmg resistance (Scheffer GL, et
al.1995). LRP-postitive patients had poorer responses to chemotherapy and shorter
overall survival as compared to LRP-negative patients (Izquierdo MA, et al. 1995).
b) Increased inactivation of drugs has been demonstrated by detoxifcation enzymes
such as glutathione-S-transferases (GST), or direct binding to nonprotein thiols such
as glutationc (GSH). A wide variety of detoxifcation pathways exist that enable a cell
to inactivate cytotoxic dmgs. The mechanisms that have received the most attention
in mediating drug resistance in ovarian cancer include increased levels of GSH, GSTs
transferases, and metallothioneins. Spontaneous conjugation of GSH with melphalan,
chlorambucil, and cisplatin has been shown in vitro (Ishikawa T, et al. 1993) and
increased levels of GSH have been found to be associated with resistance to alkyating
agent and platinum (Britten RA, et al. 1991; Godwin A, et al. 1992; Hosking LK, ct
al. 1990). The GSTs, a multigene family which catalyzes the conjugation of GSH with
electrophilic drug, have been implicated in resistance to alkylating agent,
anthracyclines, and platinum (Meijer C, et al. 1990; Black SM, et al. 1990). The
results from studies of GSTs in predicting patient response to chemotherapy indicate
that neither tumour GST activity nor expression level is predictive of response to
chemotherapy in ovarian cancer patients (Ghazal-Aswad S, et al. 1996; Tanner B, et
al. 1997).
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c) Altered drug target. Decreased expression or alteration of a gene or its product may
enable a cell to escape the cytotoxic effect of certain chcmothcrapeutic agents. Several
reports have described alterations in (3-tubulin in paclitaxel, which can prevent
paclitaxel binding and enable a cell to circumvent the cytotoxic effects of this drug
(Dumonter C, et al. 1996;Ranganathan S, et al. 1996). Other drug targets whose
alterations are associated with chemotherapeutic drug resistance are the DNA
topoisomerases. Decreased expression or mutation of the topoisomerase I and
topoisomerase II genes has been implicated in resistance to these drugs in derived
drug resistant models in vitro (Eng WK, et al. 1990; Wang LF, et al. 1997).
d) Increased DNA repair activity. Tumour cells may be able to develop DNA repair
mechanisms that are more efficient than normal, counteracting the genotoxic effects of
cytotoxic chemotherapy, and hence contributing to resistance to DNA damaging
drugs. Increased repair of platinum-DNA adducts has been shown to be associated
with cisplatin resistance in human ovarian cancer cell lines (Parker RJ, et al. 1991),
and evidence for increased repair of cisplatin interstrand crosslinks in specific genes
and nongene regions in cisplatin-resistant cells has also been shown (Johnson SW, et
al. 1994).
In order to decrease the multidrug resistance in ovarian cancer, some drugs have been
used to reverse drug resistance. A Phase I trial of buthionine sulfoximine (BSO) plus
melphalan has been completed. BSO can be safely administered to patients at doses
that produce an 80% reduction in GSH levels at circulating lymphocyes in the
majority of drug-resistant patients (O'Dwyer PJ. et al. 1996). Clinical trials of
aphidicolin, an inhibitor of DNA polymerase alpha, have demonstrated that the drug
is essentially nontoxic and that the necessary plasma levels may be achievable,
(Auersperg N, et al. 1998). Clinical trials of Cyclosporin A ( CsA), a drug capable of
reversing multidrug-resistant phenotype, have undergone Phase I and Phase II
evaluation in ovarian cancer patient, with the CsA/carboplain regimen showing
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modest activity in platinum-resistant patient (Chambers SK., et al,1996;Manetta A,
et al. 1998).
1.4 Molecular Genetics of Epithelial Ovarian Cancer
1.4.1 Molecular epidemiology and genetic linkage
The molecular study of genes involved in carcinogenesis has opened a new field of
epidemiology. It is possible by analysis of genes thought to be important in the
aetiology of a particular tumour type to make inferences about causation; the relative
balance of inherited to somatic events and whether the somatic events are due to
environmental or spontaneous processes.
Although clearly defined predisposing/hereditary factors account for only about 5%
of patients with ovarian cancer, as judged by familial clustering, and the aetiology
may have multifactorial components, among the factors associated with ovarian
cancer, none alters magnitude of risk more than a family history of the disease. The
familial aggregation of ovarian cancer has been shown in numerous case series and
case-control studies. These studies have illustrated statistically significant increases
not only in ovarian cancer, but also breast, endometrium, and colon cancers among
relatives of women with a primary ovarian cancer (Jishi MF, et al. 1995; Zweemer
RP, et al. 1999) (see above). The observation of familial patterns of ovarian cancer
has prompted attempts to identify genes involved, and the genes BRCA1 and
BRCA2 gene are considered as the principal involved genes
1.4.1.1 The BRCA1 gene and ovarian cancer
The BRCA1 gene was identified by positional cloning methods and found to extend
over lOOkb of genomic DNA with 24 exons and encode a protein of 1863 amino
(Miki Y, et al. 1994). The BRCA1 protein sequence includes an amino-terminal
RING doman, a negatively charged region in its carboxy-terminus, and C-tcrminal
sequences, partially homologous to some of terminal deoxynucleotidyl-transferases,
and eukaryotic ligases (Callebaut I, et al. 1997). The BRCA1 protein also interacts
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with hRad51, a member of a protein family known to mediate DNA strand-exchange
functions leading to normal recombination (Scully R, et al. 1997). It is expressed in
many tissues during development, including thymus, breast and testis (Miki Y, et al.
1994), and is strongly expressed in the epithelial cell layer of the adult ovary but
expression appears to be reduced in malignant cells (Thompson et al. 1995). It is also
expressed in rapidly proliferating cell types undergoing differentiation, and its
expression is induced in oophorectomised animals after treatment with 17 beta-
oestradiol and progesterone (Marquis ST, et al. 1995). Up to now, the normal
function of BRCA1 is still unclear but may contribute to homologous recombination
and DNA repair, to embryonic, to transcriptional regulation and to ubiquitination
(Welcsh PL, et al.2000). Transfection of breast and ovarian cancer cell lines with
wild-type BRCA1 inhibits growth, although this is not the case for colon or lung
cancer cell lines, demonstrating a tissue specific effect and BRCA1 gene locates at chr
17q where LOH is a common event in ovarian cancer (Takahashi H, et al 1995;
Cornelis RS, et al. 1995). BRCA1 therefore has most of the characteristics of a
tumour suppressor gene.
More than 100 mutations in the BRCA1 gene have been described, many of which
result in premature truncation of protein transcription (Daly M and Obrams GI.
1998). It has been estimated that frequency of BRCA1 mutations in the general
population is 0.04 % to 0.20 %. However, the 185delAG and 5382insC mutations
are present in approximately 1 % and 0.1 % of the Ashkenazi Jewish population
(Ford D, et al. 1995).
It is clear that female carriers of BRCA1 mutations are at significantly increased risk
of breast and ovarian cancer ( Sutcliffe S et al.2000). Using data from families with
evidence of linkage to BRCA1, it has been estimated that the lifetime risk of ovarian
cancer is 40% to 66 % (Ford D, et al, 1994; Easton DF, et al. 1995;). In the
Washington study among Ashkenazi Jews, where only their mutations were
assessed, the risk of ovarian cancer among mutation carriers was 16 %by age 70 (Ford
D, et al. 1995). The highest risk for ovarian cancer was observed among carriers of the
5382insC mutation, and the lowest for the 185delAG mutation (Yazici H, et al.
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2000). Another study estimated the probabilities that a woman with breast or ovarian
cancer harbours a BRCA1 mutation and proposes offering DNA testing to women
with at least a 10% to 15% likelihood of carrying this mutation (Weber B, et al.
1996). These results were summarised by Weber et al (see Table 1-4)
Table 1-4 Estimated Probability of BRCA1 Mutation Based on
Family History (from Weber et al. 1996)
Family history Probability of BRCA1 mutation (%)
single affected person
Breast cancer at <30 years of age 12
Breast cancer at <40 years of age 6
Breast cancer at 40 to 49 years of age 3
Ovarian cancer at <50 years of age 7
Sister pairs
Both with Breast cancer at <40 years of age 37
Both with Breast cancer at 40 to 49 years of age 20
Breast cancer at <50 years of age, ovarian cancer
at <40 years of age 46
Both with ovarian cancer at <40 years of age 61
Families
Breast cancer only, three or more cases at <50
years of age 40
Two or more breast cancers and one or more
ovarian cancers 82
Two or more breast cancers and two or more
ovarian cancers 91
Differential occurrence of ovarian cancer by site of mutation has been a subject of
considerable interest and controversy. Findings from a British study indicate that
mutations closer to the 5' end of the gene carry a higher risk of ovarian cancer.
Specifically, they found that mutations in the 3' third of the gene are associated with
a lower proportion of ovarian cancer (Gayther SA, et al. 1995; Gayther SA, et al.
1997). Although transfection of a 3'BRCA1 mutant does not inhibit the growth of
breast cancer cells, it still does inhibit the growth of ovarian cancer cells (Holt JT, et
al, 1996). Furthermore, this 3' mutation appears to map to BRCAl's putative granin
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consensus sequence (Jensen RA, et al. 1996), and this suggests a possible mechanism
for mutational differences involved in tumours of different tissue origins. However,
other studies could not confirm this result that the intragenic position of BRCA1
mutations has a significant influence on the ratio of breast to ovarian cancer (Peelen
T, et al. 1997; Serova O, et al. 1996; Berman DB, et al. 1996). Data from the
Jerusalem series showed an opposite trend for increased rates of ovarian cancer with
mutations at the 3' end (Levy-Lahad E, et al. 1997).
It has been demonstrated that oral contraceptive use may reduce the risk of ovarian
cancer in women with mutation of BRCA1. In a case-control retrospective study, the
use of oral contraceptives for 6 or more years was associated with a 60% reduction in
risk of ovarian cancer in women with mutation in BRCA1 (Narod SA, et al. 1998).
1.4.1.2 The BRCA2 gene and ovarian cancer
A second gene, BRCA2, was mapped to Chr 13q 12-q 13 (Wooster R, et al. 1994),
and consists of an 11-12 kb messenger RNA encoded by a 27-exon gene spanning
70kb of DNA. It encodes a 3418 aa protein of about 350kd. The gene has no obvious
strong homologies; the mouse and human genes share only about 55% to 60%
homology. However, it contains 8 copies of a highly conserved repeat element
dispersed throughout the gene (Wooster R, et al. 1995). Although the most recent
findings support the involvement of BRCA2 in the repair of DNA, the exact function
is as yet unclear (Lynch HT, et al. 1998).
To date, some 100 distinct mutation have been described in BRCA2 and as is the case
for BRCA1 these are scattered through out the coding sequence and apart from
several distinct founder mutation (Levy-Lahad E, et al. 1997; Thorlacius S, et al.
1997) there are no specific hot-spots. The most frequent type of BRCA2 mutation is
frameshift, most commonly deletions. A recent study showed that the frequency of
3414delTCAG mutations appears to be high in Turkish breast/ovarian cancer families
(Balci A, et al. 1999). It has been demonstrated that BRCA2 confers a high risk of
breast cancer and ovarian cancer (Osorio A, et al. 1998). The lifetime risk of ovarian
cancer in BRCA2 mutation carriers is approximately 20 %, but the risk is
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predominantly for women above age 50 (Ligtenbcrg MJ, et al. 1999). The expression
of ovarian cancer was notably lower in carriers of mutations of BRCA2 compared to
carriers of BRCA1 mutation (Levy-lahad E, et al.1997).
1.4.2 Structural genetic alteration in ovarian cancer
1.4.2.1 Cytogenetics
There have been many cytogenetic studies in ovarian cancer (Gallion H, et al. 1990;
Deger RB, et al.1997; Park SH, et al.2000), and it is clear that the majority of
tumours are aneuploid with complex karyotypic changes (Berchuck a, et al. 1992).
Among those cytogenetic lesions that are frequently reported are those involving
chromosome 1, 3, 6, 7, 8, 9, 11, 12, 17, 19 and X (Jenkins RB, et al, 1993; Pejovic T,
et al. 1992; Taetle R, et al. 1999; Lamerz R. 1999). One study of chromosome
abnormalities in 244 cases of ovarian adenocarcinoma reported that a total of 201/224
cases had fully characterized clonal chromosome abnormalities, of which 134 showed
clonal chromosome breakpoints, and non-random occurrence of chromosome
breakpoints was detected at region 1 p 1, lql, lp2, lq22, lq3, 3pl, lq4, 6ql. 6p2,
6q2, 7pl, 7ql, 7p2, llpl, llql, llq2, 12pl, 12q2, 13pl, and 19ql, suggesting that
recurring, nonrandom chromosome abnormalities are important in the pathogenesis
and/or progression of ovarian cancer (Taetle R, et al. 1999). A specific translocation
involving chromosomes 6 and 14 was reported in 8 of 14 cases of papillary serous
adenocarcinoma of ovary (Wake N, et al. 1980). Additional reports have also
suggested a role for aberrations of chromosome 6, mainly involving deletions from 6q
(Trent J, et al. 1985). Cytogenetic analysis also has demonstrated partial deletions of
Chr 11 affecting both long and short amis (Jenkins RB, et al, 1993; Bello JA, et al,
1990; Pejovic T, et al, 1992).
In-situ hybridisation methods provide refinement to the cytogenetic data, Sonoda ct
al, observed that most carcinoma specimens displayed numerous imbalances. The
most common overlapping sites of copy number increases, in order of frequency,
were 8q24, 20ql3.2-qter, 3q26.3, lq32, 20p, 9p21-pter, 12p, and 5pl4-pter. DNA
amplification was identified in nearly 50 % of the tumours examined. The most
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frequent sites of amplification were 8q24, 3q26.3, and 20ql3.3, while other recurrent
sites of amplification included 7q36, 17q25, and 19ql3.1-13.2. The most frequent
changes could reflect the amplification of target regions containing genes such as c-
myc at 8q24, MYBL2 at 20q 13.1, EVII at3q26 ( Sonoda G, et al. 1997). One study
has shown that copy number abnormalities were more frequent in high-grade ovarian
cancer and not present in any of the benign tumours of ovary. In only 31 % cases
overall was there concordance between LOH for a chromosome arm and physical
deletion as judged by comparative genomic hybridisation (CGH). This suggested that
flanking regions which do not show LOH must contribute to the discrepancy
between published LOH and CGH analyses of the same regions and demonstrates
that concordance occurs mainly where contiguous LOH is long enough to approach
the limits of resolution defined by CGH. Of the most frequent 18 copy number
abnormalities detected, 13 were instances of increased copy number. The 6 most
frequent observable CGH reduction of copy number were 17 pter-q21, 16q, 8p21-23,
Xp and whole 19 (Iwabuchi H, et al. 1995). In another study, genetic abnormalities
were detected by comparative genomic hybridization (CGH) in 12 ovarian clear cell
adenocarcinomas. DNA sequence copy number abnormalities (CNAs) occurred in
more than 20% of the cancers. Increases in copy numbers of 8q 11 -q 13, 8q21-q22,
8q23 and 8q24-qter occurred more frequently in disease-free patients than in
recurrent/non-surviving patients. However, increases in copy numbers of 17q25-qter
and 20ql3-qter occurred more frequently in recurrent/non-surviving patients than in
disease-free patients. This suggested changes in specific chromosome copy number
associated with progression of disease (Suehiro Y, et al. 2000).
1.4.2.2 Loss ofheterozygosity (LOH) in ovarian cancer
Although LOH does not provide direct proof of a tumour suppressor gene, a high
frequency of allele loss in a specific region of a chromosome in a tumour type
indicates the possible presence of a tumour suppressor gene or genes. Ovarian
tumours have been analysed for LOH across the genome and a number of hotspots
for allele loss identified on different chromosomes. However, there are many
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ambiguities and difficulties in the interpretation of LOH data. First of all, many of the
studies have analyzed only small numbers of tumours and these may or may not have
included some benign or borderline tumours. Second, because some authors have used
microdissected tumour tissue for LOH analysis, if a sample contain a high percentage
of contaminating stromal tissue, LOH in the tumour cells may be masked. Third,
there is often considerable variation in composition of the tumour with respect to
histological subtype, tumour stage and grade, all of which might be expected to
influence the outcome of any LOH analysis. Finally, many studies use only one or
two polymorphic markers per chromosome arm and there is often great variation
between studies in the marker used. Direct comparisons between studies are therefore
very difficult and often lead to conflicting and confusing results.
To date, more than 100 LOH studies have looked at epithelial ovarian cancer, and
allelic losses for polymorphic DNA markers in epithelial ovarian cancer have been
observed on every chromosomal arm (Lynch HT, et al. 1998). Allelotyping studies of
ovarian cancers revealed that more than 30% of the tumours studied showed LOH on
chromosomes lp, 3p, 5q, 6,7 9, 8p, 11, 16q, 17, 18q 21q, 22q, and X (Wertheim I, et
al. 1996; Zborovskaya I, et al. 1999; Huang LW, et al; 2000), with the highest LOH
rates on 17p, 17q, 22q, 18q, 8p, 9q, lp, 9p, 7q, Xp, 6q, 5q, 1 lq, 13q, 19p, 21 q, 3p,
6p, lip, and 7p, in descending order (Lynch HT, et al. 1998; Zborovskaya I, et al.
1999; Huang LW, et al. 2000). LOH of >60 % has been reported for 1 lp, 1 lq, 17p,
17q, 18q, and 22q (Zborvskaya 1, et al. 1999).
The relationship between LOH and specific tumour suppressor genes in epithelial
ovarian cancer has also been reported. The establishment of linkage to chromosome
17q21 in families with an inherited predisposition to early onset breast and ovarian
cancer suggested initially that the high rates of LOH from 17q in sporadic tumours
may reflect the inactivation of BRCA1. However, with more detailed linkage analysis
in families, extensive deletion mapping in sporadic tumour, and mutation analysis in
BRCA1, the results show somatic mutations of BRCA1 are rare in sporadic tumours
and they may not play a major role in tumorgenesis in sporadic breast and ovarian
cancer (Futreal PA, et al. 1994: Merajver SD, et al, 1995; Sorlie T, et al. 1998 ).
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Recent studies showed that aberrant cytosine methylation of the BRCA1 promoter
was directly correlated with decreased levels of BRCA1 expression in human breast
and ovarian cancer (Baldwin RL, et al. 2000; Bianco T, et al. 2000). BRCA1
methylation was strikingly associated with the medullary and mucinous subtypes of
breast cancer, which are overrepresented in BRCA1 families. In ovarian neoplasms,
BRCA1 methylation was found only in tumours with LOH. The BRCA1 promoter
was unmethylated in other tumour types. These data suggest that epigenetic silencing
of the BRCA1 may be one mechanism of transcriptional inactivation of BRCA1 in
sporadic breast and ovarian carcinogenesis (Esteller M, et al. 2000)
In other studies, investigators have found that approximately 30 % of the ovarian
tumour they examined showed changes affecting p53 genes, (Tsao SW, et al. 1991;
Kohler MF, et al. 1993), mutation of p53 on 17ql3.1 is one of the commonest
genetic alterations described thus far in epithelial ovarian carcinoma (approximately
50 %) (Kupryjanczyk J, et al. 1995). LOH from the short arm of chromosome 17 has
often been assumed to represent inactivation of the p53 gene at 17p 13.1. However,
losses at 17p 13.3 were demonstrated in Stage I ovarian cancers and borderline
tumours. In the latter case, the LOH at 17p 13.3 were not accompanied by LOH at
p53 (Phillips NJ, et al. 1996). Recently a study showed that absent over-expression
of p53 was significantly associated with LOH at 17q in ovarian carcinoma (Caduff
RF, et al. 1999).
Mutation and expression of another tumour suppressor gene, pi6, have also been
studied in ovarian cancer (Rodabaugh KJ, et al. 1995). Despite the identification of 50
% homozygous deletion rate in ovarian cancer cell lines, neither mutation nor
abnormal expression of the pi6 gene has been found in ovarian tumour tissues
(Shigemasa K, et al. 1997). Recently, the studies have shown that pi6 is frequently
methylated in ovarian cancer. Therefore, p 16 silencing may be important for the
development of ovarian carcinomas (McCluskey LL, et al. 1999; Wong YF, et al.
1999).
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1.4.3; Alterations in tumour suppressor genes, oncogenes, and growth
factors ofovarian cancer
1.4.3.1 p53 in ovarian cancer
The p53 tumour suppressor gene is the most frequently inactivated gene described
thus far in ovarian cancer. It encodes a 53-kd nuclear phosphoprotein that is
expressed at low levels in virtually all normal cells, and is composed of 11 exons, the
first of which is non-coding and localised 8 to 10 kb upstream of exons 2 through 11
on the short arm of human chromosome 17. There are five conserved domains within
the coding regions of the gene, which contain 80 % to 90 % of described functional
p53 mutations. The functions of normal or wild-type p53 have been shown to be
involved in 1) DNA damage response pathways; 2) cell-cycle arrest at the Gl-S
checkpoint before DNA replication and at the G2-M checkpoint prior to mitosis
(facilitates DNA damage repair and prevents mutation and aneuploidy, respectively),
and 3) inducing apoptosis in cases where irreparable DNA damage has occurred (Lee
G, et al. 1995; Siddik ZH, et al. 1998; Kupryjanczyk J, et al. 2000).
Functional p53 mutation usually affects trans-activation domains. More than 90 % of
the substitution mutations reported so far in malignant tumours are clustered between
exons 5 and exons 8 and most are localised in the evolutionarily conserved regions.
Most p53 mutants divide into two classes: 1) DNA contact mutants; that are unable
to bind specific DNA target sequences because of substitution of crucial DNA
residues, including mutational hot spots; 2) structural mutants; that lose specific
protein function. Central core mutations are the main mutations affecting trans-
activation. It has been suggested that greater than 60 % loss of p53 function is needed
to result in a tendency towards neoplastic transformation or growth (Pfeifer GP.
2000; Spandidos DA, et al. 2000; Wallace-Brodeur RR and Lowe SW. 1999).
Mutation of p53 is observed in more than 50% of ovarian cancer, and is observed at
multiple structural sites, but there is no single site or codon that is distinctive or
unique to ovarian cancer( Kohler MF, et al. 1993). Over-expression of p53 has not
been reported in borderline tumours of the ovary and appears to be correlated with an
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increasing histologic grade, and it is clear that the frequency of over-expression of
mutant p53 is significantly higher in advanced stage III/IV disease relative to stage I
cases (Berchuck A, et al. 1994). Therefore, it is possible that loss of p53 may confer
an aggressive phenotype associated with more rapid progression. However, the
prognostic significance of p53 expression in ovarian cancer remains to be fully
determined, although some studies suggest that over-expression of p53 is associated
with an unfavourable outcome. In the largest study, investigators examined p53
expression in 284 patients with epithelial ovarian cancer and detected p53
immunorcactivity in 177 (62 %). In a univariate analysis, but not in a multivariate
analysis, p53 expression was associated with decreased survival. In a subset of
patients with early-stage disease, p53 expression approached statistical significance
as an independent prognostic factor (Hartmann LC, et al. 1994). Recently, one study
also showed that the p53 mutation frequently occurs in recurrent ovarian cancer and
that alteration of p53 status affects salvage chemotherapy and may therefore predict
outcome (Irie T, et al. 2000).
It has been suggested that loss of functional p53 might confer a chemoresistant
phenotype because p53 plays a role in chemotherapy-induced apoptosis. In this
regard, several studies have examined the correlation between chemosensitivity and
p53 mutation in ovarian cancers in vitro. Some have suggested a relationship between
p53 mutation and loss of chemosensitivity, but in other equally valid studies, such a
relationship has not been observed (Brown R, et al.1993; Eliopoulos AG, et al. 1995;
Righetti SC, et al. 1996; Perego P, et al. 1996). It is likely that the status of the p53
gene is just one of a multitude of factors that determines chemosensitivity.
1.4.3.2 Alteration ofoncogenes in ovarian cancer
The HER-2/neu tyrosine kinase is a member of a family of related transmembrane
receptors, which encode a 185 kd transmembrane receptor that is highly homologous
with the EGF receptor (Tzahar E, et al. 1998). Over-expression of HER-2/neu has
been reported in 26 % of human ovarian cancer and has been shown to be associated
with poor prognosis in some studies (Berchuck A, et al. 1990; Slamon DJ, et al. 1989)
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but not all studies (Kacinski BM, et al. 1992; Rubin SC, et al. 1993). Amplification of
HER-2/neu has been demonstrated to be significantly associated with particular
histological cell types and higher histological grade (Seki A, et al. 2000). Some studies
also showed that over-expression of HER-2/neu may contribute to drug-resistance
(Yu D, et al. 1998) and poor response to chemotherapy (Yu D, et al. 2000; Nijman
HW, et al. 1999). It has been shown that transfection of HER-2/neu into normal
ovarian epithelial cells can induce a malignant phenotype in vitro including the ability
of cells to grow in an anchorage-independent fashion and to form tumours in nude
mice. Conversely, monoclonal antibodies that interact with HER-2/neu can decrease
growth of breast or ovarian cancer cell lines that over-expression this receptor
(Pietras RJ, et al. 1998; Rodriguez GC, et al. 1993 ). Introduction of the viral El gene
downregulates HER-2/neu expression and inhibits growth of ovarian cancer cell lines
that over-express HER-2/neu, and also increases sensitivity to the cytotoxic effect of
paclitaxel (Yu D, et al. 1998).
Ras genes encode 21-kd proteins that localize to the inner aspect of the cell
membrane and have intrinsic GTPase activity. It is estimated that point mutations in
Ras genes are present in about 1/3 of cancers (Kinzler KW and Vogelstin B. 1997). In
human cancer, activating mutations in Ras are observed at codonsl2, 13, or 16. The
encoded amino acids at these three locations appear to play a critical structural role in
the active site of Ras, such that missense mutations at one of these codons destroys
the ability of Ras to correct GTP to GDP, which then chronically transmits its
growth stimulatory signal. In epithelial ovarian cancer, the most frequently observed
ras-mutation is that of K-ras codon 12. The incidence of K-ras mutations at codon 12
is 23 % to 63 % (Cuatrecasas M, et al. 1997; Suzuki M, et al. 2000), and associates
with mucinous ovarian cancer (about 50 %) (Suzuki M, et al. 2000), and correlated
with the malignant potential of the neoplasms ( Varras MN, et al. 1999) K-ras
mutations are also common in borderline epithelial ovarian tumours, occurring in 20
% to 50 % cases (Mok SC, et al. 1993). This suggess that K-ras mutational activation
is an early event in ovarian tumorigenesis.
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The alpha llOKd subunit of phosphatidy inositol 3 kinase (PI3 kinase) is amplified
in at least 80 % of ovarian cancer, and associated with increased kinase activity.
Inhibition of kinase activity can slow growth of ovarian cancer cell lines, and
consistent with the possibility that signalling through this pathway is important for
regulation of cell proliferation and/or apoptosis (Shayesteh L, et al. 1999). Recently,
the study also showed that PI3 kinase antagonists could inhibit cell growth and
tumorigenicity in human cancer cell lines (Razzini G, et al. 2000). The AKT serine-
threonine kinases are activated by the products of PI3 kinase and can inhibit
apoptosis by phosphorylating BAD and/or caspase 9, and amplification or over-
expression of AKT occurs in 14.4 % of ovarian cancers. Furthermore, a significant
correlation was observed between amplification and over-expression of AKT and
undifferentiated histology and median survival of patients (Bellacosa A, et al. 1995).
Amplification of the C-myc oncogene occurs in some epithelial ovarian cancers. C-
myc was reported to be amplified in 31 % of epithelial ovarian cancers (Aunoble B,
et al. 2000). In a recent study in which 51 epithelial ovarian cancers were analysed, a
similar incidence of C-myc over-expression was observed (37 %). In this study, C-
myc over-expression was more frequently observed in advanced stage serous cancer
(Tashiro H, et al. 1999).
1.4.3.3 Alteration ofgrowth factors in ovarian cancer
Growth of ovarian cancer can be stimulated by several peptide and lipid growth
factors. Peptide ligands that bind to the epidermal growth factor receptor (EGFR) are
produced by ovarian cancers including EGF, transforming growth factor alpha (TGF-
a ), and amphiregulin (Stromberg K, et al. 1994). Three factors have been identified in
ovarian tumours and cancer cell lines. TGF- a is reported to be present in 50 % to
100 %, EGF in 28 % to 71 % and amphiregulin in 18 % of malignant ovarian tumours
(BauknechtT, et al. 1990; Morishige K, et al. 1991; Stromberg K, et al. 1994). TGF-
a and EGF stimulate the growth of ovarian cancer cell lines in vitro, indicating that
these factors are mitogenic for this disease (Morishige K, et al. 1991; Crew AJ, et al.
1992). Antibodies against TGF- a can inhibit the growth of ovarian cancer cell lines
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that continue to express EGFR, consistent with autocrine growth stimulation
(Stromberg K, et al.l 992).
The transforming growth factor-P (TGF- (3) is involved in cell growth regulation,
tissue remodelling, angiogenesis and immune suppression. Three forms of TGF-J3
have been identified in human systems, TGF- (3 1, 2 and 3. TGF-|3 can inhibit
proliferation of normal ovarian surface epithelial (OSE) cells (Henriksen R, et al.
1995). During malignant transformation, expression of TGF- |3 is lost in 40 %,
interrupting potential autocrine growth inhibition (Flurteau JA, et al. 1999). In
different cancer cell lines that have been established in culture, exogenous TGF- (3
can inhibit, fail to affect or even stimulate growth (Berchuck A, et al. 1992). When
ovarian cancer cells are isolated directly from ascites fluid, growth can still be
inhibited with TGF- P in more than 90 % of specimens (Flavrilesky LJ, et al.l995).
In primary ovarian cancer, mRNA for three isoforms, TGF- P 1, 2, and 3 has been
detected in 46 %, 66 % and 66 % respectively of malignant tumours, the predominant
pattern of expression being either dual or triple co-expression (Bartlett JM, et al.
1997). The TGF- P2 receptor was present in over 90 % of samples. Patterns of
expression were similar between malignant, borderline and benign tumours. TGF- P 3
was associated with advanced stage and reduced survival, suggesting that perhaps the
influence of this factor on angiogenesis and other features of tumour progression are
more significant than direct inhibitory effects on growth (Bartlett et al. 1997). In
support of this, an association between TGF-P expression and features of
angioenesis in ovarian tumours has been identified. (Nakanishi Y, et al. 1997).
1.4.4 Attachment Invasion, metastasis and angiogenesis
Although the mechanisms and regulation of metastasis are still unclear, the complex
process of invasion consists of multipl steps. These steps mainly include that during
tumour progression, tumour cells detach from the primary tumour and then attach to
underlying basement membrane, invade the local stroma, degrading the extracellular
matrix components, and move into adjacent blood vessels. Then neoplastic cells
circulate in the bloodstream until they become attached to the wall of a blood vessel.
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This is followed by secretion of proteases to generate access through the vessel wall,
after which cells invade surrounding tissues, where they proliferate and form a new
tumour mass. In ovarian cancer, locoregional peritoneal dissemination rather than
blood-borne metastasis represents the major problem in tumour progression
1.4.4.1 Tumour cell detachment and adhesion
In order to invade, a tumour cell first has to detach from its neighbour and then attach
to the underlying basement membrane. During the invasive cascade, both cell-cell
and/or cell-stroma interactions play an important role. Connection through cell
adhesion molecules, integrin, and cadherins stabilize tissue integrity, whereas loss or
alteration of these cell surface proteins has been shown to be associated with
increased metastatic potential (Varner JA, et al. 1996). Cell polarity and organization
during spreading and migration are regulated by cell interaction with extracellular
matrix proteins through the integrin family, and with other cells through the
cadherins. Activation of these factors passes signals from the outside into the cell and
thus directs cell behaviour.
Cadherins are transmembrane glycoproteins that mediate extrcellular calcium-
dependent cell interaction and are involved in epithelial cell-cell communication. In
one study, a decrease of E- cadherin expression in ovarian surface epithelial cells
caused a reduction in cell adhesiveness during progression of the transformation of
ovarian surface epithelium to ovarian carcinoma (Hoffman AG, et al. 1993). E-
cadherin has also been demonstrated to function as a metastasis suppressor molecule
in several cell lines (Semb H, et al. 1998; Vleminckx K, et al. 1991).
Integrins are heterodimeric protein complexes, which link cytoskeletal microfilaments
(e.g. Actin, vinculin and talin) to extracellular matrix protein such as laminin,
fibronectin, collagen and vitronectin. Integrins mediate their binding through a specific
tripeptide motif, and this tripeptide has been shown to inhibit tumour cell invasion
in-vitro and in-vivo. A balance of integrin expression is thought to be required for
optimal invasiveness of tumour cell. Integrin under-expression does not allow tumour
cells to adequately attach to the basement membrane (Aznavoorian S, et al. 1993).
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Similarly, intcgrin over-expression may inhibit the capacity of tumour-cells to dis-
attach from the basement membrane and therefore render those cells less invasive
(Giancotti FG and Ruoslahti E. 1990). until now, integrins have not only been
identified as cell adhesion molecules but also are recognized as signalling molecules for
regulation of apoptosis ( Meredith JB Jr, et al. 1996; Kheradmand F, et al. 1998), gene
expression (Lafrenie RM and Yamada KM. 1998), cell proliferation (Porter JC and
Hogg N. 1998), invasion and metastasis (Joseph-Silverstein J and Silverstein
RL.1998), and angiogenesis (Friedlander M, et al. 1995).
Over expression of a specific 67kD laminin receptor (67LR) has shown to be
important for cancer cell adhesion to and invasion into the extracellular matrix (Liotta
LA, et al. 1984) and also with progression of various cancers (Pellegrini R, et al.
1995). Expression of 67LR has been shown to be increased in patients with
progressive ovarian cancer (van den Brule FA. 1996).
1.4.4.2 Basement membrane degradation by tumour cells
To be successful with the invasion process, tumour cells have to secrete enzymes
that degrade the extracellular matrix barriers. Overexpression of one or more of these
enzymes has been shown to occur in almost all cells of the tumour-host environment.
Degradation of the basement membrane is not dependent solely on the amount of the
proteolytic enzymes present, but on the balance of activated proteases and their
naturally occurring inhibitors (Liotta LA, et al. 1991). A positive correlation with
tumor aggressiveness has been shown for a variety of degradative enzymes, including
heparanase, and seryl-, thiol-, and metal-dependent enzymes (Price JT, et al. 1997).
Many investigations have shown that matrix metalloproteases (MMPs) play an
important role in tumour cell invasion across the basement membrane (Huang LW, et
al.2000). MMPs are a family of neutral enzymes secreted as latent proenzymes.
There are five subclasses grouped according to substrate specificity: interstitial
collagenases, gelatinases, stromelysins, membrane type-MMPs, and elastases.
Increased MMP activity has been detected and shown to correlate with invasion and
metastic potential in a wide range of cancer, including ovarian epithelial cancer (Liotta
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LA, et al. 1991). Fishman et al showed that epithelial ovarian carcinoma cells derived
from primary ovarian tumours, metastatic lesions, or ascites overexpressed MMP-2
and MMP-9 (Fishman DA, et al. 1997). The results of another study showed that
MMP-9 expression in tumour cells was found to be significantly enhanced in serous
and mucinous ovarian carcinomas compared with benign and borderline tumours
(Huang LW, et al.2000). MMP-7 was also found to be overexpressed frequently in
mucinous ovarian cancer (Shigemasa K, et al.2000). MMPs are inhibited by a family
of five endogenous inhibitors known as the tissue inhibitors of
metalloproteases(TIMPs) (Gomez DE,et al.1997). The balance between the levels of
activated MMP and free TIMPs determines the balance between matrix degradation
and matrix formation. Altering this equilibrium affects the progression of the invasive
phenotype. It has been shown that TIMP-2 can inhibit bFGF-induced stimulation of
endothelial cell proliferation independent of its ability to inhibit MMP activity
(Murphy AN, et al. 1993). MMPs and their inhibitors have been demonstrated to be
present in most epithelial ovarian carcinoma and molar ratios of TIMP-l/MMP-9
and TIMP-2/MMP-2 were higher in the adenoma category (Furuya M, et al.2000).
TIMP-1 and TIMP-2 have been shown to inhibit tumour-induced angiogenesis in
experimental systems (Gomez DE, al.1997).
Plasminogen activators (PAs) are serine-specific proteases that convert inactive
plasminogen to active plasmin, a trypsin-like enzyme that degrades a variety of
proteins, including fibrin, fibronectin, type IV collagen, vitronectin, and laminin.
Plasminogen activator exists in two forms: tissue-type plasminogen activator(tPA),
the primary plasminogen activator in plasma, and urokinase plasminogen activator
(uPA) uPA is involved primarily in cell-mediated proteolysis during macrophage
invasion, wound healing, invasiveness, and metastasis (Conese M and Blasi F. 1995).
Production of uPA in normal ovarian epithelial cells was reported as 17-to 38-fold
lower than that found in ovarian carcinoma cells (Moser TL, etal.1994). Pedersen et
al demonstrated increased uPA-receptor expression in ovarian tumours associated
with short overall survival of patients (Pedersen H, et al. 1994). The interaction of
uPA and its receptor plays an important role in direct and indirect extracellular matrix
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degradation, thus potentiating invasive events (Miyake H, et al. 1999). The action of
uPA can be counteracted by several naturally occurring inhibitors of the uPA/plasmin
system, such as plasminogen activator inhibitor-1 (PAI-1) and plasminogen activator
inhibitor-2 (PAI-2). Elevated expression of uPA and its inhibitor (PAI-1) in tumour
extracts of ovarian cancer has been associated with increased invasion, increased
incidence of relapse, and shorter overall survival (Schmitt M. et al. 1995).
Furthermore, several studies have shown a correlation in which both uPA and PAI-2
levels were associated with a poor prognosis in advanced ovarian cancer, whereas
higher levels of PAI-2 only was associated with better prognosis and less
disseminated disease (Chambers SK, et al. 1995).
1.4.4.3 Tumour cell migration
The process of tumour cell migration is very complex. Studies has shown that
proteolysis alone cannot be responsible for the entire invasion cascade. Therefore
after degrading the basement membrane, the tumour cell must actively migrate to the
adjacent tissue compartment that it will occupy. Cell motility begins with
polarisation and orientation of the cell followed by formation of pseudopodia, a
membrane extension, at the cell's leading edge. The pseudopium then forms
attachments with the ECM and produces a contractile force to move the cell forward
by a series of attachment and dis-attachment steps including cellular receptors that
bind the matrix, and specific signals that give direction and urgency to migration,
including extracellular matrix components, growth factors, scatter factors, and
tumour-secreted factors. Examples of growth factors that stimulate tumour cell
motility include the insulin-like growth factors (IGF-I, -II), hepatocyte growth factor
(F1GF), and the fibroblast growth factors. IGF-I has been shown to induce a
chemotactic response in human ovarian cancer (Kohn EC, et al.1990). HGF is a
paracrine motility factor that acts at picomolar concentrations to stimulate motility
of epithelial cells (Stoker M, et al. 1991). The cell surface-associated ectokinase,
autoxin (ATX), a potent motility-stimulating glycoprotein, may stimulate motility
directly by binding a cell surface receptor (Clair T, et al. 1997). Furthermore, some of
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tumour cells have to survive the stage of vascular transport and arrest in capillary
beds of distant organs to engage in a second round of invasion and extravasation,
whereby neoplastic cells exit from the vessel lumen into the surrounding stromal
tissue (Quigley JP, et al. 1998).
1.4.4.4 Angiogensis
Angiogensis, the formation of new blood vessels from a pre-existing vascular
network, has been shown to be essential to tumour survival (Folkman J. 1992).
Angiogenesis is a multistep process. It involves endothelial cell vascular sprouting,
these sprouts then elongate and invade into local stroma toward the tumour.
Furthermore, these neovessels develop lumens and connect with existing vascular
networks as functional capillaries. Augiogensis of tumour has correlated with
progression-free survival, overall survival, and the presence of locoregional
dissemination in ovarian cancer (Paley PJ, et al. 1997).
Angiogensis of tumour is regulated tightly by a network of inducing and inhibiting
factors under physiologic conditions, whereas in pathologic condition, such regulation
is altered or absent. The switch of endothelial cells from quiescence to rapid growth is
regulated by angiostimulatory and angiostatic signals (Hanahan. 1997). Numerous
angiostimulatory or angiostatic factors have been identified.
Vascular endothelial growth factor (VEGF) is the most notable angiostimulatory
factor. VEGF is a growth factor that stimulates vascular permeability (Ferrara N.
1995). The functions of VEGF are mainly to induce capillary tube formation; increase
vascular permeability, and stimulate endothelial cell migration (Ferrara N et al. 1992).
VEGF expression is upregulated in ovarian cancer (Paley PJ, et al. 1997) it has been
shown that VEGF is expressed selectively in tumour cells but not in endothelial cells,
indicating that VEGF is a paracrine mediator of angiogenesis. Many studies have also
demonstrated that there are significant associations between the VEGF expression
and invasion, metastasis and angiogenesis in ovarian epithelial cancer, and its
expression reflects tumour progression (Gadducci A, et al.1999; Shen GH, et
al.2000).
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1.5 The Role of Chromosome 11 in Epithelial Ovarian Cancer
The studies have demonstrated that the disruption of multiple genetic loci is
associated with epithelial ovarian cancer, and LOH on a chromosome can suggest the
presence of a tumour suppressor gene (TSG) at that locus. LOH in epithelial ovarian
cancer has been observed on every chromosomal arm (Lynch HT, et al. 1998). The
studies of LOH of chromosome 11 have shown that LOH of chromosome is
associated with the progression and poor prognosis of ovarian cancer, therefore, there
may be important TSGs involved in the progression of ovarian cancer on
chromosome 11 (Launonen V, et al. 1998; Gabra H, et al. 1996).
Studies of chromosome 11 microcell-mediated transfer have demonstrated that normal
chromosome 11 can inhibit the growth of cancer cell (O'Briant K, et al. 1997; Kugoh
H, et al. 2000). O'Briant et al used microcell-mediated transfer human chromosome
11 and lip into a human lung adenocarcinoma cell line and found that all four
chromosome 11-containing hybrid clones showed significantly reduced
tumorigenicity in nude mice and growth in liquid culture (O'Briant K, et al. 1997 ).
Kugoh ct al also reported that human bladder carcinoma cell line that contained
chromosome 11 by using microcell-mediated transfer showed a remarkable change in
cell morphology. They flattened and ceased growing, or senescenced, prior to
population doublings (Kugoh H, et al. 2000). These results support the hypothesis
that chromosome 11 contains one or more tumour suppressor genes.
In ovarian cancer, Rimessi and colleagues transferred chromosmes 3 and 11 into
ovarian carcinoma cell line HEY. The result showed that transfer of chromosome 3
induced senescence and growth arrest as well as suppression of tumorigenicity. But
the effect of chromosome 11 introduction into HEY cells was markedly different.
Cellular morphology and the immortalised phenotype were unaltered. However, the
in vitro growth rate and clonogenicity in soft agar were reduced. Tumorigenicity was
not consistently controlled by chromosome 11 transfer (Rimessi P, et al. 1994).
Although this study downgrade the role of chromosome 11 since it does not suppress
tumorigenicity in the nude mouse assay, the pattern that Rimessi's group and
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O'Briant's group observed in lung cancer cell lines might, in fact, be quite consistent
with the action of a late-acting tumour progression suppressor which although it does
not determine fundamental neoplasia, has more subtle effects not easily detected
using the crude assays available, perhaps reflected here in altered growth rate and
cloning efficiency, but nevertheless a powerful determinant of tumour progression.
Recently, YACs, one containing the candidate gene ATM at 11 q23.1, and two
contiguous YACs overlying most of the 1 lq25 deleted region, were used to transfect
into murine A9 fibrosarcoma cells. Selected transfectant clones were assayed for in
vivo tumorigenicity in c-nu/nu mice. All the 11 q YAC transfectant clones
demonstrated significant tumour suppression compared to the control (Koreth J, et
al. 1999) these results define tumour suppressor loci on chromosome 11 q by
functional complementation.
1.5.1 Loss ofheterozygosity of chromosome lip
Although no specific tumour suppressor genes for sporadic epithelial ovarian cancer
have been cloned, LOH studies have implicated a number of chromosomal sites as
regions harbouring potential tumour suppressor genes. Loss of normal TSGs may
allow for the expression of tumorigenicity or lead to tumour progression.
The frequency of LOH at chromosome 1 lp in ovarian cancer has been shown to peak
at chromosome 11 p 15 (Lu KH, et al. 1997; Weitzel JN, et al. 1994; Kiechle-Schwarz
M, et al. 1993; Viel A, et al. 1992; Zborovskayal I, et al. 1999; Eccles DM, et al.
1992; Gall ion HH, et al. 1992; Zheng JP, et al. 1991; Lee JH, et al. 1990), although
not all of these investigations have demonstrated this high level of loss (Zheng JP, et
al. 1991; Kiechle-Schwarz M, et al. 1993). Detailed mapping of this region identified
two separate minimal deleted regions in nonmucinous ovarian carcinomas. An 11 -cM
region on chromosome 1 lp 15.5-15.3 extending from D11S2070 to D11S988 including
the HRAS locus and a 4-cM region on 11 p 15.1, also defined by the marker
D11S1310. The frequency of LOH in these two regions are 43 % and 32 %
respectively, with an overall 39 % LOH for both regions (Lu KH, et al. 1997),
suggesting two novel candidate TSG loci. The proximal loci at 11 p 13 exhibits lower
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levels of LOH in ovarian cancer (Bruening W, et al. 1993; Vandammc B, et al. 1992;
Viel A, et al. 1992). Most of the studies have shown a significant correlation of chr
lip LOH with poorly differentiated (Lu KH, et al. 1997; Kiechle-Schwarz M, et
al. 1993; Zheng JP, et al. 1991) and more advanced (Viel A, et al. 1992) ovarian
cancer. Lu et al also reported that detection of 1 Ipl5.1 is strongly associated with
high-grade nonmucinous epithelial ovarian cancer (Lu ICH, et al. 1997). Table 1-5
outlines the major studies that have defined regions of LOH of chromosome 1 lp in
ovarian cancer.
Table 1-5 Ovarian Cancer Common LOH Regions on Chromosome
He
chromosome site loci % LOH
1 lp 15 T24-C3 35
1 lp 15 HINS214 29
1 lp 15 HRAS 38
11 p 15.1 D11S1310 32
1 lp 15.2 PTH 31
11 p 15.4 CALC 37
1 lpl5.5-15.3 D11S2070-D11S988 43
1 lpl 5.5 HBD /INH 30
11 p 13 S17/FSH/S16/CAT 29
Many candidate genes have been identified within these regions and the relationship
between the LOH of chromosome 1 lp 15.5 and 11 p 15.1 and some candidate tumour
suppressor genes have been investigated. For example, the TSGlOlgene, a proposed
tumour suppressor gene located on Chr lip 15.1, has been investigated in ovarian
cancer. Despite 32 % LOH in this region, the study's conclusion was that there was
no evidence to suggest that inactivation of this putative tumour suppressor gene
played a role in the pathogenesis of ovarian cancers (Carney ME, et al. 1998). The
major literature about candidate genes within these regions as well as relationship
with ovarian cancer is summarised in Table 1-6
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Table 1-6 Candidate Genes within Chr llpl5.5 or llpl5.1 and The
Relationship with Ovarian Cancer
Gene Location Major function Relationship with
at 1 lp ovarian cancer
p57 15.5 Blocks the growth of human No study in ovarian
astrocytomas and induces cell cancer
senescence(Tsugu A,.et al.2000)
SSSA/R052 15.5 Putative tumour suppressor gene No study in ovarian
in lung cancer (Kim YC, et al.2000) cancer
H19 15.5 Putative growth suppressor gene Express and LOH in
regulating IGF-1I (Feinberg AP. the majority of serous
1999) epithelial tumours.




et al. 1999; Kim HT, et
al. 1998)
TSSC1/TSSC3 15.5 Tumour suppressing
TSSC4/TSSC6 subtransferable No study in ovarian
candidates(Hu RJ, et al. 1997) cancer
IGF2 15.5 Autocrine regulator of cell pro¬ Loss of IGF-II
liferation (Muller S, associating with
et al 2000 advanced ovarian cancer
(.Chen CL, et al. 2000 )
SPN 15.5 Suppressing cell cycle entry, and No study in ovarian
inhibiting cell proferation(Zang X, cancer
et al. 1999)
MTR1 15.5 Homology to MLSN1, which is No study in ovarian
downregulation in melanoma cancer
(Prawitt D,et al.2000)
p27/KIP 15.5 Cyclin dependent kinase inhibitor Frequent downregul¬
negative regulator of cell pro¬ ation and associated
liferation (Desdouets C with worse prognosis
and Brechot C. 2000) (Sui L, et al. 1999)
TSG101 15.1 Putative tumour suppressor gene No evidence to
(Carney ME, et al. 1998) suggest that loss of
this putative tumour
suppressor gene play
a role in pathogenesis
of ovarian cancers
(Carney ME, et al.1998).




(Baker ME, et al.2000)
CLP 15.1 Cardiac LIM protein, regulating
growth inhibition (Charpentier
E, et al. 2000
No study in ovarian
cancer
KAI-1 15.2 Putative metastasis suppressor in
prostate cancer (Maraj BH, et al.
2000)
Frequent downregul-




WT1 13 Responsible for tumour suppress
in Wilms tumor
(OjiY,etal. 1999)
No mutation in ovarian
cancer(Bruening W, et
all 993)
1.5.2 Loss ofheterozygosity ofchromosome llq
Although proximal allele imbalance at 11 ql 3 has been reported for ovarian cancer, the
frequency of LOH at 11 ql3 showed low levels, about 14 % to 25 % (Foulkes WD, et
al. 1993; Weitzel JN, et al. 1994; Emmert-Buck MR, et al. 1997), suggesting that
LOH at this region is less important in ovarian cancer.
Distal allele imbalance at 1 lq in ovarian cancer was first reported by Foulkes et al at
1993 (Foulkes WD, et al.l 993). Since then, other investigators have also reported
LOH at distal llq in ovarian cancer. A notable feature of these studies was the
definition of several regions of LOH with the interval Ilq22-q25 (Launonen V, et
al. 1998; Watson RH, et al. 1997; Gabra H, et al. 1996; Davis M, et al. 1996; Foulkes
WD, et al. 1993). These results are outlined in Table 1- 7
Table 1-7 Ovarian Cancer Common LOH Regions on Distal
Chromosome llq
chromosome site loci % LOH
1 lq22-23.3 S85/STMT-1/S144/S29 /CD3D 40
/SI 47
11 q24.1 SI 47 67
1 lq22-23.2 D11S35-D11S933 42
1 lq23.3-24.3 D11S934-D11S1330 65
1 lq23.3-qter D11S925-D11S1336 54
D11S912-D11S439 49
1 lq23.3-24.1 D11S1336-D11S1328 34
1 lq22.3-25 D11S1340-D11S912 61
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Furthermore, the relationship between LOH of chromosome llq22-25 and clinical
significance has been investigated. The analysis of LOH from the Ilq22-q25 region
between D11S35 and D11S968 in 40 ovarian tumours revealed that there were two
distinct regions of loss, a large centromeric region between D11S35 and D11S933
(1 Iq22-q23.3) and atelomeric 8.5-Mb region lying between D11S934 and D11S1320
(1 lq23.3-24.3). Specifically, LOH of the latter region (chrllq23.3-24.3) was
significantly associated with poor survival in ovarian cancer patients (Gabra H, et
al. 1996). This was the first evidence showing this relationship with chromosome
1 lq22-25 region in ovarian cancer. More recently, another clinical study of LOH of
chromosome llq23-25 in ovarian cancer further confirmed this result. In this
investigation, LOH was detected in 61% of the patients. LOH at 1 lq23.3 seemed to
be associated with significantly reduced survival times (P = 0.005) and serous tumour
histology (P = 0.036). LOH of at the more distal 1 Iq24-q25 location correlated with
a higher tumour stage (P = 0.003), serous tumour histology (P = 0.015), and the
finding of residual tumour (P = 0.047)(Launonen V, et al. 1998). These results further
indicate that gene associated with prognosis in ovarian cancer would be located at
1lq23-25.
Many candidate tumour suppressor genes have been identified within these regions.
Some of them have been analysed in ovarian cancer. The major literature about
candidate genes within these regions as well as the relationship with ovarian cancer is
summarised in Table 1-8.
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Table 1-8 Candidate Genes within Chr 11 q and The Relationship
with
Ovarian Cancer
Gene Location Major function Relationship with
at 1 lq ovarian cancer
ATM 22-23 Plays acritical role in maintaining





PPP2R1B 23-24 Candidate tumour suppressor gene
(Wang SS,et al. 1998)
Infrequent mutations of
the gene in ovarian
cancer(Wu R,et al. 1999)
PGR 22-23 Progesterone receptor gene,
putative tumour suppressor gene
(Lancaster JM.1998)
Inhibitor role on breast
and ovarian cancer
(Rowe SM, et al. 1995)
IGSF 23.2 Putative tumour suppressor gene
immunoglobulin superfamily gene
(Gomyo H, et al. 1999)
No study in ovarian
cancer
NPAT 22-24 Putative tumour suppressor gene
(Imai T, et al. 1997)
No study in ovarian
cancer
CHK1 23-24 Encoding a protein kinase required
for DNA damage checkpoint
function (Sanchez Y, et al. 1997)
No study in ovarian
cancer
PIG8 24 p53-target gene, ply an role in
negative cell growth control by
functioning as an apoptotic
effector of p53 activity
(Gu Z, et al. 2000)
No study in ovarian
cancer
APLP2 24 Encoding a human sperm membrane
protein (Leach R, et al. 1999)
No study in ovarian
cancer
KCNJ1 24 Encoding various isoforms of the
human poassium channel
(Bock JH, et al. 1997)
No study in ovarian
cancer
SNC19 24-25 Putative tumour suppressor genes
(Zhang Y, et al. 1998)
No study in ovarian
cancer
MEN1 13 Encoding a putative growth-
supptrssor protein, menin
binding JunD, a transcriptional
factor belonging to the AP-1
complex, involving in
deregulation of the RET-
signalling pathways
(Calender A.2000)
No study in ovarian
cancer
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1.6 The Role of Homeobox Genes in Neoplasms
Homeobox genes are a large family of genes that contain a common 183-nucleotide
sequence, first identified as a common feature of several classes of genes known to
control developmental pathways in Drosophila (McGinnis W, et al, 1984). They
encode a 60-amino-acid protein domain, The homeodomain, responsible for
recognition and binding of sequence-specific DNA motifs (Gehring WJ, et al. 1992),
and act as transcriptional modulators. It is the co-ordinate regulation of network of
genes, both temporally and spatially, that leads to establishment of normal
segmentation and differentiation patterns in the embryo (Hunt P and Krumlauf
R.1992).
The relationship between homeobox genes and cancer still remains unclear. However,
the hypothesis of an association between homeobox genes and the oncogenic process
has been strengthened by a number of observations. Many studies have demonstrated
that homeobox genes are involved in many cancers such as leukaemia, breast, kidney,
lung, colon and so on. First; constitutive expression of some homeobox genes can be
oncogenic in mice (Aberdam D, et al. 1991). Second; comparing with normal organs,
the alteration in expression patterns of several homeobox genes have been reported in
variety of malignant lesion (Cillo C, et al. 1999). Third; co-ordinate regulation of
homeobox genes has been showed to play an important role in human cancer cell
differentiation (Scott MP. 1997). Finally; functional analysis of homeobox genes in
cancer cell lines showed that several homeobox genes are upregulated in cancer cell
line, but other are downregulated and may function as tumour-suppresser genes (Gao
AC, et al. 1998).
1.6.1 Homeobox Genes: Genome Organization and Roles in
Development
Different homeobox gene families have evolved that encode the homeodomain (HD)
(Duboule D and Morata G. 1994). Among these, the Drosophila Antennapedia (Antp)
HD defines a consensus sequence referred to as a class I HD and these are also
known as the clustered homeobox genes. They are organized in four genomic clusters
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of approx 100 kb in length, each of cluaster containing several homeobox genes
arranged in linear order. To date, 39 of Hox gene shas been defined by virtue of their
homology with the genes of this homeotic complex of Drosophila (Deschamps J and
Meijink F.1992). The Drosophila clusters are referred to as HoxA, HoxB, HoxC, and
HoxD. They are localised to chromosomes 7,17,12 and 2 respectively and comprise
9-11 genes per cluster arranged linearity (Innis JW. 1997) (see Figure 1-1).
Figure 1-1 Schematic Representation of Four Hox Loci
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In mammalian embryos, clustered homeobox genes start to be expressed at
gastrulation. They collectively control the identity of various regions along the body
axis from the branchial area through to the tail (Graham A, et al.1989). This action
occurs following the rules of temporal and spatial colinearity, with 3' homeobox
genes expressed early in development and controlling anterior regions, followed by
progressively more 5' genes expressed late in development and controlling more
posterior regions ( Dekker EJ, et al. 1992). In particular, the 3' homeobox genes of
groups 1 to 4 primarily control the development of the embryonic region
corresponding to the hindbrain (Lumsden A, et al.1996). Central homeobox genes of
group 5 to 8 control the thoracic portion of the body, whereas 5' homeobox genes of
9 to 13 control the lumbosacral region. This spatiotemporal colinearity also holds for
Drosophila homeotic genes (Duboule D and Morata G. 1994). The physical
organization of clustered homeobox genes appears essential for their expression and
responsible for major biological function probably yet to be identified. The entire
clustered homeobox genes are expressed in the embryonic central nervous system
(Giampaolo A, et al. 1989). The many functions of Hox genes in development are
outlined in Table 1-9
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Tablel-9 The Function of the Clustered Homeobox Genes in
Normal Development
Gene Function
Hox Al, B1 and D1
HoxA2 and B2
HoxA3 and D3
Hox A4, B4, C4, and D4
Hox A5, B5 and C5
Hox A6,B6 and C6
Hox A7 and B7
HoxB8, C8 and D8
HoxA9, B9, C9 and D9
Hox A10, CIO and D10
HoxAl 1 and D11
HoxC12 and D12
HoxAl3, B13, C13 and D13
Playing a key roles in anteroposterior axis formation and
being detected extensively throughout the embryo in the
neural tube adjacent mesenchyme, paraxial mesoderm,
somites and gut epithium and bcaudal region of the
embryo (Mark M, et al. 1993).
Controlling dorsoventral rat patterns of neruronal
development in rostral hindbrin and normal sternum
morphology. (Davenne M, et al.1999).
Neural-crest-derived and somatic -
mesoderm-derived tissue (Manley NR, et al. 1997).
Plays a main role in conferring positional information
along the anteroposterior axis to specify the identity of
the third and seventh vertebrate.(Graham A, et al. 1988;
Horan GS, et al 1994; Kuliev A, et al .1996;)
A role in the generation of tissues derived from or induced
by the embryonal mesoderm (Fuller JF, et al.1999).
Acting as genetic controller of multiple genes involved in
development and cell differentiation (Malicki J,et
all 990).
A role in the assignment of positional identity along the
axis of the embryo(MahonKA, et al.l 988), and
regulating gene transcription in hematopoietic and
lymphoid tissues (Deguchi Y, et al.l 991).
Being necessary for formation of limbs(Izpisua-Belmonte
JC, et al. 1990). and playing a key role in regulation
of cartilage differentiation (Yueh YG, et al.1998).
Having both specific and redundant functions
in lumbosacral axial skeleton patterning and in limb
morphogenesis at the stylopodal level. (Fromental-
Ramain C, et al.l996; Chen F, et al.l997), controlling
development of the mammary gland in response to
pregnancy (Chen F, et al. 1999), and playing a role in
T-cell development(Izon DJ, et al. 1998; Lawrence
HJ, et al.l997).
Having a key role in the morphogenesis of the urogenital
mesenchyma(Kolon TF, et al.l999),in regulating
endometrial development during the menstrual cycle
(Osborne J, et al. 1998) and formation of hindlimb
(Peterson RL, et al.l993).
A role in endometrial development, implantation, and
maintenance of pregnancy (Morgan, et al.l 992) and
invloved with spleen development Davis AP, et
al.1995).
Role for the Hox-D12 gene during endoderm
differentiation in teratocarcinoma embryoid bodies
(Labosky PA, et al.l993).
Playing a key role in limb development)( Godwin AR and
Capecchi MR. 1998)
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Other type of homeobox genes are non-clustered or divergent homeobox gene, named after
their Drosophilahomologs: paired, empty spiracles, orthodenticle, and muscle segment
homeobox genes (Duboule D, 1994). They are scattered throughout the genome and fall into a
number of groups on basis of the similarity of sequence. To date, more than 150 non-
clustered genes have been cloned and identified (Manak JR and Scott MP. 1994) The main
roles of divergent homeobox genes in development are outlined in Table 1-10



















Multiple function in the differentiation and proliferation of cell
during embryogenesis.
As a transactivator of the GH and PRL genes, and as a regulator
of the TSH beta gene (Pellegrini- Bouiller J, et al.1997).
Involvied in cell cycle regulation (Verrijzer CD, et al.1990).
Stimulating B-cell-restricted expression of immunoglobulin
genes through binding sites in immunoglobulin gene promoters
and enhancers (Corcoran LM and Karvelas M. 1994).
Hierarchy of regulator genes (Ovitt CFand Scholer HR. 1998).
A major transcription regulator in Schwann cell
differentiation (Blanchard AD, et al. 1996)
Play a role in nervous system during embryogensis
(Hagino-Yamagishi K, et al.1998).
Involved in the control of development and
expressed in the CNS and paraxial mesoderm and
its derivatives (Torban E and Goodyer P.1998; Eccles.1998).
Play a general role in dorsal-ventral patterning of appendages
and the central nervous system (Ahlgren U, et al 1997).
A role in the terminal differentiation of the intestine
(Bonner CA, et al. 1995).
Play an important role in the proliferation and differentiation of
intestinal epithelial cells (Valcanis H, et al.1997).
A function related to signalling at the adherent
junction and possibly with other more complex roles in
cells committed to terminal differentiation (Midgley CA, et
al.1997). Being a tumour suppresser gene (Polakis P. 1999).
Involved as regulator with Hox genes in segmental identity
(Vollbrecht E, et al.l991).
Being required for normal development of the
mid/hindbrain region, and its function appears to be
necessary at the neural plate stage for the correct specification
and normal proliferation or survival of anterior hindbrain
precursors (Wassarman KM, et al.1997).
Involved in coordinated gene expression during embryonic
development and as transcriptional regulator of genes encoding
several cell adhesion molecules.
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1.6.2 Therelationship between homeoboand cancer
It is now well established that many cancers arise from a disruption of the normal
programme of cell growth and differentiation. Therefore, based on the role of
homeobox genes as important development regulatory genes, it has been proposed
that homeobox genes may be important in oncogenesis (Blatt C. 1990; Castronovo V,
et al. 1994).
1.6.2.1 The Hox genes in cancer
1.6.2.1.1 The expression pattern ofHox genes in solid tumours
1.6.2.1.1.1 The expression of Hox genes in renal cell carcinomas
Hox B5 and Hox B9 are expressed in the normal adult kidney; however, the majority
and renal cell carcinomas tested do not show expression of these Hox genes (Cillo C,
et al. 1992;Barba, et al. 1993). Hox CI 1 is not expressed in normal kidney; however,
Hox Cll transcripts are present in renal cell carcinomas (Cillo C, et al. 1992).
Whereas HoxD4 transcripts are normally found in adult kidney, only a subset of
these transcripts are frequently found in the renal cell carcinomas (Barba D, et
al.1993). Furthermore, in Wilms'tumor, there are also different expression patterns
compared with normal adult kidney. Two abundant HoxCll transcripts were
detected, whereas HoxCll expression is generally undetected in normal kidney
(Cillo C, et al.1992). Another study showed that the epithelial Wilm's tumour
expressed only an aberrant 0.3 kb HOXDIO transcript (Redline RW, et al.1994).
1.6.2.1.1.2 The expression of Hox genes in colorectal carcinomas
In the normal colon, Hox Al through 4 are usually expressed; but they are often
silent in colorectal carcinomas, and Hox D11 is overexperssed in colorectal
carcinomas compared with normal colon (De Vita G, et al.1993; Barba D, et
al.1993). Hox B7 and Hox D4, both of which are expressed in the normal colon,
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demonstrate altered transcript patterns in some colorectal carcinomas (De Vita G, et
al.l 993). HoxA7and HoxDll exhibit altered expression in metastatic lesions
compared with primary colorectal and normal intestinal mucosa. Novel transcripts
are expressed or different amounts of mRNA is observed in metastastic as oppose to
primary colon cancer. In contrast, HoxA13 and HoxB9 display identical expression
pattern in normal colon, primary colorectal cancer and corresponding liver
metastases when these are derived from a single patient, whereas these genes are
silent in the corresponding normal liver (Barba D, et al.1993). So in the same tumour
model, Hox genes may exhibit an organ-specific function. Furthermore, human
HOXB6, B8, C8 and C9 are overexpressed at various stages of colorectal carcinomas
and HOXB8 has been shown to interact with the tumour suppressor genes involved
in colorectal cancer such as APC (Vider BZ, et al. 1997).
1.6.2.1.1.3 The expression of Hox genes in lung cancer
Studies have analysed the expression of the whole Hox gene network in human small-
cell lung cancer (SCLC) because this tumour type originates from the neural crest.
Attention was paid to the relationship between the expression pattern of Hox genes
and tumour progression as well as the histological type. The results showed: a) in
primary and metastases of classic histology, no major differences in HOX genes
expression with regard to both the number of active genes and the transcript classes
were identified. Only minor differences at the level of individual genes, mostly
concentrated at the 5'end of the HOXC and D loci were identified in SCLC. The
over-all number of active HOX genes was remarkably constant, b) In the primary
tumour derived from variant histology, virtually the entire HOXB locus was
expressed but HOXB4 was silent, two blocks of 3 genes in the HOXC locus (C8, C9
and CIO) and in HOXD locus (D9, D10 and D11) were silent in half of the samples.
Compared with the primary tumour, metastases showed dramatic changes. Two Hox
loci, HOXB and C, were almost completely silent, in which HOXB4 and HOXC5
were barely detectable, c) Comparing classical with variant SCLC in the metastases,
25 out of 38 HOX genes were switched on in the classical type whereas the variant
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type displayed only 19 active genes. HOXA1, A6 and A10 were expressed in the
classical type but turned off in the variant type. HOXB5 and B6 were silent in the
classical type but active in the variant. Conversely, the HOXB7 was active in
classical but silent in variant type. HOXD9 and Dll were expressed in the classical
but were switched off in the variant (Cillo C.1994). These results indicated that
classical and variant histologic type and different tumour progressive stage displayed
differential patterns of HOX gene expression and highlighted that HOX genes are
switched off during variant SCLC progression. Another report analysed the
expression of HOX genes in primary and metastatic human small-cell lung cancer
(SCLC) xenografted in nude mice, in order to investigate whether HOX gene
expression correlates with the histology and stage of SCLC progression. The results
showed that different SCLCs display differential patterns of HOX gene expression.
Furthermore, in SCLC, the number of actively expressed HOX genes might be
substantially lower in metastatic cancers than in primary tumours. The alteration in
HOX gene expression in SCLCs mainly concerns the HOX B and C loci (Tiberio C,
et al.1994). This finding suggests that downregulation of HOX genes may play a role
in small-cell lung cancer progression, possibly through their implication in tumour
suppression.
1.6.2.1.1.4 The expression of Hox genes in breast cancer
The first report regarding the role of Hox genes in breast was a study in normal and
neoplastic mouse mammary gland. These results showed that the members from each
of the four major Hox gene clusters were expressed in normal mice mammary but in
mammary adenocarcinomas and in transplant lines of the benign, precancerous tissues
from which the cancers arose, Hoxc-6 was expressed at low levels in the precancerous
tissue and was not expressed in cancers. In contrast, Hoxa-1 was expressed only in
cancers, not in normal gland or in precancerous mammary tissues (Friedmann Y, et
al.1994), suggesting that Hox genes may play a role in a late stage in the stepwise
development of mammary malignancies. The study on expression of HOX genes in
human breast cancer cell lines revealed that HOXA1, HOXAIO, HOXB6and
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H0XC6 are expressed in breast cancer cell lines, and these genes are involved with a
role in the development and progression of human breast cancer (Castronovo V, et al.
1994). Furthermore, HOXA1 was over-expressed in a variety of human breast cancer
lesions (Chariot A and Castronovo V.1996). So HOXA1 may be required for the
establishment of breast cancer cells and alteration of HOXA1 expression could play a
role in breast cancer progression.
1.6.2.1.1.5 The expression ofHox genes in gynecologic tumours
mRNA expression of HOXDIO relative to beta-tubulin is significantly lower in
endometrial carcinomas than in normal endometrium. Furthermore, the ratio of
HOXDIO to beta-tubulin expression varies inversely with the histologic grade of the
tumour (P = .0009). Human HOXDIO gene expression is altered in endometrial
carcinoma and varies with the histologic grade of differentiation (Osborne J, et
al.1998). Also, HOXC5 and HOXC8 expression are selectively turned on in human
cervical cancer cells compared to normal keratinocytes (Alami Y, et al.1999).
1.6.2.1.2 The role of Hox genes in oncogenesis
The role of Hox genes in oncogenesis is still not very clear, but some lines of evidence
have suggested that Hox genes may have a role in oncogensis.
1), Constitutive expression of HoxB8 genes could be oncogenic in mice. HoxB8 gene
rearrangement was first detected in WEHI-3B mouse myeloid leukaemic cells. The
rearrangement is due to insertion of an intracisternal A particle 5' upstream to HoxB8
(Blatt C, et al.1988). Furthermore, that normal bone marrow cells were infected with
retroviruses bearing the genes for IL-3 or IL-3 plus HoxB8 showed that there was a
clear difference between bone marrow cells infected with IL-3 virus alone and cells
infected with the IL-3/HoxB8, both in vitro and in vivo. Soft agar growth of IL-3-
infected cells resulted in diffuse colonies due to migration of terminally differentiated
granulocytes and macrophages, whereas the cells infected with the virus containing
both genes formed large and compact colonies containing myeloid precursors and
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only few mature cells. Many of these colonies could be established as lines in liquid
culture. These results may indicate that HoxB8 expression impedes terminal
differentiation of bone marrow cells. Infection of mice with the IL-3/HoxB8 virus
resulted in aggressive leukaemia. All 16 animals transplanted with infected cells
developed myeloid disease that was aggressively tumorigenic, whereas IL-3 virus
provoked a non-transplantable myeloid hyperplasia (Perkins A, et al. 1990). The
results suggest that homeobox genes can regulate key differentiation processes such
as self-renewal capacity and that their inappropriate expression can be oncogenic.
2), NIH3T3 transfected with Hox B8 produced fibrosarcomas in nude mice. All 12
nude mice subcutaneously injected with the transfected cells developed fibrosarcomas
leading to the death of the animals after 4 to 6 months. Injection of the same cells
directly in the liver of mice led to more aggressive tumour, causing death within 6
weeks (Aberdam D, et al. 1991).
3), Blockade of HOX gene function using antisense oligonucleotides has revealed that
several HOX genes appear to influence either myeloid or erythroid colony formation
(Lawrence HJ, et al.1996).
4), Some HOX genes (HOXB2, HOXB4, HOXB7) that they are expressed in normal
tissue were methylated in xenografted small-cell lung cancers (Flagiello D, et al.1996),
suggesting a possible mechanism for gene silencing.
5), Antisense oligomers targeting HOXB7 mRNA markedly inhibited cancer cell lines
proliferation and specifically abolished expression of basic fibroblast growth factor
(bFGF) (Care A, et al.1996). Also, transfection of HOXB7 gene into SkBr3 cells,
breast cancer cells line, induced bFGF expression and increased growth rate of cancer
cell lines (Care A, et al. 1998). These indicate a key role for constitutive HOXB7
expression in cancer cell proliferation via bFGF.
6), Hox D3 was involved in angiogenesis because it could mediate conversion of
endothelium from the resting to angiogenic/invasive state (Boudreau N, et al.1997).
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1.6.2.2 Divergent homeobox genes in cancer
1.6.2.2.1 The POU homeobox gene family in cancer
Brn3 has been found to be not only highly expressed but also strikingly elevated in
the pituitary tumours and small cell lung cancer (Leblond-Francillard M, et al. 1997)
and use of retinoic acid and antisense against Brn-2 can enhance differentiation of P19
mouse embryonal carcinoma cells into smooth muscle cells (Suzuki T, et al.1996),
suggesting Bm genes may be oncogene.
OCT3 and OCT11 were expressed in both human breast cancer cell lines and human
primary breast tumours, but not in normal human breast tissue (Jin T, et al.1999).
Therefore, these genes could play role in mammary gland carcinogenesis, but their
role is unknown.
Although several investigators have reported Pit-1 gene expression in human
pituitary adenomas (Yamada S, et al.1996; Pellegrini I, et al.1994; Sanno N, et
al.1996), there was no correlation between Pit-1 transcripts and biological behaviour
or histological findings in pituitary adenoma (Yamada S, et al. 1996).
1.6.2.2.2 The PAX homeobox genes family in cancer
PAX5 is misexpressed in glioblastoma multiforme and was increased in a range of
astrocytomas (WHO grade II-IV) which originated in the forebrain. Expression of
PAX5 was limited to those cells which also expressed the oncogenes myc, fos, or jun
singularly or in combination. (Stuart ET, et al.1995) Its expression is inversely related
to the expression of p53 in the same neoplasms because PAX5 inhibits p53-
dependent transactivation. The human p53 gene harbours a PAX binding site within
its untranslated first exon that is conserved throughout evolution. PAX5 is capable of
inhibiting both the p53 promoter and transactivation of a p53-responsive reporter in
cell culture. Mutation of the identified binding site eliminates PAX protein binding in
vitro and renders the promoter inactive in cells (Stuart ET, et al.1995). PAX2 and
PAX8 are also able to interact in a similar manner with p53. According to the critical
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role played by p53 in the evolution of different types of cancer, the action of the
PAX genes in oncogenesis is crucial. On other hand expression of PAX3 has been
found in most of the specimens analysed of Ewing's sarcoma family of tumours,
including cell lines and patient material (Schulte TW, et al.1997). Expression of PAX
2 and PAX8 has been detected in the Willm' Tumour and the Wilms' tumour-
suppressor gene WT1 can down-regulate Pax-2 expression (Dressier GR.1996).
PAX5 is also misexpressed in medulloblastoma (Kozmik Z, et all995). Three
established transitional cell carcinoma cell lines and 79% of primary transitional cell
carcinoma of the bladder (TCCs) expressed PAX5 mRNA. There was a significantly
higher proportion of PAX5 expression in malignant than in benign urothelium. A
higher proportion of tumours with increasing de-differentiation expressed PAX5,
which correlates well with the expression pattern of PAX5 in development. In well-
differentiated tumours (grade 1), half expressed PAX5, compared with 84% of
moderately too poorly differentiated tumours)(Adshead JM, et al.1999).
Furthermore, the high incidence of PAX5 expression suggests its potential use as a
diagnostic tool and therapeutic target in TCC.
1.6.2.2.3 The NK homeobox gene family in cancer
Human NKX3.1 is known to map to a prostate cancer hot spot and is proposed as a
prostate-specific tumour suppressor gene (Bhatia-Gaur R, et al.1999). Northern blot
analyses indicate that this gene is expressed at high levels in adult prostate and at a
much lower level in testis, but is expressed little or not at all in several other tissues.
The NKX3.1 gene maps to chromosome band 8p21, a region frequently reported to
undergo a loss of heterozygosity associated with tissue differentiation and loss of
androgen responsiveness during the progression of prostate cancer (He WW, et
al.1997). Therefor, NKX3.1 is a candidate gene for playing a role in the opposing
processes of androgen-driven differentiation of prostate tissue and loss of that
differentiation during the progression of prostate cancer. However, single-strand
conformational polymorphism analysis of 48 radical prostatectomy cancer specimens
and 3 metastases for the entire coding region of NKX3.1 showed no tumour-specific
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sequence alterations in 50 specimens and total absence of the gene in 1 specimen
known to have a biallelic deletion of 8p21 (Voeller HJ, et al.1997).
1.6.2.2.4 Cdx homeobox genes in cancer
The expression of Cdx gene was found to be either reduced or absent in colon-cancer
cell lines and colorectal cancer tissues (Mallo GV, et al.1997) but be expressed in
normal epithelial cells of the small intestine and colon (Silberg DG, et al. 1997),
suggesting that decrease in human Cdxl and/or Cdx2 expression is associated with
colorectal tumorigenesis. Meanwhile, The mutation analysis for 85 cases of colorectal
tumours revealed that one with extensive microsatellite instability (RER+
phenotype) has mutations in both alleles of CDX2. Both mutations occur in coding
regions which contain repetitive elements and are consistent with those found in RER
+ tumours (Wicking C, et al.l 998). But, recently another survey reported that in 49
sporadic colorectal carcinomas and ten hereditary non-polyposis colorectal cancers
(HNPCC) there was no microsatellite instability and mutation (Yagi DK, et al. 1999).
Introduction of Cdxl and/or Cdx2 cDNA into colorectal cancer cell line with
expression of Cdxl and/or Cdx2 showed that; 1) Growth rate of cells overexpressing
Cdx2 decreased by half, whereas overexpression of Cdxl had no effect. However,
cells overexpressing both Cdxs had a growth rate reduced to 20% of control. 2) In
cells overexpressing Cdxl or Cdx2, tumorigenicity and resistance to apoptosis
induced by serum starvation, ceramide, or staurosporine were not changed compared
with control cells; yet phorbol ester-stimulated cell migration was decreased by 50%.
3) In cells overexpressing both Cdxl and Cdx2, tumorigenicity was decreased by
50%, and resistance to apoptosis was significantly lowered, and stimulated cell
migration was further decreased to 15% of control compared with cells expressing
Cdxl or Cdx2. 4) cells overexpressing both Cdxs showed strongly decreased Bcl-2
expression, which could account for their increased sensitivity to apoptosis (Mallo
GV, et al.1998). These findings further confirmed that loss of Cdxl or Cdx2
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expression is associated with tumour development and invasiveness in colorectal
tumours.
1.6.2.2.5 The APC homeobox gene in cancer
The adenomatous polyposis coli (APC) gene, responsible for familial adenomatous
polyposiscoli, is one of the tumour suppressor genes involved in tumorigenesis of
colorectal cancer.
There is quite a body of literature that demonstrated that APC gene has been
mutated (including initially somatic and germ line mutations) during the development
of sporadic colorectal cancers as well as in familial adenomatous polyposis (FAP).
These studies confirmed that: 1) Clinical investigation revealed that mutation of the
APC gene was associated with LOH at the APC locus (Miyoshi Y, et al. 1992). 2)
The great majority of the mutations found would result in expression of COOH-
terminally truncated protein (Nagase H, et al.1992). 3) The great majority of these
mutations accumulate in the central region of the of the APC gene and occurred
within the first half of the coding sequence (Miyoshi Y, et al.1992). 4) Most
identified point mutations in the APC gene are transitions from cytosine to other
nucleotides (Nakatsuru S, et al.1993). 5), The location of germ-line mutations tends
to correlate with the number of colorectal polyps and age in FAP patients (Friedl W,
et al.1996). 6), Inactivation of both alleles of the APC gene seems to be required as an
early event for development of adenomas and carcinomas in the colon and rectum as
well as some of those in the stomach (Polakis P. 1995; Levy DB, et al.1994)
The APC gene was also shown to regulate cell growth and cell death. Growth control
by APC may relate to its ability to downregulate beta-catenin, which is essential for
the function of cadherins, a family of Ca2+-dependent cell-cell adhesion molecules (in
the assembly of adherents junctions), by linking them to (alpha)-catenin and the actin
cytoskeleton (in nuclear signalling) (Barth AI, et al.1997). In cancer, mutations in
APC ablate its ability to regulate beta-catenin, and mutations in beta-catenin prevent
its downregulation by wild-type APC. Owing to its beta-catenin binding, APC can
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modify the pool of beta-catenin, but truncated APC is unable to regulate this pool
thereby altering adhesion and cell signalling. APC truncation was therefore
hypothesized to alter cell multiplication and cells are no longer able to undergo
apoptosis (Mahmoud NN, et al.1999). The protein products of mutant APC genes
present in colorectal tumours were found to be defective in this activity.
Furthermore, colorectal tumours with intact APC genes were found to contain
activating mutations of beta-catenin that altered functionally significant
phosphorylation sites (Morin DJ, et al.1997). These results indicate that regulation
of beta-catenin is critical to APC's tumour suppressive effect and that this regulation
can be circumvented by mutations in either APC or beta-catenin. Whereas, expression
of wild-type APC caused a pronounced reduction in total beta-catenin levels by
eliminating an excessive supply of cytoplasmic beta-catenin indigenous to the
colorectal cancer cell line. This reduction was due to an enhanced rate of beta-catenin
protein degradation. Truncated mutant APC proteins lacked this activity
(Munemitsu S, et al. 1995). On the other hand, clinical investigations also confirmed
that the absence of wild type APC protein affects the subcellular localization and
expression levels of beta-catenin in human colorectal cancer tissues (Inomata M, et
all 996).
1.6.2.2.6 The GBX genes in cancer
The human GBX2 homeobox gene is overexpressed in TSU-PR1, LNCaP, PC-3, and
DU145 metastatic prostate cell lines relative to the normal prostate (Gao AC, et al.
1996). These results suggest that the homeobox gene GBX2 may participate in
metastatic progression in prostatic cancer. Furthermore, GBX2-overexpressing TSU-
prl and PC3 human prostatic cancer cells were transfected with an eukaryotic
expression vector containing an antisense GBX2 homeobox domain cDNA. When
tested in vitro, the clonogenic ability of the GBX2 antisense transfectants was
reduced by approximately 50% in both cell lines. When implanted, the tumorigenicity
of the antisense GBX2 transfectants from both human prostatic cancer cell lines was
inhibited by more than 70% compared to the parental cells (Gao AC, et al. 1998).
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Thus, expression of GBX2 gene is required for malignant growth of human prostate
cells.
The GBX2 gene was also identified as a target gene of the v-Myb oncoprotein
encoded by the avian myeloblastosis virus (AMV). GBX2 activation by c-Myb
requires signal transduction emanating from the cell surface while the leukemogenic
AMV v-Myb constitutively induces the GBX2 gene. Mutations in the DNA binding
domain of AMV-Myb render it independent of signalling events and concomitantly
abrogate the collaboration between Myb and CCAAT Enhancer Binding Proteins
(C/EBP), which are involved in granulocyte differentiation. Ectopic expression of
GBX2 in growth factor-dependent myeloblasts induces monocytic features and
independence from exogenous cytokines, reflecting distinct features of AMV-
transformed cells (Kowenz-Leutz E, et al.1997).
1.7 The Barx2 Gene in Cancer
1.7.1 Themolecular organization ofthe Barx2 gene
The Barx2 gene, a divergent homeobox gene, was first found and isolated during
screening experiment of a mouse cDNA expression library using a concatamer of the
sequence CCATTAGPyGA (Jones FS, et al. 1997), and was homologous with the
class of invertebrate homeobox proteins of the Bar subfamily. Homeodmains of Bar
subfamily all contain a glutamine residue at position 50 in the third helix of the
homeodomain. These properties shared by several other homeodomain proteins
including all members of the Antennapedia family confer a binding preference for
target sites containing the core sequence CATTA. Barx class homeodomains are
further distinguished form those of the Antennapedia family by threonine and
tyrosine residues at positions 47 and 49 respectively (Scott MP, et al. 1989; Kappen
C, et al. 1993). Barx2 is most closely related to the Barxl gene and encodes a
homeodomain that is 87% identical. Barx2 gene shares a specific segment of 17 amino
acid containing a number of basic residues with Barxl designated the Barx basic region
(BBR) located immediately downstream of the homeodomain.
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Barx2 also exhibits several other notable features, including a putative leucine zipper,
a polyalanine tract within the amino-terminal region (in mouse only) and an acidic
domain within the carboxyl-terminal region (Jones FS, et al. 1997), which has been
confirmed to function as a repressor domain in other studies (Hanna-Rose W and
Hansen U. 1996).
The human Barx2 gene encodes a homeodomain protein of 254 amino acids, which
has a glutamine residue at position 50, and binds optimally to the DNA consensus
sequence YYTAATGRTTTTY (Kriasner A, et al. 2000), which is closely related to
the Barx2 binding sequences in the N-CAM and LI-CAM (Jones FS, et al. 1997),
but somewhat more divergent from the sequences in human calcitonin gene promoter
(Kriasner A, et al. 2000).
The human Barx2 gene contains four exons with a CpG island consisting of two Mse
I fragments, and three introns. The gene cover about 14 kb of denomic DNA and
encodes an mRNA of 1.9-2 Kb. Figure 1-2 shows the structure of the Barx2. The
exons and introns of the Barx2 are outlined in Table 1-11. The Barx2 gene is located
at chromosome llq25 between the markers D11S912 and D11S1320 (Hjalt TA and
Murray JC. 1999; Krasner A, et al.2000).
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Leucine Zipper Homeodomain BBR
Table 1- 11 The Exon and Intron within Barx2 Gene
Exon no Exon size (bp ) cDNA position Intron no Intron size (kp )
1 1099 1- 281 1 2.1
2 301 282- 582 2 2.7
3 85 583- 667 3 8.0
4 603 668-1270
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1.7.2 Thenormal function of the Barx2 gene
1.7. 2. 1 The Barx2 isinvolved in coordinated gene expression during
embryonic development.
During development, Barx2 is expressed at the sites of epithelio-mesenchymal
interactions. The expression of Barxl and Barx2 also overlap in the nervous system,
particularly in the telencephalon, spinal cord, and dorsal root ganglia. Barx2 was also
prominently expressed in the floor plate of development midbrain and in Rathke's
pouch. During craniofacial development, Barxl and Barx2 showed complementary
patterns of expression: whereas Barxl appeared in the mesenchyme of the
mandibular and maxillary processes, Barx2 was observed in the ectodermal lining of
these tissues. Intense expression of Barx2 was observed in small groups of cells
undergoing tissue remodelling, such as ectodermal cells within indentations
surrounding the eye and maxillo-nasal groove and in the first branchial pouch, lung
buds, precartilagenous condensations, and mesenchyme of the limb (Jones FS, et al.
1997). So the Barx2 gene is a co-ordinator of gene activity during embryonic
development.
In adult, the Barx2 is expressed in salivary gland, mammary gland and placenta
(Krasner A, et al. 2000). Initial work on the Barx2 in our lab has shown that the gene
is expressed in normal human ovarian surface epithelium.
1.7. 2. 2 The Barx2 gene functions as transcription regulator ofgenes encoding
several of celladhesion molecules (CAMs ).
The Barx2 may have dual functions as regulator for the LI-CAM gene. In cellular co-
transfection experiments, Barx2 activated LI-CAM regulator sequence constructs
containing the CCATTGPyGA motif and repressed the activity of constructs
lacking this sequence. These results suggest that Barx2 may regulate expression of
LI-CAM gene. In cells that express the LI-CAM gene, it may function as an
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activator, but in cells that do not express LI-CAM, it may function as a repressor.
The LI-CAM gene is a transmembrane glycoprotein belonging to the
immunoglobulin superfamily and is essential in the development of the nervous
system as well as being expressed on neurons and Schwann cells and plays a key
role in axon outgrowth and pathfinding through interactions with various
extracellular ligands and intracellular second messenger systems (Fransen E, et
al.1997; Meech R, et al. 1999). Mutations in human LI-CAM gene are responsible
for a variety of congenital neurological disorders, including hydrocephalus, mental
retardation, and agenesis of the corpus callosum (Wong EV, et al. 1995).
The Barx2 homeodomain is also sufficient for binding homeodomain binding sites
sufficient (HBS) from neuron-glia CAM (Ng-CAM) and neural CAM (N- CAM)
and the Barx2 may regulate these genes. The presence of a 17-amino acid Barx basic
region resulted in decrease in binding to HBS sequences from the Ng-CAM, whereas
it led to a increase in binding to HBS from the N-CAM promoter. In co-transfection
experiments, Barx2 repressed N-CAM promoter activity. When a 24-residue N-
terminal region of Barx2 was absent, Barx2 activated the N-CAM promoter
(Edelman DB, et al. 2000).
A recent study of sheep wool follicle development has demonstrated that the Barx2
is expressed in the epithelial component of the developing follicle and in the outer
root sheath of the adult follicle in pattern that is similar to E-cadherin. This suggests
that the Barx2 may have a general function in controlling adhesive processes in
keratinising epithelia (Sander G, et al.2000).
1.7. 2. 3 The Barx2 gene plays a role in regulateing CREBfamily.
The Barx2 gene contains leucine zipper motifs. It has now been demonstrated that
the Barx2 gene can interact with members of the cyclic AMP response element
(CRE)-binding protein (CREB) family, CREB1 and ATF2, potentially via leucine
zipper motifs, and play a role in dual modulation of the function of transcription
factors of the CREB family (Edelman DB, et al. 2000). CREB was initially isolated
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from rat brain tissue (Montminy MR, et al. 1987; Yamamoto KK, et al. 1988) and
found to be ubiquitously expressed. CREB belongs to the leucine zipper class of
protein (Borrelli E, et al. 1992) and can form heterodimers in specific combinations.
CREB might be responsible for programmed nerve-cell survival (Walton MR, et
al.2000) and is involved in the formation of memory in organisms with diverse
phylogenetic background from mollusks to mammals (Lamprecht R. 1999).
1.7.2. 4 TheBarx2 gene is identified as a regulatory element in the ras/raf pathway
Within the calcitonin gene promoter, gene involved in increased transcription via the
ras/raf pathway, a ras/raf responsive transcriptional element (RRE) has been identified
(Thiagalingam A, et al.1996). The Barx2 protein-binding domain was identified as
being sufficient to confer responsiveness of a reporter gene to ras/raf activation
(Krasner A, et al. 2000) and the Barx2 therefore may take part in regulation of the
ras/raf pathway.
The ras/raf pathway activates several protein kinase cascades, which can result in the
subsequent activation of transcription factors; these, in turn, can alter gene expression
and cell phenothype in terms of the regulation of cell proliferation, differentiation,
and morphology (Yamamoto T, et al.1999).
1.7.3The Barx2 gene in cancer
One of the hypothesis underlying this thesis is that the Barx2 gene may be a
candidate tumour suppressor gene because it is located within minimal critical region
LOH region, is a regulator of CAM expression and is expressed developmentally at
the site of epithelio-mesenchymal interaction.
The barx2 gene is located at chromosome 1 lq25 between the markers D11S912 and
D11S1320, within a minimal region associated with frequent LOH in ovarian cancer,
breast cancer and colorectal cancer (Habra H, et al.1996; Negrini et al. 1995; Davis M,
et al. 1996; Connolly KC, et al.1999). It has also been demonstrated that disruption
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of this region is associated with poor prognosis in ovarian cancer patients (Habar H,
et al.1996; Launonen V, et al. 1998; Launonen V, et al. 2000).
As mention above, the Barx2 gene functions as a transcriptional regulator CAMs.
More evidence is now appearing to suggest that disturbance in protein-protein
interaction in the CAMs complex, especially in the E-cadherin-catenin adhesion
complex, is one of the main events in the early and late steps of cancer development.
It has been found that the expression of CAMs was associated with the invasive and
metastatic behaviour of tumour cells. For example, loss of expression or function of
CAMs, intracellular molecules that interact with CAMs, can result in the loss of
CAMs mediated adhesion and a more invasive phenotype (Debruyne P, et al. 1999;
Rowlands TM, et al. 2000; Sommers CL. 1996). Besides their role in establishing
tight cell-cell adhesion, CAMs also play a role in cell signalling and promotion of
neoplastic growth (Wijnhoven BP, et al. 2000), suggesting its dual role in human
cancer. Therefore, alteration of the function of Barx2 may influence CAMs functions.
The Barx2 gene is involved in regulating CREB family. Previous studies have showed
that the expression of CREB correlated directly with the metastatic potential of
melanoma cells (Rutberg SE, et al. 1994). Furthermore, transfection of a dominant
negative KCREB into melanoma cells showed that the expression of the KCREB
construct in metastatic melanoma cells decreased their tumorigenicity and metastatic
potential in nude mice. The KCREB-transfected cells displayed a significant decrease
in MMP-2 (collagenase type IV) mRNA and activity that resulted in a decrease in
invasiveness through the basement membrane, an important component of tumour
invasion and metastasis. In addition, the cell surface adhesion molecule that was
involved in the metastasis of human melanoma (Luca M, et al. 1993; Xie S, et al.
1997) was down-regulated in the KCREB-transfected cells (Xie S, et al. 1997).
Transfection of KCREB into the melanoma cells also increases their sensitivity to
UV and ionising radiation and renders them susceptible to thapsigargin induced
apoptosis (Jean D, et al. 1998).
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The barx2 was also involved in mediating ras/raf dependent transcripion of the
calcitonin gene via a ras/raf responsive transcripional element within the calcitonin
gene promoter (Krasner A, et al.2000). The clinical investigation showed that down-
regulation of the calcitonin gene was associated with the poor differentiation of
thyroid carcinoma cells and also with adverse patient survival (Ball DW. 1996).
Hypermethylation of the calcitonin gene has been described in various hematologic
malignancies (Thomas X, et al. 1999; Ihalainen J, et al. 1993).
Although some lines of evidence have suggested that the Barx2 gene may have a role
in oncogensis, until now, there has not been direct evidence that the Barx2 gene is
involved in cancer. So the objectives of this project were the further analysis of the
LOH region to refine the LOH minimal region and , if confirmed to remain in the
region, the formal structural and functional analysis of Barx2 as a candidate tumour
suppressor gene.
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. MATERIALS AND METHODS
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2.1 Refinement ofthe Region ofFrequent Loss ofHeterozygosity of
Chromosome llq D11S1894-D11S11309 Region in Colorectal
Cancer.
In order to further refine the TSG region at chromosome llq between D11 SI 894 and
D11S1390 (4.5Mb) and also confirm location of Barx2, 14 polymorphic loci in this
region were investigated using microsatellite analysis in colorectal cancer tumour/blood
pairs. It is due to previous LOH studies have demonstrated that LOH at chromosome
llq between D11S1894 and D11S1309 occurs frequently in ovarian and colorectal
cancer (using same polymorphic markers and got same results in ovarian and colorectal




Matched normal/tumour samples from 50 patients with colorectal cancer were used.
The patient characteristics are outlined in Table 2- 1 Patients with colorectal cancer
were on continuing follow-up, which ranged up to 2491 days.









































2.1.1.2 Extraction ofhigh molecular weight DNA of cancer tissue and
rapid miniprep extraction of DNA of lympocytes.
These extractions were previously done in our laboratory and all of DNA sample was
stored at 4 °C.
2.1.2 Automated laserfluorescence (ALF) analysis ofmicrosatellites
2.1.2.1 ALF- Polymerase Chain Reaction (PCR)
2.1.2.1.1 The design of primer
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The primers were designed on the basis of recently generated microsatellite index
maps for locus, informativeness and spacing.
All oligonucleotides were obtained from the ICRF oligonucleotide laboratory, and
were fluorescently labelled.
2.1.2.1.2 The treatment of oligonucleotides
20 JLtl of NaOAc (3 M, pH 5.6), 80 JLll of 25 mM MgCl, 100 fll of sterile distilled
water and 600 JU.1 of 100% cold ethanol were added to each primer and then incubated
in -70° C for 30 minutes or incubated in -20° C for overnight.
The sample was centrifuged at 1300 g for 20 minutes at 4 °C then removed all of the
liquid. Added 1 ml of 70 cold ethanol and then centrifuged at 1300 g for 15 minutes at
4 °C then removed ethanol.
The primer was dried at room temperature for 10 minutes and then added 100 ju.1 of
sterile distilled water to resuspend it.
10 JLll of the primer solution was added to 990 JLLl distilled water. The concentration of
primer was estimated by Spectrophotometric reading of absorbance at 260 nm (O.D.
260).
2.1.2.1.3 Optimization of reaction condition of PCR
PCR was performed in a reaction volume of 25 JLtl. The reaction condition of PCR for
different primers was first optimizated with different concentrations of MgCl2. and
then different quantities of genomic DNA were tested at that reaction condition for
PCR. Figure2-1 shows the result of optimization PCR with different concentrations
of Mgcl2 by using primer 969
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Figure 2-1 Optimization PCR with Different Concentration of
MgCb by Using Primer 969
H20 5 2.5 2.0 1.5 1.25 1.0 marker
(Concentration of MgCl2,pi) 100 bp
gpw
PI
Table2-2 shows all optimizations of reaction conditions of ALF- PCR for
chromosome 1 lq24 polymorphic microsatellite mapping in this project.













D11S4150 2.5 0.5 1.5 0.25 0.25 0.8 18.95
D11S1894 2.5 0.5 1.5 0.25 0.25 0.8 18.95
D11S4126 2.5 0.5 1.5 0.25 0.25 0.8 18.95
D11S874 2.5 0.5 1.5 0.25 0.25 0.8 18.95
D11S4131 2.5 0.5 1.5 0.25 0.25 0.8 18.95
D11S912 2.5 0.5 1.25 0.25 0.25 0.8 19.2
GATA69G01 2.5 0.5 1.5 0.25 0.25 0.8 18.95
D11S1884 2.5 0.5 1.5 0.25 0.25 0.8 18.95
D11S1320 2.5 0.5 2.5 0.25 0.25 0.8 17.95
D11S1309 2.5 0.5 1.5 0.25 0.25 0.8 18.95
GATA71A01 2.5 0.5 2.5 0.25 0.25 0.8 17.95
D11S969 2.5 0.5 2.5 0.25 0.25 0.8 17.95
D11S1895 2.5 0.5 2.0 0.25 0.25 0.8 18.45
D11S4085 2.5 0.5 2.0 0.25 0.25 0.8 18.45
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2.1.2.1.4 PCR programme for genomic PCR
A touchdown PCR programme was used as follows:
94° C for 5 minutes 1 cycle; 94°C for 30 sec/67° C for 30 sec/72 °C for 42 sec 2cycle;
94°C for 30 sec/64 °C for 30 sec/72° C for 42 sec 2cycle; 94°C for 30 sec/61°C for 30
sec/72°C for 42 sec 2cycle; 94°C for 30 sec/58°C for 30 sec/72°C for 42 sec 2 cycle;
94°C for 30 sec/55°C for 30 sec/72°C for 42 sec 30 cycle; then final 72°C for 5
minutes.
2.1.2.1.5 Checking of PCR products by Agarose gel electrophoresis
4 jLtl of reaction product with 1 pi of electrophored buffer was checked on standard
2% agarose run at 100-120 volts in lx TAE and a 100 bp DNA ladder was used as a
convenient marker for size estimates of the products, stained with ethidium bromide
and visualised under UV light. Figure 2-2 shows the result of products of ALF-PCR
for colorectal cancer samples blood/tumour pair.
Figure 2-2 the Result of Products of ALF-PCR (D11S1309) For
Colorectal Cancer Blood/Tumour Pair.
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2.1.2.2 The PCR products were run on the ABI Prism (MRC).
2.1.2.3 The method of analysis for result of microsatellites
Allelotype analysis was performed using Genescan software. Each pair of samples
was assigned to one of three groups; heterozygous, uninformative (homozygous) or
nondeterminable. For the heterozygotes the relative ratios of alleles was determined.
LOH was assigned where the tumour allele ratio differed from the normal allele ratio
by >30 % (r < 0.7) (see Figure 2-3)
Figure 2-3 the Example of ABI Prism for PCR Products of DNA of
Colorectal Cancer
This example is result of ABI prism for PCR (D11S4126) products of DNA of
colorectal Cancer tumour/blood pairs. Figure a) showed ABI of tumour DNA, there is
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only one peak. Figure b) showed ABI prism of blood cell DNA and there are two
peaks. Comparly tumour DNA with blood cell DNA, tumour DNA had completely
lost one allele. This demonstrates loss of heterozygosity (LOH). If there are two allele
in tumour tissue and where the tumour allele ratio differed from the normal allele ratio
by >30 % (r < 0.7). It also suggests LOH. If this ratio is <30% (r> 0.7), It is assumed
that there no LOH (retention of heterozygosity). If there is only one peak in tumour
DNA and blood cell DNA, the locus is uninformative (homozygous) for that sample.
2.2 Expression OfBarx2 Gene In Ovarian Cancer Cell Lines and
Tissue
2.2.1 Reverse transcription PCR
2.2.1.1 Clinical Material
Fresh primary ovarian cancer tissues from 28 patients were obtained. The patient
characteristics are outlined in Table 2-3. Patients were on continuing follow-up,
which ranged up to 2780 days.
Table 2-3 Clinicopathological Characteristics of the Study




















2.2.1.2 Cell lines or tissue RAN preparation
2.2.1.2.1 Extraction of RNA by TRI REAGENT
Cells were Lysed directly on the culture flasks, aspirating the medium and washing
cells with PBS once then adding the TRI REAGENT (1 ml per 10 cm of culture flask).
Sample was incubated at room temperature for about 5 minutes then the cell lysate
was passed several times through a pipette to form a homogenous lysate.
0.2 ml of chloroform per ml of TRI REAGENT was added. The sample was covered
tightly then shakes vigorously for 15 seconds and allowed to stand for 10 minutes at
room temperature. The resulting mixture was centrifuged at 12,000 g for 15 minutes at
4°C.
Transferring the aqueous phase to a fresh tube and added 0.5 ml of isopropanol per ml
of TRI REAGENT used in sample preparation and mixed. The samples were allowed
to stand for 10 minutes at room temperature, then centrifuged at 12,000 g for 10
minutes at 4 °C.
The supernatant was removed and the RNA pellet was washed by adding 1ml of 75%
ethanol in DEPC water per 1 ml of TRI REAGENT used in sample preparation, then
vortexed and centrifuged at 12,000 g for 10 minutes at 4 °C.
The supernatant was removed again. The RNA pellet was dried for 10 minute and
then added an appropriate volume (50 - 100 pi) Of DEPC water. To facilitate
dissolution, the pellet was mixed by repeated pipetting with a micropipette at 55°C
for 10 minutes.
The ovarian cancer tissue total RNAs for this study were kindly provided by Kenny
MacLeod.
2.2.1.2.2 Quantitation of RNA by spectrophotometer
5)li1 of the RNA solution were added to 1295 pi of distilled DEPC water.
Spectrophotometry reading of absorbency at 260 nm (O.D. 260) is proportional to
the concentration of RNA in the sample. Absorbance at 280 nm divided by
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absorbance at 260 nm indicates the purity of the sample. A value of 1.6 to 1.8 is
optimal and ratios below or above this indicate contamination of the sample. An O.D.
260 of 1.0 is equivalent to an RNA concentration of 40 jug/ ml, allowing simple
proportional calculations to determine RNA concentration of any sample.
2.2.1.3 Treating RNA with DNase
Samples were prepared in the hood.
Each RNA sample was diluted in a volume of 50 jul and the following was added:
Reagent Quantity
DNase I (RNase free)(10u/ul) 2 jul
RNasin (40u/jtl) 1 jrl
lOx Buffer 5.8 |ul
The total volume was 58 jul. The samples were incubated at 37 °C for 1 hour.
60 jul of Phenol:Chloroform (1:1) were added, vortexed for 5 seconds then spun in
13000g for 15 minutes at 4 °C. 55 jul of the top layer was removed and put into new
tube on ice.
55 jtl of Chloroform was added, vortexed for 5 second then spun in 13000g for 15
minutes at 4 °C. 55 jul of the top layer was removed and put into new tube on ice and
precipitated with 5.5 jul of NaOAC pH5.6 and 120jul of Ethanol and incubated at -70
°C for 30 minutes.
The samples were centrifuged at 4 °C with 13000g for 15 minutes the put them
straight on ice.
The supernatant was removed and washed PNA pellet by adding 1 ml of 75%
ethanol and vortexing, and removed 75% ethanol as much liquid off as possible.
The pellet was resuspended in 20 jul of DEPC treated water. Checked quantification
of RNA by spectrophotometer as described above.
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2.2.1.4 First stand cDNA syntheses
This was performed using the 1 st Strand cDNA Syntheses Kit (AMV)
For each sample, prepared two sterile microfuge tubes.
2 pi of total RNA (0.5pg/pl) was added to each sterile microfiige tube then 5.8 pi of
DEPC treated water was added. The samples were incubated at 65 °C for 15 minutes
then were placed on ice immediately.
Two mixtures were prepared as following in sterile microfuge tube respectively.
Mixture 1
Reagent Quantity
1 Ox reaction buffer 2 ju.1
25 mM Mgcl2 4 pi
lOmMdNTP 2 pi
Oligo-p(dT) primer (0.8pg/pl) 2 pi
RNase inhibitor (50u/pl) 1 pi
AMV Reverse Transcriptase(u/pl) 0.8 pi
Gelatin f0.5mg/m0 0.4 pi
Mixture 2
Reagent Quantity
1 Ox reaction buffer 2 pi
25 mM MgCl2 4 pi
distilled DEPC water 6.2 pi
The mixture 1 was added into the sterile tube containing the sample on ice then
mixture 2 was added into the other sterile tube which also contained the sample on ice
as RT-negative control.
The sample was placed on Techne PHC-3 Thermal Cycler and then incubated as
following program;
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25 °C for 10 minutes, 42 °C for 60 minutes and 95 °C for 10 minutes.
After incubating, the samples were placed on ice immediately then centrifuged briefly.
2.2.1.5 PCR
2.2.1.5.1 The design and treatment of RT-PCR oligonucleotides primers for Barx2.
A total of 4 pair of primer were used in this project. According to the cDNA
sequence of Barx2 gene, we designed three pair of primer for each exon of Barx2 (see
Figure 2-4) in order to analyse expression for each exon as well as full length cDNA
of Barx2 in ovarian cancer cell lines and tissue. Table 2-4 shows these primers sizes,
sequences, and exons.
Figure 2-4 Human Barx2 RT-PCR Primers
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Table 2-4 the Primers of Barx2 for RT-PCR of cDNA













All of oligonucleotides were obtained from the ICRF oligonucleotide laboratory and
were treated as described above, except that distilled water was also treated with
DEPC.
2.2.1.5.2 PCR reaction of the Barx2
PCR was performed in a reaction volume of 25 jliI. The PCR reaction mixture
contained 2.5 pi of lOx buffer, 1.5 pi of 25 mM MgCl2, 0.5 |xl of lOmM dNTP. 0.2
JU.1 of Taq polymerase (5u/pl), 12.5 pmol of each primer, 2.5 pi of first stand cDNA
and 17.3 pi of distilled DEPC water. Meantime, other reactions were set up in which
the water and RT-negative product replaced first stand cDNA as negative control
respectively.
PCR was performed under the following condition; 94 °C for 5 minutes in 1 cycle. 94
°C for 30 seconds. 55 °C for 30 seconds. 72°C for 42 seconds, repeated for 35 cycles,
then 72°C for 5 minutes in 1 cycle.
2.2.1.5.3 PCR reaction ofy-actin
no
In order to identify the quantity and quality of cDNA, the RT-PCR of y-actin was
also performed for the same sample. A reaction volume for y -actin was the same as
above.
PCR was performed under the following condition; 94 °C for 2 minutes in 1 cycle. 94
°C for 30 seconds. 57 °C for 45 seconds. 72°C for 45 seconds, repeated for 35 cycles,
then 72°C for 5 minutes in 1 cycle.
2.2.1.5.4; Checking of PCR products by Agarose gel electrophoresis
5 pi of reaction product with 1 jLtl of electrophored buffer were checked on standard
2% agarose run at 100-120 volts in lx TAE and used the 100 bp DNA ladder as a
convenient marker for size estimates of the products, and stained with ethidium
bromide and visualised under UV light.
2.2.2 Northern blot
2.2.2.1 The treatment of plastics and glassware
Glassware was filled with 0.1% DEPC in distilled water and incubated overnight.
DEPC water was poured off into a steriled bottle and then baked for 4 hours at 200
°C and stored them in a sterile manner. Washed the gel tank with mild detergent and
rinsed well with distilled-DEPC water. Treated the gel tank and comb with RNase.
2.2.2.2 Blotting
1.8 % of agarose gel was prepared in distilled-DEPC water with 12 % of lOx
MOPS/EDTA and 6.1% of formaldehyde (37%) and allowed the gel to set for 1 hour
at room temperature in fume hood.
RNA was thawed on ice and then placed 10-20 pg of total RNA in 5 pi of distilled-
DEPC water. 10-20 pg of RNA ladder was placed. 25 pi of electrophoresis sample
buffer was added to each sample and the RNA ladder and then heated to 65 °C for 15
minutes and then the samples were placed on to ice. 1 pi of lmg/ ml ethidium was
ill
added bromide per tube then centrifuged the sample briefly. The samples were loaded
into the gel immediately.
The gel was run overnight at 30 volts in lx MOPS/EDTA and then the voltage was
increased to 70 volts the next day and run until the dye front was 4/5 down the gel.
The gel was photographed under UV light and the RNA marker position was
measured by using a ruler. Figure 2-5 showed an example of a northern blot gel
Figure 2-5 an Example of A Northern Blot Gel
A corner of the gel was removed for orientation. The gel was soaked in lOx SSC for
20 minutes two time in a pyrex dish with shaking platform at room temperature.
The Hybond-N membrane and five pieces of 3MM filter paper were cut to the size
of the gel. The membrane was soaked in distilled water for 5 minutes then soaked in
lOx SSC for other 5 minutes.
The gel was transfered overnight in lOxSSC. The membrane was removed after
marking the positions of the lanes in the gel. The membrane was then washed briefly
in 2xSSC. The membrane was dried at room temperature and then was UV irradiated
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by using GS GENE LINKER UV chamber (program C3). The membrane was stoked
at room temperature.
From the position of the RNA marker on the gel, a plot of log 10 of the RNA









2.2.2.3; The hybridisation and development of the X-ray film for Northern blot as
described as below.
2.2.3 RNaseH Assayofovarian cancer cell lines total RNA
10 pi of total RNA was dried down in speed oven. 10 pi of oligo(dT) was added to
15 pi of buffer A (100 mMKCL and lOmM MgCL2) then incubated it at 65 °C for 2
minutes and then annealed at room temperature in the dark for 30 minutes . Annealed
samples were digested with 2 units of RNase H in 20 pi of buffer B (50 mM KC1,
11.25 mM MgC12, 62.5 mM Tris, pH 7.8 and 1.25 mM dithiothreitol) for 30
mintues at 37 °C, after which the reactions were stopped by the addition of 50 pi of
buffer C (20 mm EDTA and 0.3 M NaOAc, pH 5.5). Following a single
phenol/chloroform extraction, the digested RNA was ethanol-precipitated overnight
at -20 °C and subjected to Northern blot analysis by using the Barx2 probe as
described above. Figure 2-6 showed the results of a running gel for RNaseH blot
113
Figure 2-6 Running Gel for RNase Blot
Rnase H
2.3 The Structure Analysis ofBarx2 Gene in Cancer
2.3.1 The Southern blot
2.3.1.1 Extraction of high molecular weight DNA of cancer cell lines
Cell lines was harvested, aspirating the medium and washing cells with PBS twice
then adding trypsin solution. After the cells became detached from the flask, Up to
lx 107 cells were collected by centrifugation at 600 g for 5 minutes at 4 °C. The
supernatant was discard without disturbing the pellet. The cells were resuspend in
0.1ml reagent A and left on ice for 5 minute. Centrifuge at 1300 g for 5 minutes at 4
°C and discard the supernatant.
2 ml of reagent B was added to the pellet and vortexed briefly to resuspend the pellet,
then the samples was incubated at 37 °C for 10 mines. Cell suspension was
transferred to a 5 ml screw-capped polypropylene centrifuge tube. 15pl of a 50jitg/ml
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RNase A solution was added and incubated at 37 °C for 30 minutes. 500 jal of sodium
perchorate was added and then mixed by inverting 7 times.
2 ml of chloroform was added and mixed by inverting 7 times to emulsify the phases.
300 jliI of Nucleon resin was added and without re-mixing the phases, centrifuges at
1300 g for 3 minutes.
Holding the tube vertically, without disturbing the Nucleon resin layer, The upper
phase was transferred to a fresh tube of minimum volume 7.5 ml. Two volumes of
cold absolute ethanol were added until the DNA was precipitated.
The DNA was pelleted, resuspended and washed in 70% cold ethanol, then the DNA
pellet was air-dried, resuspended in lxTE (pH 7.4) and finally the concentration was
estimated by spectrophotometer.
2.3.1.2 Quantification of DNA by spectrophotometer
5 or 10 fil of the DNA solution were added to 995 or 990 ju.1 distilled water.
Spectrophotometric reading of absorbance at 260 nra (O.D. 260) is proportional to
the concentration of DNA in the sample. Absorbency at 280 nm divided by
absorbance at 260 nm indicates the purity of the sample. A value of 1.8 is optimal
and ratios below this indicate contamination of the sample. An O.D. 260 of 1.0 is
equivalent to a DNA concentration of 50 fig/ ml, allowing simple proportional
calculations to determine DNA concentration of any sample.
2.3.1.3 Digestion of DNA
10 jug genomic DNA was dissolved in sterile distilled water using bore pipette tip to
measure out the DNA and then standed the sample for overnight at 4 °C in order to
fully solubilise. lOx reaction buffer was added to give a lx solution and spermidine
and BSA to final concentrations of 5mM and 0.1 mg per ml respectively. The sample
was mixed by tapping the tube and then allowed to stand for 5 minutes on ice to
equilibrate. Finally the enzyme was added ( EcoR I and BamH I respectively), 1 unit
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per 1 jug of DNA and then gently mixed with the sample by tapping the tube and
spun briefly. The samples were incubated for 1 or 1.5 hour at 37 °C. Taking out 1 pi
of digested DNA (mixing with 2 ju.1 of DNA loading buffer and 7 pi of distilled
water) to run a mini gel (1% agarose gel) in order to check if the sample was fully
digested. If the DNA was completely digested then the reaction was stopped by
adding 0.5 M EDTA (pH 7.5) to a final concentration of lOmM.
2.3.1.4 DNA precipitation
3 volumes of cold ethanol (100%) was added into the sample and then allowed to
stand for overnight at -20 C. The sample was centrifuged at 13000 g for 15 minutes at
4 C. The ethanol mixture was removed and discard and then the sample was washed
with 1 ml of 75% cold ethanol then spun at 13000g for 15 minutes at 4 C. Removed
the ethanol and discarded it and then the sample was dried in vacuum jar. The DNA
was resuspended in 20 pi of lxTE (pH 7.6) then incubated for 1 hour at 37 C. The
sample was cooled to 4 C then stored frozen at -20 C.
2.3.1.5 Blotting
0.7% of the agarose gel was prepared, then thawed and heated to 56°C for 2 minutes.
0.2 volume of electrophoresis sample buffer was added. The samples were spun
briefly then loaded slowly into the gel and 1 kb of DNA ladder was also loaded at
each side of the gel as markers.
The samples was allowed to sit in the gel for a few minutes after loading them. The
gel was run at 30 volts overnight in lxTAE buffer. The next day electrophoresis
continued at 70 volts until the dye front was 4/5 down the gel. The gel was removed
from the tank and placed in a pyrex dish on a shaking platform.
The gel was soaked in 0.5pg/ml ethidium bromide in lxTAE in the shaking platform
for 30 minutes and then destained for 10 minutes in distilled water.
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The gel was photographed under UV light with a ruler at the side of the marker lane.
The position of the ladder DNA fragments was accurately measured on the gel.
Figure 2-7 showed the blot of DNA digested with EcoR I
Figure 2-7 the Blot of DNA Digested with EcoR I
The gel was soaked in 0.2 N HCL for 10 minutes in the shaking platform and then
rinsed gel briefly in distilled water. The gel was soaked in denaturation solution
(1.5M NaCL, 0.5M NaOH) with shaking platform for 45 minutes and then rinsed
briefly in distilled water. Neutralisation solution (1M Tris pH 7.4, 1.5M Nacl) was
added for 30 minutes on the shaking platform and the solution was changed at 15
minutes and then gel was briefly rinsed in distilled water.
Hybond N membrane and 3MM filter paper were made for transfer. Wet Hybond N
membrane was incubated in 2xSSC for 5 minutes. Transfer was performed overnight
in 20xSSC.
After transfer, the membrane was soaked in 6xSSC for 5 minute and dried for 30
minutes at room temperature. The membrane was UV irradiated by using GS GENE
LINKER UV chamber with program C2.
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2.3.1.6 The preparation of probe of Barx2
Barx2 plasmid was used as template generate the Barx2 probe. The plasmid used was
construct containing full length Barx2 fused to thioredoxin in pET32a (Novagen),
with the 8 amino acid FLAG epitope added at the beginning of the Barx2 moiety.
Barx2 primer (F1/R3) was used to amplify the full length coding region sequence of
Barx2 gene. The PCR product of Barx2 was purified and used as probe. The primer
sequence and PCR condition are described as below.
Dr Barry D. Nelkin kindly donated pET32a-Barx2
2.3.1.7 The hybridisation of Southern blots
2.3.1.7.1 Pre-hybridisation
20 ml of Hybond hybridisation mixture was placed in a universal tube and heated to
68 °C in the hybridisation oven.
200 ml of 0.1% of SDS was placed in a pyrex dish then heated to boiling point.
Gauzes ( two pieces per blot) were added and incubated for 5 minutes after turned
off the heat.
120 pi of sonicated salmon sperm DNA (10 mg /ml) was placed in a sterile 1.5 ml
effendorf tube and then boiled for 5 minutes then immediately quenched on ice.
30 ml of 6x SSC was placed in a pyrex dish. Gauze was added and the blot to be
hybridised was placed on top with second a piece of gauze to cover the blot. The blot
and gauzes were rolled up into a cigar shape then placed into hybridisation bottle.
The bottle was unrolled then the 6xSSC was poured out of the bottle. 100 pi of
sonicated salmon sperm DNA with 20 ml ofhybridisation mixture was then added in
the hybridisation bottle.
The blot was incubated for 24 hours at 68 °C in the hybridisation oven.
2.3.1.7.2 The hybridisation.
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lOOpl of sonicated salmon sperm DNA was placed into a sterile eppendorf tube then
boiled for 5 minutes and cooled on ice immediately.
A solution containing 50-75 ng of probe was prepared in 13 jul of sterile distilled
water then boiled for 5 minutes and cooled on ice immediately. 4pl of High Primer
was added with 3 )ll1 of 32P dCTP, 300pCi/mmol into the solution containing the
probe. The solution was incubated for 15 minutes at 37 °C then quenched the
reaction on ice.
A Whatman glass microfibre filter was placed on sheet of plastic inside a perspex
box. 0.5 pi of probe was placed on the filter. The filter was placed into a Manifold
pump apparatus. The upper reservoir was filled with 5% TCA through under
vacuum and repeated. The filter was removed from the manifold and the 32P level was
monitored. If the level of radioactivity left on the filter after TCA extraction was low
then it was not worth carrying on and a fresh labelling reaction was set up.
A NICK column was filled with lx TE and allowed to drip through. 80 pi of lxTE
was added to the solution containing probe and then added to the centre of the
column following by 300 pi of lx TE to the column and again allowed to drip through
the column. An eppendorf tube with 100 pi SSC DNA was placed under the column
and 400 pi of lx TE was added to the column then allowed drip through the column.
This should contain a high level of32 P. The solution was incubated in the 100 °C hot
block, covered with a lead pot for 10 minutes to denature the DNA, then quenched
the on ice immediately.
500 pi of probe with solution was added in the hybridisation bottle and blot was
incubated for another 24 hours at 68 °C in the hybridisation oven.
2.3.1.7.3 Washing membrane
Hybridisation wash buffer A (2x SSC, 0.1% SDS) and B (0.2xSSC, 0.1% SDS) were
heated to 68 °C. The hybridisation liquid was poured off. Hybridisation wash buffer
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A was added and incubated for 20 minutes at 68 °C in the hybridisation oven then
discarded. Hybridisation wash buffer B was added until the bottle was half full then
incubated for 20 minutes at 68 °C in the hybridisation oven then discarded. This was
repeated.
The blot from the hybridisation bottle was placed in a plastic box with the
hybridisation wash buffer B and incubated for 20 minutes at 68 °C in the
hybridisation oven with the shaking platform.
The blot was placed it in plastic bag then exposed to X-ray film in a film cassette at
-70°C. The X-ray film was developed in a GURIX 60-AGFA developer.
200 ml of 0.1% SDS was placed into a pyrex dish and heated to boiling point. Once
the solution was boiling, added the blot into the solution and turned off the heat
source and the blot was incubated for 5-10 minutes to stop it. The blot was removed
and rinsed in 6xSSC. The blot was sealed into a plastic bag and was exposed to X-ray
film for 5-7 day to check that no radioactivity was detected.
2.3.2 Pulsed-FieldGel Electrophoresis (PFGE)
2.3.2.1 Method
PFGE allows the separation of DNA ranging in size from a few kb pairs to 10 pb
pairs. Because of the large size of these molecules, simple pipetting mechanically
shears the DNA resulting in unacceptable quality for PFGE separations. This has
necessitated procedures for lysis of whole cells embedded in agarose, allowing
purification of chromosome-size DNA without shearing.
2.3.2.2 Preparation of agarose embedded mammalian DNA
A Cell suspension was prepared in tissue culture medium ( OAW42. A2780. PE04
and FATU cell lines in RPMI-1640; OVCAR3 in MOD ) without fetal bovine
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serum. The cells were counted and removed 5xl07 cells for 500 ul of agarose plugs to
be made (100 |ul/plug for disposable mold) then placed on ice.
The 2% clean-cut agars solution was melted by using a microwave and equilibrated to
50 °C in a water bath.
The amount of Cell Suspensin Buffer calculated. For a final concentration of 0.7%
agar 0.63 ml of Cell Suspension Buffer per 1 ml of agar plugs was used. 0.37 ml of
2% CleanCut agarose per ml of agarose plugs was used.
The cell suspension was centrifuged at l,000x g for 5 minutes at room temperature.
The cells were resuspend in the volume of Cell Suspension Buffer calculated above
and equilibrated the cell suspension to 50 °C.
The calculated volume of 2% CleanCut agarose was combined with the cell
suspension and mixed gently, and kept at 50 °C , the transferred to plug molds by
using sterile pipettes and incubated for 15 minutes at 4 °Cin order to allow the
agarose to solidify.
A 50 ml conical centrifuge tube was used to which was added 200 |ul of Proteinase K
stock to 5 ml of Proteinase K Reaction Buffer for each ml of agarose plugs, the
solidified agarose plugs were pushed into 50 ml centrifuge tube containing the
Proteinase K solution, and incubated overnight at 50 °C without agitation.
2.3.2.3 Restriction enzyme digestion of pluges
A plug was placed for each digest in a sterile 1.5 ml microcentrifuge tube, and wash
once for 1 hour in 1 ml O.lx Wash Buffer, decanted and resuspend in a sufficient
amount of fresh O.lx Wash Buffer to cover the plugs. This last wash reduces the
EDTA concentration, allowing faster buffer equilibration with restriction enzyme
buffers
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Wash buffer was aspirated and 1 ml of the appropriate lx restriction enzyme buffer
was added and incubated for about 1 hour with gentle agitation at room temperature.
The buffer was aspirated off and 0.3 ml of fresh lx enzyme buffer and the restriction
enzyme Hind III and Sac I were added respectively (50 u per lOOjul plug) and
incubated overnight at appropriate temperature. The southern blot was performed
for Pulsed-field gel described as above
2.4 Mutation Analysis ofBarx2 Gene.
2.4.1 Polymerase Chain Reaction (PCR) ofgenomic DNA for amplifying Barx2 exon
2.4.1.1 The design and treatment of primer
The primers were designed on the basis of encoding sequences of human Barx2 gene
There are 4 pair of primer in total. The table 2- 5 shows primer sizes, sequences in
relation to exons.
Table 2-5 The Primers of Barx2 for PCR of Genomic DNA
Primer Sequence Size (bp ) Exon
F11/R5 5' -TACACGGACGTGAAAGCTAC-3' 213 1
5' -TCACCATGCACTGCCACG-3'
F6/R6 5' -CAGGTCCTGGCCTGCTTCCC-3' 426 2
5" -CCCACAATGGGAGCAAGTCT-3''
F9/R9 5' -CCAGGCTCCCCTTCCCTGCGGGCA-3' 309 2
5' -TCACCTGTCTGGGGTTGACAAATA-3'
F10/R1 5' -TCCTGCTGCCTCCCATTCTG-3' 300 3
5' -CAACAGCTTCCCCGCAAGCC-3'
F8/R8 5' -TGGAGGGAAGGAATTATTC-3' 349 4
5' -AGTCTCCCTCTTCCCTCAAA-3'
Oligonucleotides were synthesised at the ICRF oligonucleotide laboratory and were
treated described above.
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2.4.1.2 Optimization of reaction condition of PCR
PCR was performed in a reaction volume of 25 jil. Reaction conditions for PCR
optimization were performed for MgCl2. and template quantity. Figure 2-8 shows
results of optimization PCR with different concentration of MgCl2 by using primer
F6/R6.
Figure 2-8 the Result of Optimization PCR with Different
Concentration of Mgch by Using Primer F10/R10.
Table 2 -6 shows all optimised reaction conditions for genomic of Barx2 exon
amplification
Table 2-6 Optimization Reaction Condition for PCR of Genomic
DNA for Amplification Exon of Barx2 (pi)
Primer lOx dNTP Mgcl2 Taq Primer DNA H20
Buffer (lOmM) (25mM ) Gold Mix (50pomal/ (0.5
(u/jutl) jliI) mg/pl)
F11/R5 2.5 0.5 1.0 0.2 0.25 2.5 17.8
F6/R6 2.5 0.5 1.0 0.2 0.25 2.5 17.8
F9/R9 2.5 0.5 1.5 0.2 0.25 2.5 17.3
F10/R10 2.5 0.5 1.5 0.2 0.25 2.5 17.3
F8/R8 2.5 0.5 1.5 0.2 0.25 2.5 17.3
2.4.1.3 PCR programme
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Two touchdown PCR programmes were used as follow.
One was used for amplifying exon 1, 2 and 3 as follow;
95° C for 10 minutes 1 cycle; 94°C for 30 sec/63 °C for 30 sec/72°C for 42 sec 2cycle;
94°C for 30 sec/61 °C for 30 sec/72 °C for 42 sec 2cycle; 94°C for 30 sec/59 °C for 30
sec/72 °C for 42 sec 2cycle; 94°C for 30 sec/57 °C for 30 sec/72 °C for 42 sec 2cycle;
94°C for 30 sec/55 °C for 30 sec/72 °C for 42 sec 30cycle; then final 72 0 C for 5
minutes.
The second was used for amplifying exon 4 as follow.
95° C for 10 minutes 1 cycle; 94°C for 30 sec/61°C for 30 sec/72°C for 42 sec 2cycle;
94°C for 30 sec/59°C for 30 sec/72 °C for 42 sec 2cycle; 94°C for 30 sec/57 °C for 30
sec/72 °C for 42 sec 2cycle; 94°C for 30 sec/55 °C for 30 sec/72 °C for 42 sec 2cycle;
94°C for 30 sec/53 °C for 30 sec/72 °C for 42 sec 30cycle; then final 72 ° C for 5
minutes.
2.4.1.4 Checking of PCR products by Agarose gel electrophoresis
5 jal of reaction product with 1 ju.1 of electrophoresis buffer were checked on standard
2% agarose run at 100-120 volts in lx TAE. The 100 bp DNA ladder was used as a
convenient marker for size estimates of the products. The gel was stained with
ethidium bromide and visualised under UV light. Figure 2-9 shows the results of
products of genomic PCR for primer F6/R6 of barx2 in cancer cell lines.
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Figure 2-9 the Result of Products of Genomic PCR in Cancer Cell
Lines by Using Primer F6/R6 of Barx2.
2.4.2 Single stranded conformation polymorphism analysis (SSCP)ZHeteroduplex
mutation analysis
2.4.2.1 Electrophoresis
A non-denaturing 10% acrylamide, 3% bis-acrylamide gel was prepared. The buffer
concentration in the gel was lx TBE. 5 microlitres of PCR product were mixed with 2
microlitres of denaturing dye (95% formamide, 20mM EDTA, 0.25% Bromophenol
blue and 0.25% xylene cyanol), denatured for 3 minutes at 98°C and then placed
immediately on ice. 7 p.1 of mixture was loaded on to the gel with duck billed tips and
run in the cold room (4 °C) with lx TBE buffer in gel apparatus (PROTEAN ™ II).
The gel was run at 25 mA for 17 hours.
2.4.2.2 Silver staining
Following electrophoresis the gel was transferred on the back-plate to a dish for silver
staining.
The gel was soaked in 10% ethanol for 5 minutes, 1% nitric acid for 3 minutes, then
rinsed briefly in distilled water.
The gel was then soaked for 20 minutes in a freshly prepared solution of lmg/ml
silver nitrate in distilled water, ensuring that silver nitrate was completely dissolved
before being added to the gel. After that, the developer buffer, a solution of 15 g
125
anhydrous sodium carbonate in 500 ml of distilled water and 250 u.1 of the
formaldehyde, was prepared.
The gel was rinsed in distilled water to remove the silver nitrate and 100 ml of the
developer buffer was added until the buffer turned brown and was then discarded.
The remaining 400 ml of developer buffer was added; at this stage the nucleic acid
bands would begin to become visible in the gel. When the desired intensity had been
reached the developer buffer was discarded.
The gel was rinsed twice in the water and the reaction was stopped with 10% glacial
acetic acid for 2 minutes.
The gel was photographed and then dried on the gel drier at 80 °C for 2 hours to make
a permanent record.
2.4.3. Denaturing High Pressure Liquid Chromatograph(DHPLC)) for mutation
screening ofthe Barx2 in cancer cell lines and tumour tissues
2.4.3.1 The genomic PCR of Barx2
Genomic PCR of Barx2 (exon 1 to exon 4) was performed in total 64 cancer cell lines
and 47 cases of colorectal cancer tissues for mutation screening of the Barx2. The
method of genomic PCR for the Barx2 in cancer cell lines or tumour tissues was the
same as description above.
2.4.3.2 The mutation analysis of the Barx2 using DHPLC (WAVE,)
Mutation analysis was performed at the Imperial Cancer Research Fund Mutation
Detection Facility at St James'Hospital, Leeds, UK. DFIPLC was performed using a
Transgenomic Wave machine.
2.4.4 Subcloning ofPCR Product
2.4.4.1 Purification of PCR product
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The PCR products were gel-purified by using the Wizard PCR Preps DNA
Purification System.
A 2% low-melting temperature agarose was prepared and samples were run on low-
melting temperature agarose gel, ethidium bromide stained and visualised under UV
light. The correct slice was cut out from the gel.
The slice (about 300mg) was transferred to a microcentrifuge tube and incubated at 70
°C until the agarose was completely melted.
1 ml of resin was added to the melted agarose slice and then mixed thoroughly for 20
second. One Wizard Minicolumn was prepared for each sample. The syringe barrel
was attached to the Luer-Lok extension of each Minicolumn.
The Resin/DNA mix was pipetted into the syringe barrel and then the syringe
plunger was inserted slowly, and the slurry was gently pushed into the Minicolumn
with the syringe plunger.
The syringe was detached from the Minicolumn, and the plunger was removed from
the syringe. 2 ml of 80% isopropanol was pipetted into the syringe to wash the
column and the syringe plunger was used to gently push the isopropanol through the
Minicolumn.
The syringe was removed and the Minicolumn was transferred to a 1.5 ml
microcentrifuge tube and centrifuged for 1 minute at 13000g to dry the resin.
The Minicolumn was transferred to a new microcentrifuge tube. 50 pi of distilled
water was applied to Minicolumn and after 2 minutes, it was centrifuged at 13000g
for 1 minute to elute the bound DNA fragment. The concentration of post-
purification DNA was estimated by spectrophotometric reading of absorbency at
260 nm (O.D. 260).
2.4.4.2 Ligation using the pGEM-T Easy Vectors
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Ligation reactions were set up as described below
Reagent Quantity
T4 DNA ligase lOx Buffer 1 JLtl
pGEM-T Easy Vector 1 JLtl (50 ng)
PCR product 5 pi (about 25 -75 ng)
T4 DNA Ligase 1 pi (3 Weiss units )
deionized water a final volume of 10 pi
The reaction was mixed by pipetting then incubated overnight at 4 °C.
2.4.4.3 Transformations
For each ligation reaction, two agar/ampicillin/PTG/X-Gal plates were prepared and
equilibrated the plates to room temperature prior to plating
The tubes containing the ligation reaction were centrifuged to collect contents at the
bottom of the tubes. 2 pi of each ligation reaction was added to sterile 1.5 ml tube on
the ice.
Frozen (-70 °C) JM 109 High Efficiency Competent cells were placed in ice until
thawed. Cells were mixed by gently flicking the tube. 50 pi of cells was incubated
with ligation mixture on ice for 20 minutes.
The cells were heat-shocked for 45 seconds in a water bath at exactly 42 °C, and
immediately returned on to ice for 2 minutes.
950 pi of room-temperature SOC medium was added to the tubes containing
transformed cells and incubated for 1.5 hours at 37 °C with shaking.
100 pi of transformation culture was plated onto an agar/ampicillin/PTG/X-Gal plate
and another 900 pi of transformation culture was centrifuged and resuspended in 100
pi of SOC medium then plated onto a second agar/ampicillin/PTG/X-Gal plate.
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The plates were incubated overnight at 37 °C. After overnight incubation, the
blue/white colonies could be seen on the plates. White colonies generally contained
insert.
2.4.4.4 Bacterial culture
2.4.4.4.1, Media and additives
All media was sterilised by autoclaving prior to use.
LB media was provided by the MRC Human Genetics Unit.
Ampicillin;
Ampicillin was added to the above at a final concentration of 50 jug/ml to select for
bacteria carrying the amp antibiotic resistance marker conferred by the plasmid
transformed into the bacteria. Ampicillin (Sigma ) stock solution was prepared sterile
at a final concentration of 50 mg/ml and stored at -20 °C.
2.4.4.4.2, Bacterial culture
5-10 ml of LB containing ampicillin was added into sterile tubes. A single whole
colony was picked up from the plate and transferred to a tube, and incubated at
overnight at 37 °C with shaking. Next morning the cells were pelleted by
centrifugation (1300 rpm at room temperature for 10 minutes)
2.4.4.5 Identification ofbacterial colonies that contain Barx2 plasmid.
PCR was used to identify the bacterial colonies that contain Barx2 plasmid. Barx2
F1/R3 oligonucleotides were used as primer for PCR.
Each PCR reaction mixture contained 2.5 pi lOx PCR buffer, 1.5 pi lOmM MgCl2,
0.5 pi of 10 mM dNTP, 0.2 pi of Taq polymerase (5u/pl), 12.5 pmol of each primer
and lpl suspension bacterial colonies. The total reaction volume was 25 pi.
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PCR was performed under the following condition; 94 "C for 5 minutes in cycle. 94
°C for 30 seconds. 55 °C for 30 seconds. 72°C for 42 seconds, repeated for 35 cycles,
then 72°C for 5 minutes in cycle.
5 pi of reaction product with 1 pi of electrophored buffer were checked on standard
2% agarose run at 100-120 volts in lx TAE and used the 100 bp DNA ladder as a
convenient marker for size estimates of the products (the correct size of Barx2 is 780
bp) .The gel was stained with ethidium bromide and visualised under UV light.
2.4.4.6 Plasmid DNA preparation
QIA Spin Plasmid Kit was used to extract the plasmid DNA.
Pelleted bacterial cells were resuspended in 250 pi of Buffer PI and transferred to a
microfuge tube. 250 pi of Buffer P2 was added and gently inverted the tube 4-6 times
to mix. 350 pi of Buffer N3 was added and inverted the tube immediately but gently
4-6 times, and were centrifuged at 1300rpm at room temperature for lOminutes.
QIAprep spin columns were placed in 2 ml collection tubes, then the supernatant
which had been centrifuged was transferred to a QIAprep spin columns
QIAprep spin columns were centrifuged with 1300rpm at room temperature for 1
minute. The flow-through was discarded
QIAprep spin columns were washed by adding 0.5 ml of Buffer PB and centrifuged
at 1300rpm at room temperature for 1 minute. The flow- through were discarded.
QIAprep spin columns were washed again by adding 0.75 ml of Buffer PE and
centrifuged at 1300rpm at room temperature for 1 minute. The flow- through were
discarded, and the QIAprep spin columns were centrifuged for an additional 1 minute
to remove residual wash buffer.
QIAprep spin columns were placed in a steriled 1.5 ml microfuge tubes. To elute
DNA, 50 )Ltl of 10 mM Tris-HCL, pH 8.5 was added to center of each QIAprep spin
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columns, let stand for 1 minute at room temperature and then centrifuged it for 1
minutes.
The concentration of plasmid DNA was estimated by spectrophotometric reading of
absorbency at 260 nm (O.D. 260).
The plasmid DNA was stored at 4° C.
2.4.5 The sequencing ofthe PCR product directly or the plasmid DNA ofPCR product
subclone ofthe Barx2 gene
2.4.5.1 Reaction mixture was prepared (using ABI PRISM™ dRhodamine
Terminator C4cle Sequencing Ready Reaction Kit).
For each reaction, the following reagents was added to a tube and made the total
volume in 20 pi
Reagent Quantity
Terminator Ready Reaction Mix 8 pi
PCR product or
plasmid DNA 30-90 ng (about 2-4 pi )
Primer 3.2 pmol (1 pi )
Distilled water q.s labout 9-7 pi 1
Then mixed well and spun briefly.
2.4.5.2 Sequencing.
The tubes were placed in the HYBAID thermocycler with the following parameters:
Rapid thermal ramp was performed to 96 °C for 1 minute in 1 cycle, then 96 °C for
30 seconds. Rapid thermal ramp to 50 °C was perfromed and samples were left for
15 seconds. The rapid thermal ramp to 60 °C was performed and samples were stood
for 4 minutes, and this was repeated for 25 cycles.
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Rapid thermal ramp down to 4 °C was then performed and held until ready to DNA
precipitate.
2.4.5.3 DNA precipitation
50 jLtl of 100% cold ethanol and 2 pi of 3 M sodium acetate (pH 5.6) were added to
each tube then mixed thoroughly and incubated at room temperature for 1 hour. The
samples were centrifuged at 13000 g for 20 minutes at 4 °C and then ethanol was
removed. 0.5 ml of 70% cold ethanol was added to each tube and then centrifuged at
13000 g for 15 minutes at 4 °C. Ethanol was removed and the samples were dried in a
Universal Vacuum System for 2-5 minutes.
2.4.5.4 Analysis of sequence result
The samples were run on an ABI 377 DNA sequencer (Agnes Gallagher MRC
Human Genetics Unit), and reactions were analysed using ABI analysis software.
The Figure 2- 10 shows an example of sequence analysis by using ABI analysis
software.
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Figure 2- 10 The Example of Sequence Result in ABI Analysis
Software for the Barx 2 F6/R6 in ovarian cancer cell line
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77iis w an example ofsequence analysis using analysis software, showing direct
sequencing of the genomic PCR product ofBarx2 (F6/R6) in the ovarian cancer cell
line PE04. Each peak represents an individual deoxyribonuecleotide base (for
example; cytidine, thymidine etc.).
2.4.6 DNA methylation investigation
The methylation status of Barx2 locus segments was studied using methylation
sensitive-insensitive enzymes Hpall/Mspl. Hpall is a methylation restriction
sensitive enzyme that recognises the sequence CCGG, an isoschizomer of Mspl, and
blocked by methylation C of at CpG residue. Mspl is a methylation insensitive
enzyme, an isoschizomer of Hpall, and it can cleave the sequence even when the
internal C residue is methylated.
10 pg of cancer cell line DNA was digested with 10 units of the enzymes overnight at
37 °C and run on a 0.7% agarose gel.
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Southern blots were hybridized with a- 32 P-dCTP nick-translated DNA probe in
previously described conditions. The 5' region of the Barx2 used as probe was
derived from a PCR product using Fll/Rl to amplify exon 1 of Barx2 gene using
plasmid DNA of Barx2 as template.
2.5 TheFunctional Analysis OfBarx2 Gene
2.5.1 The transfection ofovarian cancer cell lines with Barx2 gene
2.5.1.1 Plasmid preparation
2.5.1.1.1 Plasmid
PBabe-Hygro, a 5.2 kb plasmid, was kindly donated by Barry D. Nelkin. This
plasma confers resistance to Hygromycin (hmB) under the control of a retroviral
promoter.
PBabe-Hygro-Barx2 that the full length human Barx2 cDNA was cloned into PBabe
-Hygro expression vector was kindly donated by Dr Barry D. Nelkin.
The methods of bacterial transformation and extraction of plasmid DNA were as
described above, expect that culture plate used just agar/ampicillin plate.
2.5.1.1.2 Linearisation and purification ofplasmid DNA
The plasmids were linearised by using the restriction enzyme Not I which cuts out
with the resistance marker or the resistance marker and Barx2 gene sequence in each
of the plasmids. This was done to improve the transfection efficiency of the plasmid.
The DNA was purified by using the Wizard™ DNA Clear-Up Resin.
2.5.1.2 The transfection of ovarian cancer cell lines with Barx2 gene
2.5.1.2.1 Ovarian cell lines culture
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Sterile condition were maintained routinely. Cell lines were maintained on RPMI or
DMEM/10% FCS/P+S. Cells were routinely cultured in humidified incubators at 37
°C, 5% C02. Sterile culture flasks, universal tubes, freezing vials, glassware, and
solution were used throughout. All tissue culture was carried out in a laminar flow
hood. Cells were harvested by washing twice in PBS and incubating with a minimal
amount of trypsin/versene. Cells were resuspended in 10% FCS media and pelleted at
1200 rpm for 5 minutes for further manipulation.
Cells were frozen in liquid nitrogen, after initial storage for 24 hours at - 70 °C,
preserved in freezing mix composed of 10 % RPMI in FCS. Recovery of the cells
was effected by rapid thawing of the vial in a beaker of water at 37 °C, followed by
washing twice in media, and plating into flasks.
OAW42, PEOl, PEOlcDDP PE04, PE06, A2780, ON3 and OVCAR3, which are
ovarian cancer cell lines, were used as recipient cell lines in this project. OAW42
PE04, PE06, A2780 and PEOl are maintained on RPMI/10% FCS/P+S, OVCAR3
and ON3 is maintained on DMEM /10% FCS/P+S. PEOl cDDP is a cell line derived
from PEOl but is resistant to Cisplatin about 2-3 fold and also maintained on
RPMI/10% FCS/P+S.
2.5.1.2.2 Effectene transfection of plasmid DNA into OAW42, PEOl PE04, PE06,
A2780 and PEOl cDDP cell lines.
Two to three days before transfection, 2 xlO5 cells of OAW42 cells or 3 xlO5 cells of
PEOl or PEOl cDDP were seeded per 60-mm dish in 5ml of RPMI/10% FCS/P+S.
Cells were incubated at 37 °C and 5% C02 in an incubator. The dishes should be 80%
confluent on the day of transfection.
The Effectene volume was first optimised for each cell line, keeping the amount of
DNA and time for transfection constant. After this, transfection was routinely
performed, under the following condition:
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1 jug of plasmid DNA (2 jul) was diluted in TE, pH 7.4 with the DNA-condensation
buffer to a total volume of 150 jul. 8 pi of Enhancer was added and mixed by
vortexing for 1 second.
The sample was incubated at room temperature (20-25 °C) for 2-5 minutes and then
the mixture was spun down for a few seconds to remove drops from the top of the
tube.
25 pi of Effectene Transfection Reagent was added to the DNA-Enhancer mixture.
Then the sample was vortexed for 10 second.
The sample was incubated for 10 minutes at room temperature (20-25 °C).
While incubating the sample, the media was gently aspirated from the plate, and cells
was washed once with PBS. 4 ml of fresh RPMI/10% FCS/P+S was added to the
cells.
1 ml of RPMI/10% FCS/P+S was added to the reaction tube containing the
transfection complexes then mixed by pipetting and immediately added drop-wise
onto the cells in 60-mm dishes. The dish was gently swirled to ensure uniform
distribution of the complexes.
The cells were incubated with the transfection complexes at 37 °C and 5% C02 to
allow for gene expression.
2.5.1.2.3 Lipofectin transfection of plasmid DNA into OVCAR3, A2780 and ON3
cell lines.
2x 105 cells/60-mm dish were seeded in 4 ml of DMEM /10% FCS/P+S.
Cells were incubated at 37 °C and 5% C02 for 24-48 hours. Cells were 30-50%
confluent.
The following mixtures were prepared in sterile tubes respectively;
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Mixture 1: For each transfection dilute 2 jLtg (4jli1) DNA into 100 jlxI of DMEM.
Mixture 2: For each transfection dilute 10 jlxI of Lipofectin into 100 |ll of DMEM,
and allowed to stand at room temperature for 40 minutes.
Combined the two mixtures and mixed gently then incubated at room temperature for
15 minutes.
The cells were washed once with 2 ml of DMEM.
1.8 ml of DMEM was added to each tube containing Lipofectin reagent-DNA
complexes. Mixed gently then overlaid onto cells.
The cells were incubated at 37 °C and 5% C02, A2780 for 6 hours and each of
OVCAR3, ON3 for 12 hours.
The medium containing Lipofectin reagent-DNA was replaced with 4 ml of DMEM
/10% FCS/P+S and incubated the cells at 37 °C and 5% C02 for other 48 hours.
2.5.1.2.4 Selection conditions
One exogenous dominant selectable marker was used for positive selection.
The bacterial gene Hygromycin B phosphotransferase is a gene isolated from E.Coli
which inactivates Hygromycin B (hmB), an aminocyclitol antibiotic produced by
streptomyces hygroscopicus which inhibits protein synthesis by interfering with
ribosomal translocation and with aminoacyl-tRNA recognition. Hygromycin B
resistance was mediated by the expressing plasmid.
To determine the optimal geneticin concentration of Hygromycin B in selection
medium, kill curves for Hygromycin B were performed for each of the parent un-
transfected cell lines prior to introduction of the selectable markers by either
Lipofectin or Effectene transfections.
2.5.1.2.5 Picking of resistant clones
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After selection of cells using the Hygromycin B and conditions that completely kill
parallel controls, resistant clones arising from single cells were picked at 3 weeks and
7 weeks after imposition of selection. When colonies reached about or over 1 mm in
size, the flask or dish was washed with PBS. The tip of a fine tipped pastetette was
half filled with trypsin/versene and applied to the clone, pipetting gently up and
down until the cells were dislodged and then transferred to 24 well plates containing
500 jllI of selection media. The next day morning, the media was replaced by 1-2 ml
media containing Hygromycin B at the appropriate concentration for that cell line.
2.5.2 Identification oftransfection result ofBarx2 gene in ovarian cancer cell lines
2.5.2.1 PCR of genomic DNA to identify Barx2 cDNA and Hygromycin B in ovarian
cancer cell lines transfected with Barx2 gene.
2.5.2.1.1 Rapid miniprep extraction of DNA of cell lines.
Cell lines were harvested, the medium was aspirated and cells were washed with PBS
twice. Trypsin solution was added. After the cells detached from the flask, they were
collected in medium. Using the QIAamp Kit carried out the extraction of DNA of cell
lines.
20 p.1 of proteinase K was pipetted into the bottom of a 1.5-ml microcentrifuge tube.
The cell sample (up to 10 7 in 200 jul PBS) was added to 1.5-ml microcentrifuge tube,
adding 200 jal of buffer AL to sample, mixing by vortexing for 15 sec.
The sample was incubated at 56 °C for 10 minutes, briefly centrifuged to remove
drops from the inside of the lid.
200 |ul of absolute ethanol was added to the sample, and mixed again by vortexing for
15 sec, and briefly centrifuged again.
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The lysate was applied to the QIAamp spin column and centrifuged at 6000g for 1
minute. Placing the QIAamp spin column in a clean 2 ml collection tube, the filtrate
was discarded.
500 pi of Buffer AW1 was added and centrifuged at 6000 g for 1 minutes. The
QIAamp spin column was then placed in a clean 2 ml collecting tube and discarded
the collected tube containing the filtrate.
500 pi of Buffer AW2 was added and centrifuged at full speed for 3 minutes. The
QIAamp spin column was then placed in a clean 2 ml collection tube and the
collected tube containing the filtrate was discarded then centrifuged at full speed for a
further 1 minute.
The QIAamp spin column was placed in a clean 1.5 ml collecting tube and the
collected tube containing the filtrate was discarded. 100 to 200 pi of Buffer AE was
added then incubated at room temperature for 2 minutes, and centrifuged at 6000 g
for 2 or 3 minutes to elute the DNA, and was stored at 4 °C after the concentration
was estimated by spectrophotometer.
2.5.2.1.2 Genomic PCR for testing the Barx2 insert and Hygromycin B marker in the
Ovarian cancer cell lines transfected with Barx2 gene or Hygromycin B
The Barx2 gene primer was used F1/R3 (see above).
The Hygromycin primer was used as following;
5' -ATTTCGGCTCCAACAATGTC-3'
5'-GATGTTGGCGACCTCGTAT-3'
PCR mixture and condition were the same as those described above.
2.5.2.2 Northern blot and RT-PCR for detecting expression of Barx2 gene
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in ovarian cancer cell lines transfected with Barx2 gene.
The Barx2 gene primer used was F1/R3. The PCR product of full length coding region
sequence of Barx2 was used as probe. The method ofNorthern blotting and RT- PCR
was the same as those described above.
2.5.3 Growth Curves
2.5.3.1 Setting up
Log phase cultures were harvested and 5xl04 cells were seeded in 24 well trays. The
media was changed 24 hours prior to first harvest and every 3 days thereafter. Cell
counts were harvested every 2 or 3 days depending on the cell line up to 21 days in
some cases.
2.5.3.2 Harvesting cells
The medium from the wells to be counted was removed, and the cells were washed
twice with 250 pi PBS. Then 250pl trypsin/versene was added and the cells were left
for 15 minutes to completely detach. The cells in each well were syringed 3 times and
200pl of the cell suspension were transferred to one counting pot.
2.5.3.3 Use of the coulter counter
The coulter counter was allowed to warm up for 15 minutes. The orifice tube was
rinsed with saline. A background count was taken to ensure that counter is working
properly (background counts >20 suggest caution). The sample was then counted by
aliquoting 9.8 ml saline to a counting pot and 200ul trypsinised syringed single cell
suspension was added, mixing and sampling counts from each pot three times. After
sampling, the coulter counter was rinsed with saline.
2.5.3.4 Analysis
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The cell counter were plotted against time either on logarithmic or linear plots
allowing comparisons between parent/control cell lines and cell lines transfected with
the Barx2 gene
2.5.4 MTTassay
The matrigel invasion, migration and adhesion assays outlined below both depended
on the MTT assay in order to quantitate the differences between cell lines tranfected
with Barx2 gene and control cell lines. Development of the MTT assay is outlined in
this section.
An initial MTT toxicity curve was generated to determine the optimal MTT
concentration for the 3 hour incubation. 5x103 cell were plated in each well of a 96
well plate. MTT was made up as a filter sterilised solution in BPS (2mg/ml) and
wrapped in foil (MTT is light sensitive). 24 hours later MTT at a range of
concentration between 0.005 to 1.4 mg/ml was added to the 96 wells and then
incubated for 3 hours after wrapping the plate in foil.
A computerised plate reader to read absorbance at 570 nm was allowed to warm up
for 15 minutes prior to use.
The 96 well plates were unwrapped and MTT was aspirated to a burnable waste
container. 200 pi of spectroscopic grade DMSO was added and the content of the
well was mixed to solubilise MTT. The OD at 570 nm was then read immediately
and the data was to a simple output data display program. Data was printed out and
the peak concentration indicating activity at that cell number was observed from a
graph plotting concentration of MTT versus OD at 570 nm. Figure 2-11 shows kill
curve of OAW42 for MTT. The plate was disposed of in sawdust filled bag to
burnable waste bin.
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Figure 2-11 Kill curve of OAW42 for MTT.
Kill Curve Of MTT For OAW42 Cell Line
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2.5.5 Adhesion assays
This assays quantifies the ability of cells to attach to components of extra-cellular
matrix. It was done by using Collagen-Coated Cell Wells™ (24 well tray).
Late log-phase cells were harvested and syringed to form a single cell suspension. The
cells were resuspended with RPMI (serum free). 5xl04 cells/ml/well were placed in
each Collagen-Coated Cell Well. At same time, 5xl04 cells/ml/well were placed in each
well of 24 well tissue culture tray as a control. The sample was incubated at 37 °C
and 5% C02 for 24 hours. After that, the media was removed very gently. The cells
were gently washed 3 times in serum free media. The number of cells on the well was
assessed using the MTT assay. 100 jllI of 2mg/ml MTT was added into each well and
the sample was incubated at 37 °C and 5% C02 for 3 hours with wrapped in foil.
The media was removed and 1 ml of spectroscopic grade DMSO was added. The
sample was incubated for 15 minutes at room temperature with the shaking platform
and then 200 pi aliquots of solubilised crystals were transferred to 96 well tray and
read at 570 nm on the spectrophotometer.
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2.5.6 Matrigel invasion assays
This assay is based on the principle that basement membrane plays an important
part as a barrier against tumour cell invasion. The invasion assay measures the ability
for cells to invade through a matrigel layer in vitro. It is necessary to inhibit protease
inhibitors present in serum in order to allow invasion to occur. Therefore FCS was
pre-treated by lowering the pH to 3.0 for 2 hours with HC1 and then neutralised to
pH7.3 with NaOH.
Pre-aliquoted Matrigel (Beckton Dickinson) was thawed on ice and diluted 1:5 in ice
cold pre-treated culture medium at a final concentration of 1ml.
The matrigel layer was formed in Transwell cell culture chambers (Costar) which
consist of 12 well plates with inserts containing a porous Nuclepore 12um
polycarbonate membrane. The chamber's margin at the interface with the filter was
treated by rubbing a fine layer ofparaffin was to provide a water-repellent treatment
and prevent meniscus formation thereby ensuring even matrigel thickness over the
surface of the polycarbonate membrane. The membrane was wetted with cold culture
medium and re-aspirated with a fine-tipped pastette. 140 p.1 of cold diluted matrigel
was aliquoted into each transwell and even distribution of the extracellular matrix was
ensured by tilting. The matrigel was allowed to gel by incubating at 37 °C for 30
minutes.
The cells to be used were trypsinised and washed 3 times in with cold culture
medium and resuspended at a concentration of 105 cells per 0.5 ml. 1 ml culture
medium was aliquoted into the lower compartment and 0.5 ml (105) cells were
dispensed into the upper compartment. The transwell plate was incubated in a
humidified incubator for a varying time course in order to optimise the time for the
invasion assay.
The number of cells on the upper and under-surface of the porous membrane were
assessed using the MTT assay. 50 and 100 )Ltl of MTT stain were added to the upper
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and lower compartments of the transwell respectively and incubated for 3 hours. The
crystals were removed from the under-surface of the porous membrane using a 1 cm
diameter circular Whitman filter paper, and the crystals were solubilised by
immersing it in 1 ml DMSO. The medium was decanted from the upper chamber and
the transwell was placed in a culture well containing 1 ml DMSO, and rotated on a
clinical specimen rotator. 200 pi aliquots of solubilised crystals were transferred to a
96 well plate and read at 570 nm on a spectrophotometer. Invasion was determined
as the ratio of the under-surface A570 reading relative to the upper surface A570.
On the basis of the previous experiment in our lab, 48 hours and 72 hours were used
for OVCAR3 and OAW42 invasion in matrigel respectively.
2.5.7 Transwell migration assay
The purpose of this assay was to quantify the haptotactic response of the ovarian
cancer cells to extra-cellular matrix, i.e. observation and quantification of extra-cellular
matrix component directed stimulation of cellular migration. This assay allows
assessment of the relative contribution of the components to stimulation of migration
and also allows an assessment of the effect of the Barx2 gene introduction on this
process.
Cells were prepared so they were in the log phase of growth.
2 mg/ml stock solution of MTT in PBS was prepared and then filtered (0.22p) it and
stored it at 4 °C wrapped in foil to protect from light.
The solutions of collage IV and BSA were prepared at a concentration of 10 pg/ml in
PBS and then the BSA solution was filtered.
250 jitl of the lOjig/ml of collage IV solution per well was added in a 24 well tissue
culture tray.
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The transwell cell culture insert was placed in the tissue culture well so the underside
of the well was in contact with the solution. Then incubated for 1 hour at 37 °C.
The transwell was transferred to 24 well plate contained 250 Jul of 0.1% BSA in PBS
per well and then incubated at room temperature for 1 hour.
The cells were trypsinised then washed the cells three times in 10 ml of serum free
RBMI 1640 for OAW42 and DMEM for OVCAR3. The cells were syringed four
times then counted and the cell density was adjusted to 5xl04cells per 100 jutl in
serum free RPMI 1640 for OAW42 and DMEM for OVCAR3.
The under surface of the well insert was washed twice and the BSA with 250 jul of
PBS was replaced.
400 jliI of serum free RPMI 1640 for OAW42 and DMEM for OVCAR3 was placed
in the lower compartment.
100 pi of serum free medium containing 5xl04 cells was added to the upper
compartment, and incubated for 48 hours.
10 and 40 jal of 2mg/ml MTT was added to the top and bottom compartments
respectively. Then incubated 3 hours at 37 0 C with the plate wrapped in foil.
The untreated MTT was aspirated off from the lower well and pipetted off from the
upper well.
The crystals were removed from the under surface of the well by using a 1 cm
diameter circular whatman filterpaper and soaked in a 1 ml of spectroscopic grade
DMSO. The crystals were solubilised by placing on a shaking platform for 15
minutes.
The transwell was placed in a culture well containing 1 ml DMSO and the crystals
were solubilised by placing on a shaking platform for 15 minutes.
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200 pi aliquots of solution per sample were transferred into a 96 well plate and read
at A570 nm . DMSO blanks were placed in the first column of tray to blank the plate
reader. Colorimetric analysis (see above) was performed and the percentage migration
was quantified compared with control plates (transwells coated with 0.1 % BSA only
on their under-surface).
2.5.8 The analysis ofcell cycle
A single cell suspension was prepared by trypsinisation. Cells were fixed and stained
with propidium iodide to bind DNA, then passed through the flow cytometer.
Relative DNA content was assessed and distribution of the population of the cells
with respect to the cell cycle was observed. A typical DNA histogram is shown in
Figure 2-12. Cells are predominantly 1 n with respect to DNA content, i.e., most are
in Go/Gi. The second peak is for those in G2/M phase post replication, when cell
DNA content is 2 n. Relatively few cells exist in S phase.






2.5.9 The FACSannexin-V assayfor apoptotic cells
This assay is devised to incorporate the total number of apoptotic cells released into
the media rather than looking at the rate at which cells are being committed into
apoptosis; cells which have undergone apoptosis and which are subsequently floating
around in the media are therefore included along with the early-stage apoptotic cells
which have not yet become detached.
The media was removed from each petri dish and transferred to labelled FACS tubes
then spun at 1700rpm for 4 min and discarded to leave cell pellet at the bottom of
tube.
The petri dishes were washed with 2 ml of PBS, and thenl.5 ml of trypsin was added
then incubated in incubator until cells have become detached. 1.5 ml of RPMI with
10 %FCS was added to stop the trypsin. 3 ml of cell suspension was added to each
of the relevant cell pellets, and then spun at 1700rpm for 4 min.
The pellet was resuspend in 1 ml of RPMI with 10 % FCS and left in an incubator
for 5 min, and then spun at 1700rpm for 4 min.
The pellet was resuspend in 1 ml of ice cold PBS and then spun at 1700rpm for 4
min. The pellet was resuspend in 100 jliI of ice cold Annexin-v buffer, and then 10 pi
of and 1 pi of FITC were added respectively in each tube as appropriate, and
incubated in the dark for 15 min at 4 °C.
400 pi of Annexin-v buffer was added and then the samples were run on the FACS
within 1 hour.
Apoptotic cells were then read on a display of red fluorescence at flow cytometry.
Apoptotic cells have high fluorescence and side scatter. Necrotic cells have
intermediate fluorescence and low side scatter.
147
2.5.10 Growth inhibation assay ofPEOl/PEOlcDDP with Cisplatin.
The objective of this part of work was to explore whether the Barx2 gene plays a role
in multidurg resistance in ovarian cancer cells. Two cell lines were used in this assay.
The sensitivity of the two cell lines to varying concentrations of cisplatin was directly
compared in growth assay for each other. A one cell line was PEOl platinum sensitive
parent line; the controls vector only transfected clonal derivative line PEOl-Hygl.6
and the Barx2 transfected clonal derivative line PEOl-BXll.l. The other cell lines
were PEOl cDDP parent line that is derived from PEOl but is resistant to cisplatin
about 2-3 fold, a vector control only transfected clonal derivative line PEOlc DDP-
Hyg2.2 and a Barx2 transfected clonal derivative line PE01cDDP-BX1.3.
A single cell suspension was prepared by trypsinisation and syringing for each cell
lines.
For each cell line, 2.5x 104 cells/well /I ml of IPMR/10% FCS/P+S was seeded in 24
well tray in quadruplicate per each concentration of cisplatin.
The cells were incubated at 37 °C and 5% C02 for 2 days to adhere, and then 4 wells
cells were harvested for each cell line to count the cells by the coulter counter
method.
The media was then replaced with fresh media containing varying concentration of
cisplatin between 300nm to 3 |um /ml The cells were exposed to cisplatin at 37 °C
and 5% C02 and incubated for further 72 hours. The media containg Cisplatin was
removed from the wells. The cells were refed with IPMR/10% FCS/P+Sand and then
the media without cisplatin was changed for every 4 days thereafter. The number of
colonies per plate was counted every 4 days up to 12 days by using the coulter
counter method (see above).
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3 LOH ANALYSIS FOR THE CHROMOSOME 11 q BETWEEN
D11S1894 AND D11S1309 IN CANCER
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The previous LOH data suggested disruption of chromosome 11 q23.3 - 24.3 (D11S934
to D1 IS 1320) region (4.5 Mb) frequently occurs in ovarian cancer and colorectal cancer,
and is associated with poor prognosis in epithelial ovarian cancer patient (Gabra H, et al.
1996). It has also been confirmed that the Barx2 gene is located within this minimal
region at between the markers D11S912 and D11S1320 (Krasner A, et al. 2000).
Therefore, 14 polymorphic which all were across the 4.5 Mb region within chromosome
1 lq24-25, were chosen to repeat analysis of the chromosome 11 q24 region D1 IS 1894
and D11S1309 in colorectal cancer in order to more refine the LOH analysis and
clinicopathological associations.
3.1 Re-arrangment ofPolymorphic Microsatellite Repeat Markers Order
The study used 14 polymorphic microsatellite repeat to screen a population of patients
with colorectal cancer. These polymorphic markers are outlined in Table 3-1
Table 3-1 Polymorphic Microsatellites: Identity and Location
Locus Location Name
D11S1894 1 lq24






D11S4131 1 lq24 AFMb002vdl
D11S910 1 lq24 AFM154yh2
D11S1320 1 lq24 AFM234yflO
D11S874 1 lq24
D11S4085 1 lq24 SHGC-20717
D11S969 1 lq24 -25
D11S1309 1 lq24 -25 AFM200vg5
The order of markers in the region was re-analysed by Dr Grant C. Sellar and Dr Karen
P. Watt. Bacterial artificial chromosomes (BACs) containing the markers were
identified. Genbank data base was searched using BLAST, entering the primary
sequence of repeat markers. These were then subjected to Nucleotide identify X (NIX)
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analysis. BAC clones are in the process of being sequenced as part of the Human
Genome Project. This allowed a tiling path of markers to be developed. D11S969 and
D11S1309 are not identified on any BACs and therefore NIX analysis has not been
possible for these. D11S1894 has been identified to be located in chromosome 11 q23
centromeric to D11S912. The centromeric markers (D11S1894 to D11S1884 and
D11S910 to D11S1309) have been ordered with respect to each other. GATA72A01,
D11S4126 and D11S4131 cannot yet be ordered with respect to each other but they are
represented on the same BAC and they therefore spread over a maximum of 200 kb (see
Figure 3-1).
Figure 3-1 the Order of Microsatellite Markers Used in LOH Study
CENTROME TELOMER
yellow box = these polymorphic microsatellites marker can not be ordered with
respect to each other but they are represented on the same BAC and they
therefore spread over a maximum of200 kb.
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3.2 Loss ofheterozygosity rates ofwithin Region Between D11S1894 and
D11S1309for all subgroups
Molecular analyses of blood-tumour pairs from 39 patients with colorectal cancer were
used for this part of analysis.
Loss of heterozygosity was observed with variable frequency using different markers.
The colorectal cancer samples were classified into many subgroups depending upon the
location of the disease, Dukes' stages, differentiation, vascular invasion, and perineural
invasion and mucin production. The comparisons were made between LOH and the
subgroup classification of colorectal cancer of the samples analysed. LOH results for all
markers in this study are displayed in Figure 3-2 and LOH results in subgroups are
summarised at Table 3-2 and Table 3-3. Clear examples of LOH at D11SGATA69G01
and D1 IS 1884 are shown in Figure 3-3.
In Figure 3-2, Top and Bottom, case numbers for patients' tumour/blood pairs. Left,
microsatellite loci used to detect LOH. Hatched boxes represent homozygous; filled

















































































































































































































































































































































































































































































































































































































































































































Primary LOHdata from two cases critical to the definition of the locus. Blood,
normal DNA; Tumor; tumor DNAshown at left top ofeach picture from patient's blood/
tumor pairs C1/C2 and C5/C6 (left). Microsatellite loci are shown at top. Densitometric
ratios of allele peak area were calculated (shown at bottom), and values between 0.0
and 0.7 are taken to indicate LOH
Table 3 -2 Loss of Heterozygosity Rates within Region between
D11S1894 and D11S1309 in Colorectal Cancer
Locus No. Analysed No. informative No. LOH %. LOH
D11S1894 39 12 7 58.33
D11S912 39 26 11 42.31
D11S4150 39 25 9 36.00
GATA69G01 39 9 3 33.33
D11S1884 39 9 5 55.56
D11S4126 39 28 7 25.00
GAT72A01 39 16 7 43.75
D11S4131 39 28 13 46.43
D11S910 39 19 5 26.31
D11S1320 39 20 10 50.00
D11S874 39 19 10 50.80
D11S4085 39 25 8 32.00
D11S969 39 12 5 41.67
D11S1309 39 12 4 33.30
Informative number = LOH number plus retention ofheterozygosity number
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Table3-3 Loss of Heterozygosity Rates Within Region Between




Transverse Descending Rectum Unknown
D11S1894 1/1 4/6 0/2 1/1 0/1 1/1
D11S912 3/5 4/9 0/3 0/0 2/6 2/3
D11S4150 1/4 3/7 0/2 0/0 2/8 3/3
GATA69G0 2/2 0/3 0/1 0/0 1/3 0/0
D11S1884 2/3 0/2 1/1 0/0 1/2 1/1
D11S4126 2/5 2/9 0/2 0/1 2/8 1/3
GATA72A01 1/1 5/8 1/1 0/0 1/5 0/1
D11S4131 3/5 4/9 0/3 1/1 3/8 2/2
D11S910 1/3 2/8 0/1 0/0 1/5 1/2
D11S1320 2/2 3/6 0/0 1/1 1/8 3/3
D11S874 3/4 6/9 0/1 0/0 1/4 0/1
D11S4085 1/3 4/10 0/4 0/1 2/5 1/2
D11S969 2/3 0/2 0/1 0/0 2/5 1/1
>D11S1309 1/2 1/5 0/0 0/0 1/4 1/1
LOCUS DUKES' STAGE
A B CI Unknown
VASCULAR INVASION
No Yes Unknown
D11S1894 0/0 3/7 3/4 1/1 7/12 0/0 0/0
D11S912 0/0 4/12 5/11 2/3 7/20 2/3 2/3
D11S4150 0/1 3/11 3/10 3/3 9/25 0/0 0/0
GATA69G01 0/0 2/4 1/5 0/0 3/8 0/1 0/0
D11S1884 1/1 3/6 1/1 1/1 5/9 0/0 0/0
D11S4126 1/1 3/13 2/10 1/4 7/28 0/0 0/0
GATA72A01 0/0 3/8 4/7 0/1 7/16 0/0 0/0
D11S4131 0/1 4/14 7/11 2/2 12/27 1/1 0/0
D11S910 0/0 3/9 1/8 1/2 4/18 1/1 0/0
D11S1320 0/1 2/6 5/10 3/3 9/19 1/1 0/0
D11S874 0/0 6/1 4/6 0/1 9/18 1/1 0/0
D11S4085 0/0 2/11 5/12 1/2 7/23 1/2 0/0
D11S969 0/0 3/6 1/5 1/1 5/11 0/1 0/0
D11S1309 0/1 3/7 1/4 0/0 4/11 0/1 0/0
159
Values given are the number ofcases with LOH in that subgroup/total number of
informative cases in that subgroup.
Table3-3 Loss of Heterozygosity Rates Within Region Between
D11S1894 and D11S1309 for All Subgroups (2)
LOCUS DIFFERENTIATION-OVERALL
Moderate Poor Well Unknown
D11S1894 5/8 1/1 0/2 1/1
D11S912 7/14 2/2 0/3 2/2
D11S4150 5/17 1/4 0/1 3/3
GATA69G01 2/6 1/3 0/0 0/0
D11S1884 3/7 1/1 0/0 1/1
D11S4126 5/20 1/4 0/1 1/3
GATA72A01 5/9 2/3 0/3 0/1
D11S4131 6/17 5/6 0/2 2/3
D11S910 4/12 0/3 0/2 1/2
D11S1320 5/12 1/3 1/2 3/3
D11S874 9/14 1/3 0/1 0/1
D11S4085 7/16 0/4 0/3 1/2
D11S969 3/8 1/2 1/1 1/1
D11S1309 3/9 0/2 0/0 1/1
LOCUS PERINEURAL INFILTRATION MUCIN PRODUCTION
No Yeas Unknown No Yes Unknown
D11S1894 7/12 0/0 0/0 6/11 1/1 0/0
D11S912 10/25 1/1 0/0 11/21 0/4 0/0
D11S4150 9/25 0/0 0/0 8/20 1/5 0/0
GATA69G01 3/8 0/1 0/0 3/8 0/1 0/0
D11S1884 5/9 0/0 0/0 5/9 0/0 0/0
D11S4126 5/26 2/2 0/0 6/25 1/3 0/0
GATA72A01 6/15 1/1 0/0 7/16 0/0 0/0
D11S4131 13/27 0/1 0/0 12/23 1/5 0/0
D11S910 5/18 0/1 0/0 4/14 1/5 0/0
D11S1320 10/20 0/0 0/0 9/17 1/3 0/0
D11S874 9/18 1/1 0/0 9/18 1/1 0/0
D11S4085 7/24 1/1 0/0 8/21 0/4 0/0
D11S969 5/12 0/0 0/0 5/11 0/1 0/0
D11S1309 3/11 1/1 0/0 4/12 0/0 0/0
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Values given are the number ofcases with LOH in that subgroup/total number
informative cases in that subgroup.
In total, of 39 cases of colorectal cancer which could be analysed, 28 cases (71.18 %)
had evidence of LOH involving at least one locus on chromosome 11 q24-25 between
D11S1894 to D1 IS 1309.
For all colorectal cancer, high levels of LOH (> 40 %) were found for seven loci (see
Table 3-2): D11S1894 demonstrated LOH in 7 of 12 informative (58.33%) of cases;
D11S874 in 10/19 (50.80 %) informative tumors; D11S1320 in 10/20 (50.00 %)
informative tumors; D11S4131 in 13/28 (46.43 %) informative tumors; GATA69G01 in
7/16 (43.75 %) informative tumors; D11S912 in 11/26 (42.30.2 %) informative tumors
and D11S969 in 5/12 (41.67%) informative tumors. The lowest frequencies of allele loss
in this region were detected at D11S4126 with only 25% LOH in colorectal cancer.
If one focuses on the most centromeric markers and identifies tumors with secure loss in
this region, a consensus region of deletion can be identified and the shortest region of
overlap (SRO) determined. These are shown in Figure 3.3 to 3.5 (Hatched boxes =
homozygous, filled boxes = LOH, empty boxes = retention of heterozygosity). In cases
where a locus with LOH is separated by an uninformative locus from another that
remain heterozygous, that uninformative locus was included within the shaded bars as
part of the deletion since this region could have been lost. This type of analysis suggests
3 shortest region of overlap corresponding to 3 consensus regions of deletion/allele
imbalance a) between GAT72A01 and D11S4131; b) between D11S912 and D11S4150
and c) between D11S1320 and D11S4085 (see Figure 3.4 to 3-6). The size of these
region is <200kb, 200kb and 2Mb respectively. The frequency of LOH was 58.6% at
D11S912 to D11S4150, 50.0 % at D1 IS 1320 to D114085 and 42.1 % at GAT72A01 to
D11S4131. Of the total 39 cases, 10 cases (25.6 %) had LOH at all loci. 11 cases
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3.3 The relationship between LOH and clinicopathological features of
colorectal cancer.
Fisher's exact test was used to analyse whether loss of individual markers or of the
SROs was significantly associated with the clinicopathological features of colorectal
cancer.
3.3.1 Allele imbalance and location ofdisease
No association was evident between LOH at any of the loci tested and the site of
colorectal cancer with respect to the colon (see Figure 3-7).






Location ofdisease in colorectal cancer. AS; ascending. SI; sigmoid. TR; transverse.
RE; rectum
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3.3.2 Allele imbalance and differentiation grade
The only trend towards significance was between D11S 4131 LOH and pathologic
differentiation grade (p= 0.0561). The poorly differentiated tumor had particularly high
levels of LOH at D1 IS 4131 (See Figure 3-8).
Figure 3-8 The Relationship Between % LOH and Differentiation
Grade
Order of Microsatllites
Differentiation grade ofcolorectal cancer. Mod; moderate differentiation. Poor; poor
differentiation
3.3.3 Allele imbalance and clinical stage
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No significant difference was seen at any locus, comparing early stage with lately stage
in colorectal cancer patients. The only apparent trend towards significance was between
D11S4085 LOH and Dukes' stage. More advanced stage had higher levels of LOH at
D1 IS 4085 (p=0.07)(Figure 3-9).














Clinical stage ofcolorectal cancer. A; Dukes' stage A. B; Dukes' stage B; C; Dukes'
stage CI
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3.3.4 The relationship between minimal deleted regions(SROs) and
features ofcolorectal cancer.
There were no significant difference between LOH at SROs and clinicopathological
features of colorectal cancer. These results were outlined at Table 3-4
Table 3-4 The Relationship between LOH at SROs and
Clinicopathological Features of Colorectal Cancer.
SRO Dukes' Stage Differentiation Grade
A B C NK Well Moderate Poor NK
D11S912
-D11S4150 0 8/15 6/11 3/3 0/3 11/22 3/4 3/3
(53.3) (54.6) (50.0)
GAT72G01
-D11S4131 0/1 6/19 8/16 0/1 0/4 9/28 5/7 0/1
(31,6) (50.0) (32.1)
D11S4131
-D11S4085 0/0 8/20 8/15 3/3 1/3 13/28 3/7 3/3
(40.0) (53.3) (46.4)
Values given are the number of cases with LOH in that subgroup/total number of
informative case in that subgroup (% LOH in brackets).
NK = not known
3.4 Relationship between survival ofpatient with colorectal cancer and
LOH
In order to assess effects on survival of LOH at individual markers, Kaplan-Meier/Log
Rank analysis was performed. There was no significant correlation between losses at
individual markers and survival of patients with colorectal cancer. The analysis
results were summarized in Table 3-5
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Kaplan-Meier/Log rank analysis was also performed to assess effects on survival of
LOH at SROs. Deletions of the SROs were not significantly associated with
survival of patients with colorectal cancer. The results are outlined in Table 3-6.
Table 3-6 The Results of Kaplan-Meier/Log Rank Analysis for the
Consensus Region
Consensus Region p value
D11S912—D11S4150 0.5829
GATA72AO 1 —D11S4131 0.2450
D11S1320—D11S4085 0. 7403
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4. EXPRESSION OF BARX2 IN OVARIAN CANCER
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The preceding investigation showed that frequent LOH was present at chromosome 11
q24-25 in cancer (Gabra H, et al. 1996), suggesting the presence of tumour suppressor
genes in this regions. Barx2 is also located within the critical 8.5 Mb LOH region of
chromosome 11 q24-25 (Krasner A, et al. 2000). This raises the question; is Barx2 a
TSG? To begin to address this question, it is important to understand the expression of
Barx2 in normal ovarian epithelium tissues, ovarian cancer cell lines and ovarian cancer
tissues. Fresh samples were obtained from 10 cases of normal ovarian tissue, 28 cases of
primary epithelial ovarian cancer tissue and 10 ovarian cancer cell lines. RNA of theses
samples was extracted, and then RT-PCR and Northern blotting were performed
according to standard methods as described in section of the materials and methods.
4.1 Results of reverse transcription polymerase chain .
A total of 4 pair of RT-PCR primer (Fl/Rl, F2/R2, F3/R3 and F1/R3) were used in this
project. According to the cDNA sequence of Barx2 gene, we designed four pair of
primer for Barx2 (see Figure 4-1) in order to analyse expression for each exon as well as
full length cDNA of Barx2 in ovarian cancer cell lines and tissue.
Figure 4-1 Human Barx2 RT-PCR Primers
►
F1 | F2 I F3
An 1 Exon2 | Exon3 Exon4
R1 R2 R3
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4 .1.1 Theexpression ofBarx2in normal ovarian epithelium
Figure 4-2 shows the expression of Barx2 (F1/R3) in 10 normal ovarian epithelium
tissues. These samples came from the patients with uterine leiomyoma. After total
hysterectomy and unilateral salpingo-oophorectomy, the pathologist confirms the
ovaries as normal. RNA was isolated from preoperatively stripped ovarian epithelium.
The results show that there is a 780bp PCR product in all normal ovarian epithelium.
Figure 4-2 the Expression of Barx2 (F1/R3) In Normal Ovarian
Epithelium
4.1.2 The expression ofBarx2 in ovarian cancer cell lines.
A total 4 separate experiment of semiquantitative RT-PCR have been performed to test
the expression of the Barx2 in 10 ovarian cancer cell lines. Figure 4-3 to Figure 4- 7
show the results of a representative experiment of semiquantitative RT-PCR, in which
the Barx2 expression is assayed in ovarian cancer lines using different primer
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combinations (Fl/Rl, F2/R2, F3/R3 and F1/R3). All of results of expression of Barx2 in
ovarian cancer lines are outlined in Table 4 -1
Figure 4-3 The Expression of Barx2 Fl/Rl in Ovarian Cancer Cell
Lines












Figure 4-5 The Expression of Barx2 F3/R3 in Ovarian Cancer Cell
Lines




Figure 4- 7 The Expression of y-act In Ovarian Cancer Ceil Lines
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Table 4 - 1 The Expression of Barx2 in Ovarian
Cancer Cell Lines
Cell Barx2
Line Fl/Rl F2/R2 F3/R3 F1/R3
OAW42 _* - - -
A2780 - - +* -
OVCAR3 + + + +
OVCAR5 + + + +
PEOl + + + +
PEOlcDDP - + + +
PE04 - - + +
PE06 - - + +
PEOl 6 + + + +
SW262 + + + +
*- = Negativefor expression ofBarx2
*+= Positive for expression ofBarx2
In summary, (1) In a total of 10 ovarian cancer cell lines, 5 of 10 are
downregulated/absent for expression of Barx2 Fl/Rl, and 4 cell lines are
downregulated/absent in expression of Barx2 F2/R2, and only 1 cell line is
downregulated/absent in expression of Barx2 F3/R3. It is worth noting that in most of
the ovarian cancer cell lines, downregulated/absent expression of Barx2 is principally at
Fl/Rl. One explanation for this difference observed between the primer pairs is an
alteration in the nucleotide sequence bound by the Fl/Rl primer in exon2. Alternately,
we may just be observing a variation in the sensitivity of different primer pairs to
discriminate levels of Barx2 expression. The expression of Barx2 as detected by F1/R3
RT-PCR is downregulated/absent in OAW42 and A2780. (2) When expression of Barx2
full-length cDNA (F1/R3) was tested, two products were generated in all of ovarian
cancer cell lines running at 780bp and 500bp. (Figure 4-6).
4.1.3 The expression ofBarx2 in ovarian cancer tissue
4.1.3.1 The frequency of the Barx2 in ovarian cancer tissue
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Figure 4-8 to Figure 4-10 show the expression of Barx2 (Fl/Rl, F2/R2 and F3/R3) in 28
ovarian cancer tissue respectively. Figure 4-11 show the expression of g-actin in the
same ovarian cancer tissue The result was summarised in Table 4-2.
Figure 4-8 The Expression of Barx2 (Fl/Rl) In Ovarian Cancer Tissue
12 18 19 25 52 20 33 59 60 69 71
Barx2Fl/Rl
^ 8
72 76 77 87 88 91 93 94 95 96 98 55 99 «! EC
Figure 4-9 The Expression of Barx2 (F2/R2) In Ovarian Cancer tissue
2 5 8 9 12 18 19 25 52 20 33 59 60 69 71 72 76
Tt.i. H7T77/R-7- * rnmmmmmmw'
:0;O.O.U.d.U:dAW.U.U.U.U;U.d;0.b:b;:
77 87 88 91 93 94 95 96 98 55 99
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Figure 4-10 The Expression of Barx2 (F3/R3) In Ovarian Cancer
Tissue
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Table 4-2 The Expression of Barx2 in Ovarian Cancer
Primer No. analysed No.informative Positive Negative
N % N %
Fl/Rl 28 25 13 52.0 12 48.0
F2/R2 28 25 15 60.0 10 40.0
F3/R3 28 25 17 68.0 8 32.0
In summary, 28 examples of ovarian cancer tissue were tested for expression of Barx2
by RT-PCR using three different primer pairs and the expression of y-actin in same
tissues was assessed by RT-PCR as a control. The relative intensity of RT-PCR products
was determined using Lab-works (UVP) software and producing a ratio of Barx2 to
Actin in each sample. In a total of 28 samples, 25 were analyzed except 3 cases where
expression of y-act was negative. The positive rate of Fl/Rl, F2/F2, F3/R3 and F1/R3
was 52.0%, 60.6 %, and 68.7 % respectively. Ovarian tumor samples overall show a
decreased level of Barx2 expression compared with the normal ovarian epithelium.
4.1.3.2 Relationship between expression of Barx2 and pathological
parameters in epithelial ovarian cancer
The 25 cases of ovarian cancer analysed in this studies comprised of 5 endometriod, 15
serous, 2 clear cell carcinoma, 3 mixed mesodermal tumour (MMT). The expression
level of Barx2 in clinicopathological subgroups (pathology, stage and differentiation
grade) by RT-PCR as a continuous variable is summarised in Table 4- 3. Figure 4-12 to
4-14 shows the relationship between the expression level of Barx2 in ovarian cancer and
the clinicopathological parameters.
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Table 4- 3 The Expression of Barx2 in Clinic-pathological Subgroups of
Ovarian Cancer
Clinicopathological No Barx2/Actin ratio(Mean ±SD)
subgroups Fl/Rl F2/R2 F3/R3
Pathology
CC/EM 7 1.61 ±1.4 1.70 ±1.6 2.43 ±0.9
SER/MMT 18 5.86 ±13.2 8.25 ±19.4 5.27 ±15.9
Stage
I+ 11 8 7.94 ± 17.4 9.9 ± 24.5 10.7 ± 23.6
III+IV 13 3.16 ±7.2 4.7 ± 11.9 1.5 ± 1.0
Unknown 4
Grade
Poor 13 2.94 ±7.2 5.1 ±11.9 1.4 ±1.1
Mod/Well 8 8.5 ±17.2 11.5 ±25.6 10.6 ±23.6
Unknown 4
CC= clear cell carcinoma, EM= endometrioid carcinoma, SER= serous
carcinoma, MMT = mixed mesodermal tumour Mod/well = moderation
or well differentiation grade of ovarian cancer. Poor = poor
differentiation grade ofovarian cancer
Figure 4-12 The Relationship between The Expression Level of Barx2
and Pathologic Type of Ovarian Cancer
CC= clear cell carcinoma, EM = endometrioid carcinoma, SER— serous carcinoma,
MMT = mixed mesodermal tumour
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Compared the expression level of Barx2 by RT-PCR using the Fl/Rl, F2/R2 and F3/R3
primer pairs with pathological subtypes of ovarian cancer, although mean Barx2/actin
ratio of Fl/Rl, F2/R2 and F3/R3 in clear cell carcinomas and endometrioid carcinoma
were lower than these in serous carcinoma and mixed mesodermal tumour ( 1.61 vs 5.9
in Fl/Rl, 1.7 vs 8.3 in F2/R2 and 2.4 vs 5.3 in F3/R3 respectively), there is no
statistically significant difference (p value is 0.95, 0.84 and 0.16 respectively).
Figure 4-13 The Relationship between the Expression Level of Barx2
and Pathologic Grade of Ovarian Cancer.
Mod/well = moderation or well differentiation grade ofovarian cancer.
Poor = poor differentiation grade ofovarian cancer
Although no significant association was evident between the expression of Barx2
and pathologic grade of ovarian cancer, there is a trend towards higher Barx2
expression levels in moderation or well differentiation grade of ovarian cancer
compared with poor differentiation grade of ovarian cancer, p value is 0.064
(F1R1), 0.37 (F2/R2) and 0.064 (F3/R3) respectively.
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Figure 4- 14 The Relationship between the Expression Level of Barx2
and Clinic Stage of Ovarian Cancer
The mean Barx2/actin ratio of Fl/Rl, F2/R2 and F3/R3 in stage I-II is 7.94, 9.89 and
10.7 respectively. Compared with the mean Barx2/actin ratio of Fl/Rl, F2/R2 and
F3/R3 in stage III-IV ( 3.16, 4.70 and 1.49 respectively), there is not statistically
significant difference, (p = 0.27, 0.6, and 0.064 for Fl/Rl, F2/R2 and F3/R3
respectively)
In summary, the expression level of Barx2 Fl/Rl, F2/R2 and F3/R3 in the serous
carcinomas carcinomas and mixed mesodermal tumors were compared to endometrioid
carcinomas and clear cell carcinoma, P values are 0.95, 0.84 and 0.16 respectively.
There is also no significant difference in the expression level of Barx2 Fl/Rl, F2/R2 and
F3/R3 between moderately or well differentiated and poor differentiated tumors.
Although the expression level of Barx2 in early clinical stage (I - II) was seemed higher
than that in late clinical stage (III-IV), the difference were not significant (p = 0.27, 0.6,
and 0.064 for Fl/Rl, F2/R2 and F3/R3 respectively). From these data, the expression of
the Barx2 does not appear to be associated with pathological type and grade or clinical
stage in epithelial ovarian cancer.
Subsequently, the expression of Barx2 in ovarian cancer was reanalyzed by Barx2 F1/R3
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RT-PCR as a continuous variable in a series of ovarian cancer that comprised many of
the tumor samples analyzed in this study. Barx2 expression (mean Barx2/actin ratio) by
semiquantitative PT-PCR was found to be significantly lower for endometrioid/clear cell
variants of ovarian cancer (p=0.03) (see Figure 4- 15) as compared to serous/mixed











Semiquantitative RT-PCR, showing Barx2/Actin ratio for each of22 samples ofRNA
extractedfrom primary ovarian cancer classified according to histology. Mean ratios
for each group are indicated by a horizontal bar
CC=clear cell carcinoma, EM- endometrioid carcinoma, SER= serous carcinoma,
MMT= mixed mesodermal
4.1.3.3 Relationship between expression of Barx2 and survival of patient with
ovarian cancer.
All patients were on continuing follow-up, which ranged between 30 and >2780 days.
The relationship between the expression of Barx2 and survival of patients with epithelial
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ovarian cancer was analyzed.
The mean Barx2 (Fl/Rl)/actin ratio of patients with survival more than 1.5 year is
higher (6.22) than that of patients with survival less than 1.5 year (0.29). At these
survival cutoffs, the difference in expression of Barx2 was very significant (p=0.0048)
(see Figure 4-16). In contrast, however, no significant relationship to be found between
the expression level of Barx2 F2/R2 and F3/R3 and survival of patients (p = 0.097 and
0.977 respectively).
Figure 4-16 Relationship between Expression Level of Barx2 Fl/Rl and
Survival of Patients with Ovarian Cancer.
>1.5 year <1.5 year
Survival time
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4.2 Barx2 Expression by Northern blotting
The results of RT-PCR have shown that expression of Barx2 is absent in some ovarian
cancer tissues and cell lines. In order to confirm and quantitate further the results.
Northern blotting was performed to investigate the expression of Barx2 in ovarian
cancer cell lines The Northern analysis was performed twice and the expression levels
found to be reproducible. Figure 4-17 show the results of Northern blot for expression of
Barx2 in ovarian cancer cell lines.
Figure 4- 17.The Results of Northern Blot for Testing the Expression of
Barx2 in Ovarian Cancer Cell Lines.
Northern blot of ovarian cancer cell lines probed with Barx2. This result showed strong
expression of a 1.74 - 2.2 Kb band in ovarian cancer cell lines PEOl, PE014 and
OVCAR3. PEOl and PE014 represent ovarian cancer cell lines from two patients early
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in the course of their disease. PE04/ PE06; and PE023 were derived from the same two
patients following relapse after cisplatin chemotherapy. PEOlcDDP was derived from
PEOl by in-vitro cisplatin exposure. The in vivo and in cisplatin resistant
cell lines showed obviously reduced Barx2 expression (normalised to y-actin), compared
with the corresponding platinum sensitive cell line. Figure 4-18 showed that expression
of Barx2 is downregulated in the PEOl series. Several other ovarian cancer lines
showed low or absent Barx2 expression, particularly OAW42 and A2780. As OAW42
does not endogenously express Barx2 (as determined reproducibly by RT-PCR and
Northern blotting studies), it was a suitable cell line to explore function analysis of
Barx2 following transfection of a Barx2 expression construct (see section 6)
Figure 4- 18 Downregulation Expression of Barx2 in Ovarian Cancer
Cell Lines PEOl series
Comparing the expression of Barx2 in PEOl, PEOlcDDP, PE04 and PE06 have only
57.7 %, 14.6 % and 9.5 % of the Barx2 expression level (relative to actin) of PEOl
respectively.
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4.3 The results of RNaseH experiment
A broad band corresponding to Barx2 was detected in the ovarian cancer cell lines
Northern blotting suggested the existence of multiple transcriptional isoforms (Figure 4-
17). In addition, RT-PCR using the full length coding region primer pairs F1/R3
detected at least two Barx2 transcript (780bp and 500bp RT-PCR products; Figure 4-5).
These apparent isoforms may result from a) variation in length of Barx2 transcript poly
A tail in different cell lines; b) different Barx2 isoform due to alternative exon or
splicing of an alternative 3'UTR.
The purpose of performing a RNaseH experiment was to remove the Poly A tail from
the total population of transcripts, thereby normalising for any variation poly A tail
length. RNA/DNA hybrids formed between transcript poly A tails and oligo- dT primers
following incubation are recognised and digested by Rnase H (see Figure 4-19).
Figure 4- 19 The Principle of RNaseH Experiment
Start Stop T T T T (oligo dT)
5'UTR Coding Sequence 3'UTR AAAA (poly A tail)
i
RNaseH
RNA-DNA Hybrids Rnase H
digestion Removes poly A Tail
A Northern blot of RnaseH- oligo dT RNA hybridized with a full length Barx2 probe
reveals three apparent isforms, (see Figure 4-20), which arise due to a mechanism other
than variation in poly A tail length.
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Figure 4- 20 The Expression of Different Barx2 Isoforms in Ovarian
Cancer Cell Lines
4.4 Sequencing of Barx2 cDNA
Semiquantitative RT-PCR and Northern blot data together for Barx2 expression in
ovarian cancer cell lines have provided evidence for the existence of at least two
transcript isoforms, one was about 700 to 780 bp and other one was about 440bp to
500. It suggested that there would be two transcription isoform in the Barx2 gene. In
order to investigate further the difference between the two transcription isoforms of
Barx2 in ovarian cancer, Barx2 F1/R3 RT-PCR products from OVCAR3, OVCAR5
and PE06 (see Figure 4-21) were directly sequenced or subcloned and then
sequenced.
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Figure 4-21 the Expression of Barx2 (F1/R3) In Ovarian Cancer
Cell Lines
PE06 OVCAR5 OVCAR3 Marker
The pGEM-T Easy vector systems Promega were used to subclone these RT-PCR
products. The vectors of this system are prepared by cutting Promega's pGEM-
5Zf(+) and pGEM-T easy vector with EcoR V and adding a 3' terminal thymidine to
both ends. These single 3'-T overhangs at the insertion site greatly improve the
efficiency of ligation of a PCR product into the plasmids by preventing
recircularization of the vector and providing a compatible overhang for PCR
product generated by certain thermostable polymerases. They also contain T7 and
SP6 RNA polymerase promoter flanking a multiple cloning site (MCS) within the a-
peptide coding region of the enzyme p-galactosidase. Insertional inactivation of the
a-peptide allows recombinant clones to be directly identified by color screening on
indicator plates.
These vectors contain multiple restriction sites within the MCS, which allow for the
release of the insert by digestion with a single restriction enzyme. Figure 4-22
shows the results of EcoRI digestion subcloned Barx2 F1/R3 RT-PCR products
from OVCAR3, showing presence of different insert size
188
Figure 4-22 the Result of Digestion with EcoRI for Subclones of
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0VCAR3-1 and -2 represent that this subclone was derived from 780 bp or 500 bp
product ofRT-PCRrespectively. The final digit (1 to 8) represents the clonal
number.
Plasmid DNA was isolated from a total 35 subclone , Insert were then sequenced
using Barx2 F1 and R3 primer flanking the MCS.
All sequence was analyzed with ABI-seq analysis package and compared with Barx2
mRNA sequence in GenBank (NCBI) nucleotide database by BLAST 2.0 searching.
The results are outlined in Table 4-3.
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Table 4-3 Results of RT-PCR Products Sequencing in Ovarian Cancer
Cell Line
cell line RT-PCR product sequencing Genbank of Barx2 Exon
size(bp) primer sequence match(bp) 1 2 3 4
OVCAR3 700-780 F1 224-920 + + + +
440-500 F1 210-282 + - -
582-908 - + +
700-780 R3 185-865 + + + +
440-500 R3 231-282 + - -
582-878 - + +
OVCAR5 700-780 F1 223-792 + + + +
440-500 F1 218-282 + - -
582-928 - + +
700-780 R3 185-878 + + + +
440-500 R3 218-282 + - -
582-878 - + +
PE06 700-780 F1 223-792 + + + +
400-500 F1 219-282 + - -
582-928 - + +
700-780 R3 219-757 + + + +
400-500 R3 179-281 + - -
582-856 - + +
+= sequence can match with exon
-= sequence mismatch with exon
The results showed that the sequence of 780 bp Barx2 F1/R3 RT-PCR product cover
Barx2 exons 1 to 4. However, the 500bp RT-PCR product was found to be delected for
Barx2 exon2 (285bp) (see Figure 4-22).
Computer analysis shows that deletion of exon 2 would result in a frame shift mutation
in exon3, introducing a termination codon. As exon 2 and exon 3 encode the
homeodomain , such a protein product (if ever, made) would be lacking the
homeodomain and may consequently act as a dominant negative isoform. The presence
of such an isoform may severely disrupt the normal function of the Barx2 protein in its
regulation of specific target genes.
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STRUCTURAL ANALYSIS OF BARX2
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Northern blot and RT-PCR analysis data have shown that expression of Barx2 is
downregulated/absent in proportion ovarian cancer tissue and cell lines. We decided
to look for mutation in these sources expressing Barx2 and to identify whether
sequence alterations occurred. Southern blot, pulsed-field gel electrophoresis (PFGE),
mutation and methylation analyses were performed to determine whether any
structural alterations of the Barx2 gene are present in ovarian cancer tissues and cell
lines.
5.1 Southern blotting analysis
High molecular weight (HMW) genomic DNA was extracted from 19 ovarian cancer
cell lines. DNA was digested with EcoR I or BamH I. Size separated after running
agarose gel and Southern blotting was hybridized with a full length Barx2 prob. The
results are showed in Figure 5-1 (EcoR I) and Figure 5-2 (BamH I). The result of
Southern blotting (EcoR I) was summarized in Table 5-1
Figure 5-1 The Result of Southern Blot (EcoR I)
marker ovarian cancer cell lines






Southern blot of EcoR I digested HMW DNA probed with Barx2 full length probe
shows that restriction fragment (2.5 Kb and 3.6 Kb) are present in most of the cancer
cell lines tested. Some of the cell lines also show evidence of two larger hybridizing
fragments of 11.2 Kb and 6.6 Kb
Table 5-1 the Result of Southern Blot (EcoR I)
Southern CELL
No INE
11.2Kb 6.6Kb 3.6Kb 3.5Kb
1 SW48 ND ND + +
2 LOVO ND ND + +
3 HT115 ND ND + +
4 HT117 + + + +
5 HT215 + + + +
6 HTC18 + + + +
7 A2780 + + + +
8 PE023 + + + +
9 OVCAR5 + + + +
10 OVCAR4 ND ND + +
11 OVCAR4 + + + +
12 OVCAR3 + + + +
13 SW626 + + + -
14 OAW28 ND ND + +
15 OAW42 ND ND + +
16 PEOlcDDP ND ND + +
17 PEOl ND ND + +
18 PE06 ND ND + -
19 PE04 ND ND + +
ND= not determinable
17/19 cancer cell lines have two strong restriction fragments of 3.6 Kb and 3.5 Kb.
However, the 3.5 Kb fragment is not detectable in OAW28 and PE06, although the
3.6 Kb fragment is in all cases.
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Figure 5-2 the Result of Southern Blot (BamH I)
marker
lkb 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Southern blot ofBamH I digested HMW DNA probed with Barx2 full length probe
shows that two strongly restriction fragments ( and 3.6Kb), and two weekly
hybridizing restriction fragments (10Kb and 6.67Kb)
The conclusion is therefore that the Barx2 gene, at this level of detection, is not
rearranged in any of the 19 cell lines tested. Therefore, this is unlikely to be the
mechanism underlying affected Barx2 expression in these cell lines.
5.2The Result of Pulsed-Field Gel Electrophoresis (PFGE).
In preceding investigations, the data has shown that expression of Barx2 is
downregulated/absent in the ovarian cancer cell lines OAW42, A2780, PEOl-CDDP
,PE04 and PE06. But there were no difference between these ovarian cancer cell
lines in Southern Blot. The experiment of Pulsed-Field Gel Electrophoresis was
performed in order to analyze further whether there would be altered long-range
structure in OAW42, A2780, PEOl, and PE04 ovarian cancer cell lines. Figure 5-3
showed the results of PFGE.
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Figure 5- 3 The Result of Pulsed-Field Gel Electrophoresis
OAW42 A2780 PEOl PE04
The cell lines digested with Hind III for southern blot probed with Barx2 full length
probe showed two restriction fragments (Figure 5-3 a). The cell lines digested with
SacI for southern blot probed with Barx2 full length probe showed only one




5.3.1 The single stranded conformation polymorphism analysis (SSCP)
analysis (HDA) for Barx2 in ovarian cancer cell lines.
Physical mapping demonstrated that Barx2 was located within the chromosome
11 q25 region that was associated with frequent loss of heterozygosity in ovarian
cancer. In addition, Barx2 expression was absent or reduced in some ovarian cancer
cell lines and tumor tissue. To fulfill the Knudson's two-hit hypotheses for
inactivation of a tumour suppressor gene, investigations of possible mutation of
Barx2 as a likely method of inactivation or altered function was explored.
SSCP and HDA are quick, simple techniques which provide a good starting point for
mutation analysis. The DNA segment of interest is amplified by polymerase chain
reaction, the strands of the PCR product are denaturated, then separated by gel
electrophoresis under nondenaturing conditions. Each individual strand may self-
anneal and fold to achieve the most thermodynamically stable conformation.
Electrophoretic differences occur with as little as a single base change (Orita M, et al.
1989). I used a protocol (provided by Richard Axton, MRC Human Genetics Unit
Edinburgh) whereby SSCP and HAD can be carried out together. This relies on the
observation that under SSCP conditions, a significant proportion of a PCR product
can reanneal prior to electrophoresis. The capture of both single and double stranded
DNA on the same polyacrylamide gel allows data from both techniques to be
gathered at the same time.
We designed four pairs of PCR primer to allow amplification of each of the 4 exon of
Barx2 individually. Although not publicly available at the time, our collaborator Dr
Barry Nelkin (John Hopkins University, USA) provided us with the genomic
organization and partial nucleotide sequence of the Human Barx2 gene. The sequence
information encompassed the exon-intron boundaries, permitting design of PCR
primers from within introns. Therefore, PCR amplification was possible allowing for
analysis of coding of complete exon sequence and also splice junction sites where
nucleotide changes may alter normal transcriptional splicing event (see Figure 5-4).
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Exon-specific genomic PCR products from 9 ovarian cancer cell lines were analyzed
four by the combined SSCP/HAD method. A total of 4 experiment were performed.
Representative results are shown in Figure 5-5 to Figure 5- 8, and are all summarized
in Table 5-2
Figure 5-5 The SSCP of Barx2 (exonl) In Ovarian Cancer Cell
Lines
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Figure 5-6 The SSCP of Barx2 (exon2) In Ovarian Cancer Cell
Lines




Figure 5-8 The SSCP of Barx2 (exon4) In Ovarian Cancer Cell
The top bands represent single stranded DNA bands and the bottom Bands are
double stranded in the gels. There are no band shifts in the gels
Table 5- 2 The Results of SSCP/HAD for Barx2 in Ovarian
Cancer Cell Lines
ovarian F11/R5 F6/R6 F8/R8 F10/R10
cancer lines exon 1 exon 2 exon 3 exon 4
S D SH S D SH S D SH S D SH
A2780 + + - + + - + + - + + -
OAW42 + + - + + - + + - + + -
PEOl + + - + + - + + - + + -
PE04 + + - + + - + + - + + -
PEOlcDDP + + - + + - + + - + + -
PE06 + + - + + - + + - + + -
OVAR3 + + - + + - + + - + + -
OVAR5 + + - + + - + + - + + -
PEOl 6 + + - + + - + + - + + -
S= Single stranded band, D= Double stranded band, SH= Shifted band.
In all of the cell lines tested, no shifted bands were detected, indicating that no
mutations were present
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It is also possible that under the experimental conditions, particular mutations would
not be detectable and only become evident by repeating the SSCP/HDA assay using
altered sets of condition.
The SSCP/HDA experiment was further repeated. The concentration of PA gel was
decreased to 8 % and run time increased to 20 hours but at 4 0C in order to separate
top single stranded band better. These results are shown in Figure 5-9 to Figure 5-10
and summarized in Table 5-3.
Figure 5-9 The Results of SSCP for Barx2 (exon 4 and 2) In
Ovarian Cancer Cell Lines
s §
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Figure 5-10 The Results of SSCP for Barx2 (exon 1 and 3) In
Ovarian Cancer Cell Lines
All of band in the gel is single stranded band
Table5 -3 The result of SSCP/HAD for Barx2 in
PE01,PE04,PE01cDDP and PEQ6
ovarian cancer exon 1 exon 2 exon 3 exon 4
lines
S D SH S D SH S D SH S D SH
PEOl + + + + + + + + -
PE04 + + + + + + - + + -
PEOlcDDP + + + + + + - + + -
PE06 + + + + + + - + + -
S= Single stranded band, D= Double stranded band, SH= Shifted band.
In all cell lines, no shifted bands were found for any exon, indicating that there was no
Barx2 mutation in these ovarian cancer cell lines.
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5.3.2 Mutation analysis ofBarx2andi entific tion ofsingle nucleotide
polymorphism ofcancer cell lines and tumour tissue using the Transgenomic
Wave™
PCR primers were designed to allow amplification of individual Barx2 exons. Larger
PCR fragments were used for Denaturing High Pressure Liquid Chromatography
(DHPLC) analysis of cancer cell lines and colorectal tumour/blood pair DNA (high
molecular weight). Figure5-11 showed the results of genomic PCR of Barx2 (exon2)
in cancer cell lines. The genomic PCR of Barx2 exonl and exon2 was performed
individually in a total of 69 cancer cell and 48 colorectal tumour/blood pairs.
Figure5-ll The Results of Genomic PCR of Barx2 (exon2) In Cancer
Cell Lines.
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DHPLC was performed using a Transgenomic Wave machine. For cell line DNAs,
alteration of the known sequence from wild type was assessed by mixing Exon PCR
products from each of the cell lines with Exon PCR products derived from
monoallelic Barx2 PAC DNA in a 1:1 mix for heat denaturation and re-annealing to
identify heteroduplex.
Sequence alteration detection is based on the principle that individuals who are
heterozygous in a mutation or polymorphism have a 1:1 ratio of wild-type and
mutant DNA. A mixture of hetero-and homoduplexes is formed when the PCR
product is hybridised by heating to 95 °C and cooling slowly. The DNA from
individuals who have two mutant alleles (homozygous mutation) will only form
homoduplexes and must therefore be mixed with wild-type DNA and hybridised in
order to detect heteroduplexes. After this treatment, a sample will contain a mixture
of hetero- and homoduplexes (see Figure 5-12). However, DNA from homozygous
wild-type individuals will form only one species, the homoduplex wild-type
(Underhill PA, et al. 1996)
Figure 5-12 Creation of A Mixture of Hetero- and Homoduplexes
Though Hybridization












Mutation are visualised on the Wave™ as a characteristic pattern of peaks
corresponding to the mixture of heteroduplexes and homoduplexs formed when wild-
type and mutant DNA are hybridized.
Total 69 cancer cell lines expect for 4 cell lines that PCP did not work, PCR products
of individual Barx2 exons in 65 cancer cell lines and 48 colorectal tumour/blood
pairs were screened using Wave ™ for detecting mutation of Barx2 respectively.
Genomic PCR products from the cell lines were analysed both with and without
addition of the PAC clone derived wild-type product. Heterozygous alterations in
Barx2 sequence should be detectable without addition of any wild type product
Figure 5-13 shows an example for mutations by DHPLC using Transgenomic Wave
in ovarian cancer cell lines. The results are summarised in Table 5-4
Figure 5-13 an Example of Result of Mutation Scanning in Cancer
Cell Lines.
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a) Cancer cell line DNAwithout spiking with wild-type DNA. peak
only b) Spiking cell line DNA from (a) with wild-type DNA, A homoduplex peak,
indicates that cell line (a) is homozygous wild-type, c) Another cancer cell line
DNA without spiking with wild-type DNA. Homoduplex peak only, d) Spiking cell
line DNA from (c) with wild-type DNA. Heteroduplex peak beside homoduplex
peak, indicates either heterozygous mutation or polymorpism.
Heteroduplex formation was observed by DHPLC in ovarian cancer cell line SKOV3
following spiking with wild-type PAC-derived PCR product, indicating that presence
of a sequence difference between the cancer cell line exon 2 of Barx2 and wild-type
exon 2 (wild-type Barx2 PAC-derived PCR product). Sequencing of cell lines
SKOV3 exon 2 PCR product revealed the presented missense: Ser— Pro creating a
Hae III site (The sequencing work was done by Dr Karen Watt in our lab). This
missense mutation was not contained within the homeobox sequence encoded by
exon 2, and is not a clear example of an inactivating mutation.
Table 5-4 the Summary of Identification of Single Nucleotide
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5.3.3; Direct DNA sequencing analysis for Barx2 in ovarian cancer cell lines
Although RT-PCR and Northern blot data have shown that expression of Barx2 is
downregulated or absent in several ovarian cancer cell lines, there was no evidence
to demonstrate inactivating mutation of Barx2 in these ovarian cancer cell lines.
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Sequencing of PCR products is a powerful technique that enables a direct search for
mutations in a defined fragment of DNA.
Genomic PCR products for individual exons from the PEO series, PEOl
PEOlcDDP, PE04 and PE06 were generated (Figure 5-14) and sequenced directly.
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CLUSTAL X multiple sequence alignment was used to compare PEOl sequence
with PEOlcDDP, PE04 and PE06. In addition, DNA from fibroblasts isolated
during the initial derivation of PEOl was also used to generate Barx2 exon-specific
PCR products. PEOl fibroblast DNA represented normal DNA in this comparison.
The alignment analysis of genomic PCR products for Barx2 gene in PEO-Fibroblast
PEOl, PEOl-CDDP, PE04 and PE06 was summarised in Figure 5-15.
206
MMMMM MIOIO M so so SO so so so to to m so so so to to so
UHOOW © © ** vo vo o vo o VO o vo o vo o wo <so «fc
00M09-JM «o Ch to Cft M rfa. O CD MOVWDiS Oft on lis -4 eft so




Figure 5-15The CLUSTAL X window in multiple sequence alignment. An alignment
of Barx2 exon 2(F6/R6, F9/9) sequences in PEO-Fibroblast PEOl, PE01-CDDP,
PE04 PE06 and OVCAR3 (from top to bottom in order) were displayed.
Exceptional sequences were shown as a white background. The overall direct
sequencing of genomic PCR products did not reveal any difference in coding
sequence between PEOl, PE01-CDDP, PE04 PE06, 0VCAR3 and PEO-
Fibroblast. In conclusion no somatic inactivating mutations are present in these
ovarian cancer cell line series.
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5.4 Methylation analysis for Barx2 in cancer cell lines
In the absence of somatic inactivation mutations, a study of the methylation status of
the CpG islands at 5'end of the Barx2 gene was undertaken to investigate its possible
role in downregulated/absent expression of Barx2 in ovarian cancer cell lines.
Methylation of cytosine located 5' to guanosine is known to have a profound effect
on the expression of genes. In normal cells, methylation occurs predominantly in
CG-poor regions, while CG-rich areas, CpG islands, remain unmethylated. Aberrant
methylation of normally unmethylated CpG islands has been associated with
transcriptional inactivation of defined tumour suppressor genes in human cancers
(Momparler RLand Bovenzi V.2000). Many studies have confirmed that methylation
of DNA may contribute to tumorigenesis through silencing of genes which are
usually hypomethylated and critical in control of the cell cycle (e.g. tumour
suppressor genes) and cellular differentiation (Kay PH, et al. 1997).
DNA digested with methylation sensitive restriction enzymes is one way that
determines the methylation status of cytosine (Laird PW and Jaenisch R. 1996). In
order to demonstrate whether methylation is a possible mechanism for gene
silencing, Southern blots were prepared. DNA of cancer cell lines digested firstly
with BamHl and Hind III and then digested with methylation sensitive and non-
sensitive restriction enzymes Mspl and Hpall respectively. Blots were then probed
with the Barx2 F11/R5 (5' UTR to exon2). The results were summarised in Figure5-
16.
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The alteration in the hybridisation pattern observed between Hpall and Mspl-
digested cell line DNA in the Southern analysis suggested that Barx2 5'CpG island is
methylated in PEOlcDDp, PE06, PE014 PE016, OVCAR3, 2780 AD, Hela PEA2
41M and MDA. Cell lines previously demonstrated to have downregulated Barx2
expression apparently show evidence of CpG island methylation, thereby providing a
mechanism for gene silencing.
211
Following this study, however, methylation-specific PCR, a new and highly sensitive
technology for the detection of gene methylation (Herman JG, et al. 1996) was
performed by Dr Grant C. Sellar and Genevieve J. Rabiasz in our lab to determine
the methylation status of cytosine in ovarian cancer cell lines and tumour tissue.
PCR primers spanning the CpG-rich Msel fragments were designed to assess CpG
island somatic methylation. The six primers covered a region covering the two Msel
fragments and extending from -1097 to +282 with respect to the translational start
site. Eighty epithelial ovarian normal/tumour pairs and 38 matched ovarian cancer
biopsies prior to and following relapse after cisplatin chemotherapy were analysed.
The results showed that the homeobox gene Barx2 is not methylated in ovarian
cancer, in contrast to the initial findings from the southern blot analysis presented
here.
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FUNCTIONAL ANALYSIS OF BARX2
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Frequent LOH at chromosome llq24-25 was associated with poor survival in
epithelial ovarian cancer (Gabra H, et al 1996). Microcell mediated transfer of
chromosome 11 to the ovarian cancer line NIH:OVCAR3 had revealed a phenotype
of invasiveness suppression and suppression of cell migration and adhesion
associated with 4.5 Mb region on the chromosome 11 q24 between D11S912-
D1 IS 1320 (Gabra H, et al.unpublished). Barx2 is located at chromosome 11 q25
between the markers D11S912 and D1 IS 1320 (Krasner A, et al. 2000), suggesting
that Barx2 as a functional candidate epithelial ovarian tumor suppressor gene.
Transfections of Barx2 into OVCAR3, OAW42, PEOland PEOlcDDP were
performed in order to further analyze the function of the Barx2 gene in ovarian
cancer.
6.1 Transfecting Barx2 into Ovarian Cancer Cell lines.
6.1.1 Setting up the optimal lethal concentration of hygromycin B for all ovarian
cancer cell lines used.
An expression construct (pBABE Barx2) containing the full length human Barx2
cDNA subcloned in pBABE hygro was obtained from Dr Barry Nelkin. The parental
vector contains the hygromycin selectable marker and therefore, the optimal lethal
concentration of hygromycin B for all ovarian cancer cell lines transfection expression
construct was determined.
Several ovarian cancer cell lines were characterized with respect to their toxicity
profiles to hygromycin B in order to determine the most utilitarian lines. Thus,
survival was empirically calculated for several ovarian cancer cell lines for
hygromycin B. The optimal lethal concentrations of hygromycin B for all lines used
is outlined in Table 6-1
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Table 6-1 the Optimal Lethal Concentrations of Hygromycin B for
All Lines Used
Cell Lines Toxicity
PEOl 75 jug/ml for 3 week
PEOcDDP 75 |Ug/ml for 3 week
PE04 80pg/ml for 3 week
PE06 80p.g/ml for 3 week
OVCAR3 128p,g/ml for 2 week
A2780 60p.g/ml for 2 week
OAW42 150|ug/ml for 2 week
ON3 125p.g/ml for 2 week
6.1.2 Preparation of pBABE Barx2 and pBABE Hygro plasmid DNA
pBABE Barx2 and pBABE Hygro plasmid DNA were initially transformed into
competent JM109 cells. Isolation of plasmid DNA from transformed single colonies
was performed using QIAGEN QIAquick mini spin kits. To check the integrity of
the Barx2 insert purified plasmid DNAs were digested with restriction enzyme
(EcoR I, Hind III and BamH I) and also amplified by Barx2 F1/R3 PCR. Figure 6 -1
to 6-2 shows these results.
Construct DNAs were also linearized with Notl to increase the effect of transfection.
Figure 6-3 shows the result of linearization of pBABE Barx2 plasmid DNA with
Notl.
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Figure 6-1 The Results of Digesting pBABE Barx2 Plasmid DNA
with Restriction Enzymes
>1.4kp bandand 380bp band (with Hind III); >1.4kb and 1.2kb band (with Ecorl);
and >1.4 Band (with BamH I). These sizes offragments tallied with those expected
from the plasmid construct. Non-digesed plasmid DNA appears as a band that is
higher than that ofdigested plasmid DNAs.
Figure 6-2 The Result of PCR (F1/R3) for pBABE Barx2 Plasmid
DNA
PCR (F1/R3) for plasmid DNA showed a specific 780 bp Barx2 fragment.
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6.1.3 Determining optimal effective oftransfection condition for ovarian cancer cell
lines used
Initially, optimal effectene condition for transfection were established empirically for
these ovarian cancer cell lines (outlined in section 2) These are outlined in Table 6-2
Table 6-2 Optimal Effectene Conditions for Ovarian Cancer Cell
Lines Used
Cell line effectene volume(ul) enchance volumc(p.l) DNA(pg)
OAW42 10, 25, 50 8.0 0.2
PEOl 25 8.0 0.2
PEOlcDDP 25 8.0 0.2
PE04 10, 25,50 8.0 0.2
PE06 10, 25, 50 8.0 0.2
A2780 10, 25,50 8.0 0.2
However, no clones were produced for OAW42, A2780, PE04 and PE06 in 2
separate Barx2 and vector transfection experiment. In order to improve transfection
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efficiency, the transfection selector kit was used The results of OAW42 transfection
selector kit experiment are outlined at Table 6-3
Table 6-3 The Results of OAW42 Transfection Selector
No effectene vol urne(pi) enchancer volume(pl) DNA(pg) cell density
1 2 1.6 0.2 ++
2 5 1.6 0.2 +++
3 10 1.6 0.2 +++
4 4 3.2 0.4 +++
5 10 3.2 0.4 +++++
6 20 3.2 0.4 +++
7 8 6.4 0.8 ++++
8 20 6.4 0.8 ++
9 40 6.4 0.8 +
10 Control (serum + effectene) +
11 Control (serum) +
This data showed that the suitable conditions of transfection in OAW42 are;
effectene 10 pi, enchancer 3.2 pi and transfecting DNA 0.4 pg.
Lipofectin was used to transfect pBABE Barx2 into OVCAR3, ON3 and A2780.
The lipofection conditions use the lipofection protocol (outlined in section 2). The
optimal lipofectin conditions were established empirically for these ovarian cancer
cell lines and are outlined in Table 6-4.
Table 6-4 Optimal Lipofectin Conditions for Ovarian Cancer Cell
Lines Used
Cell line Lipofectin (pi) DNA(pg) Incubation time (hour)
OVCAR3 10 2 6
ON3 10 2 6
A2780 10 2 12
6.1.4 The transfecton of the human Barx2 gene into ovarian cancer
cell lines
Between 2 and 4 separate transfection experiments were performed for each cell line.
For each experiment, the ovarian cancer cells were seeded in three plates per
lipofectin or effectene condition. The results are summarized in Table 6-5
218
Table 6-5 Summary ol Transfection Experiment
Cell line Experiment Method Result
No
OAW42 1 eftectene not transfectable
2 effectene not transfectable
3 effectene 2 pBABE-Hygo-Barx2
clones, 1 distinct population, 1
distinct, no pBABE-Hygro clone
produced
4 effectene Distinct clones in pBABE -Hygro no
pBABE -Hygro- Barx2 clone produced.
A2780 1 Lipofectin not transfectable
2 eflectene not transfectable
3. effectene distinct clones in pBABE-Hygo no
pBABE-Hygro- Barx2 clone produced
distinct population clones in pBABE-
PE01 1 effectene Hygro, distinct clones
in pBABE-Hygro- Barx2
2 eltectene Distinct population clones in pBABE -
Hygro, distinct clones in pBABE-
Hygro- Barx2.
1 effectene distinct population clones in pBABE -
PEOl Hygro, distinct clones in pBABE-
cDDP Hygro- Barx2
2 effectene distinct population clones inpBABE-
Hygro, distinct
clones in pBABE-Hygro-Barx2
PE04 1 effectene not transfectable
2 eftectene not transfectable
3 eifectene not transfectable
PE06 1 eftectene not transfectable
2 effectene not transfectable
3 effectene not transfectable
ON3 1 Lipofectin distinct population clones in pBABE-
Hygro-Barx2
2 Lipofectin distinct population clones in pBABE -
Hygro, distinct clones in pBABE -
Hygro- Barx2
OVCAR 1 Lipofectin distinct population clones in pBABE -
3 Hygro, distinct clones in
pBABE-Hygro-Barx
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The transfection experiment for OVCAR3 was performed by Dr Hani Gabra.
Several cell lines were derived following transfectiion using either the lipofection or
effectene protocol, and these are summarsed in Table 6-6.
Table 6-6 Designation of Clonally Derived Cell Lines Obtained by
Plasmids Transfection






6.2 Molecular analysis of ovarian cancer cell lines transfected with
Barx2
6.2.1 Detection ofBarx2 fulllength cDNA by genomic PCR (using primer F1/R3) in
ovarian cancer cell lines transfected with Barx2.
The objective of this part of the work was to determine whether the Barx2 gene has
been transfected into the cancer cell lines. As the plasmid expression construct
became genomically integrated, genomic PCR was used to amplify the inserted
fragment of Barx2 in a series of clones derived from different separate transfection
experiments. PCR amplification of the Hygromycin (HmB) selectable marker from
transfection derived clones was also preformed to amplify HmB fragment in these
clones as a control. Figure 6- 4 and 6-5 shows examples of genomic PCR for Barx2
(F1/R3) in clones derived from transfection with pBABE-Barx2 or pBABE-Hygo
only. All results are summarized in Table 6- 7.
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Figure 6-4 Genomic PCR for Amplifying Insert Fragment of Barx2
or Hygro in OVCAR3 transfected BX and EH
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Toppanel shows the results ofgenomic PCR (F1/R3) for amplifying Barx2 insert in
BX and EH OVCAR3-derivedclonal transfected cell lines The majority of clones
derivedfrom Barx2 OVCAR3 transfection are positive for insert of but BX3.2
is negative, suggesting that it is a transfection revertant that has lost the Barx2 insert.
Also allclones derived from control vector transfected cell lines are negative for
Barx2 insert, but positive for Hygromycin (see bottom panel). As expected, OVCAR3
is negativefor both Barx2 insert and Hygromycin.
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Figure 6-5 Genomic PCR for Insert Fragment of Barx2 or Hygro in
CB and CH
Figure 6.5A) Examples of genomic PCR (F1/R3 for the Barx2 insert in CB
(PE01cDDP/pBABE-Barx2) and CH (PEOlcDDP/pBABE-Hygro) clone series. Most
of clones derived from PEOlcDDP transfected with Barx2, except for CB 2.4 and
CB2.3, are positive for the Barx2 insert. All clones derived from control vector
transfected cell lines are negative for the Barx2 insert, but positive for Hygromycin
marker (see Figure B). PEOlcDDP is negative for Barx2 insert and also for the
Hygromycin marker.
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Table 6-7 Summary of Genomic PCR Results for Amplification of
Barx2 Insert or Hygromycin Marker in Clonal Cell Lines
Following Transfection
Cell Lines Insert Fragment of Hygro Insert Fragment of Barx2
OVCAR3
BX 1.1 +++ ++
BX 3.2 +++ +/-
BX 1.2 +++ ++
BX 3.6 +++ ++
BX 3.3 +++ +++
BX 4.2 +++ +++
BX 1.4 +++ +++
BX 1.3 +++ +++
BX 3.4 +++ +
EH 1.4 +++ -
EH 2.2 +++ -
PEOlcDDP
CB 1.3 ++ +++
CB 3.3 ++ ++
CB 1.7 ++ ++
CB 1.4 ++ +++
CB 1.12 ++ +
CB 3.7 ++ ++
CB 3.6 ++ +++
CB 3.9 ++ ++
CB 1.6 ++ ++
CB 2.4 ++ -
CB 1.11 ++ ++
CB 2.3 ++ +/-
CH 1.2 ++ -
CH 2.2 +++ -
CH 1.4 +++ -
CH 1.5 ++ -
CH 2.1 ++ -
CH 1.1 ++ -
CH 1.3 ++ -
CH 2.3 ++ -
PEOl
PB 1.7 +++ ++
PB 2.1 +++ ++
PB 6.1 +++ +++
PB 7.1 +++ ++
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PB 8.1 +++ ++
PB 11.1 +++ +++
PB 13.1 +++ ++
PB 15.1 +++ ++
PB 15.2 +++ ++
PB 16.2 +++ +
HY 1.6 +++ -
HY 2.7 +++ -
HY 1.3 +++ -
HY 1.5 +++ -
OAW42
42B 1.1 +++ ++
42B 1.2 +++ +++
42B 1.10 +++ +/-
42B 1.4 +++ +++
42B 1.6 +++ -
42B 1.7 +++ +
42B 1.3 +++ +++
42H 7.2 ++ -
42H 7.3 ++ -
42H 7.4 ++ -
42H 7.5 ++ -
ON 3
OB 1.2 ++ ++
OB 1.4 ++ ++
OB 3.4 ++ ++
OB 3.1 ++ ++
OB 5.2 ++ ++
OB 6.1 ++ +
OB 6.2 ++ +++
OB 7.1 ++ +
OB 7.2 ++ +
OB 8.2 ++ +/-
OB 9.1 ++ +
OB 10.1 ++ +/-
OB 12.1 ++ +
+++ - ++ = strong PCR product
+ = weak PCR product
- = No PCR product
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6.2.2-.Detecting Barx2expression in clones derived from OAW42 transfected with
Barx2.
As mentioned above (see section 5), OAW42 does not endogenously express Barx2.
After transfecting Barx2 full length cDNA into OAW42, Barx2 F1/R3 RT-PCR was
used to detect expression of Barx2 in series of clones derived. (Figure 6-6)
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These data show that there were different levels of expression of Barx2 in clones
derived from OA W42 transfected with Barx2. The expression ofBarx2 was strongly
positive in 42B 1.2and42B 1.7.Weakin 42B1.3 and absent in 42B1.6. Actin control
RT-PCR are positivefor all cell lines.
6.2.3; Detecting the expression ofBarx2 in clones derived from OAW42 transfected
with Barx2 by Northern Blot
To more fully quantify the different levels of Barx2 expression, a Norther blot of
225
total RANs isolated from the series of OAW42 Barx2 transfected cell lines was
hybridized with a full length Barx2 cDNA probe, following by Y-actin. (Figure 6-7).
Figure 6- 7 Northern Blot Analysis of Barx2 Expression in clones
derived from OAW42 transfected with Barx2.
Northern blot comparing RNA from OAW42 parent cell line, Hygromycin control
vector transfected clonal derivatives 42H 7.5 and 42H 7.2, and four Barx2
transfected clonal derivatives 42B 1.2,1.6, 1.3 and 1.7 sequentially probed with
Barx2 and Actin. 42B 1.2, 1.3 and 1.7 clearly express Barx2.42B1.6 did not express
Barx2 consistent with both RT-PCR data (Figure 6-6) and also the lack of integrated
Barx2 insertfrom genomic PCR (Table 6-7).
6.2.4 Detecting the expression of Barx2Fl/Rl in clones derived from PEOlcDDP
transfected with Barx2 by RT-PCR
The expression of Barx2 by Fl/Rl RT-PCR is negative in PEOl cDDP cell line
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(Figure 4-2). Therefore, in order to confirm that the plasmid DNAs had been
transfected into this cell line, Barx2 Fl/Rl RT-PCR could be used to detect whether
Barx2 is expressed in these Barx2-transfected PEOlcDDP clones. (Figure 6-8)
Figure 6-8 Expression of Barx2 Fl/Rl in Barx2 Transfected Clonal
derivatives, Hygro Transfected Clonal derivatives and Their Parent
Cell Lines
The expression of Barx2Fl/Rl detectable by Fl/Rl RT-PCR is present in "CB"
Barx2-transfected PEOlcDDP cell lines. The expression of Barx2 is still absent in
PEOlcDDp parent cellline and Hygromycin control vector transfected
derivatives—CH celllines.
6.3 The functional analysis ofBarx2 in ovarian cancer cell lines
6.3.1 In-vitro growth of ovarian cancer cell lines transfected with Barx2
For each of the cell line used for transfection, three or four Barx2 transfections, two
pBABE Hygro transfections and parent cell lines were analyzed in an vitro growth
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assay. Experiments were performed three times, and results obtained were similar in
each case. Representative experiments (lxlO4 cells initially seeded) with
quadruplicate samples shows Figure 6-9 to 6- 12
Figure 6- 9 bvyvitroGrowth of pBABE Hygro Control Transfected
pBABE Barx2 Transfected OVCAR3 Cell Lines










Transfection of OVCAR3 cell line yielded several lines with variable expression of
Barx2. BX4.2 and BX3.6, the highest pBABE-Barx2 copy number clones, were
strongly suppressed for cell growth compared with controlcs. BX3.4, a clone with
lower pBABE-Barx2 copy number clones, was also suppressed for cell growth
comparing with controls, but much less than BX4.2 and BX3.6 (see Figure 6-4). This
suggests that the extent ofcell growth-inhibition was dependent on exogenous Barx2
expression level in OVCAR3.
BX3.2, EH1.4 and EH2.2 growth characteristics are superimposable, with no
significant difference detectable. It was shown previously that BX3.2 is a transfection
revertant , having lost the Barx2 insert (Table6-7), thereby explaining why their
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growth characteristics were similar.
Figure 6-10 In^vitro Growth of pBABE Hygro Control Transfected













These data showed that there was no significant difference in cell growth comparing
42H 7.5 and 42H 7.3 derivedfrom control vector transfected OAW42 with parent cell
line. 42B1.3, 42B1.2 and 42B1.7, the Barx2 expressing transfected clones (Figure 6-6)
were suppressed for cell growth compared with parent and clones derived from
vector control transfection.
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Figure 6-11 In^vitro Growth of pBABE Hygro Control Transfected




Vector only control transfections PH1.6 and PH 7 showed no significant difference
in cell growth compared with PEOl parent cell line. PB11.1, PB13.1 and PB 6.1, the
highest pBABE-Barx2 copy number clones clones (Table 6-7), were strongly
suppressed for cell growth compared with PEOl parent and control vector clones
PHI. 6 and 2.7.
230
Figure 6- 12In^vitro Growth of pBABE Hygro Control Transfected
pBABE Barx2 Transfected PEOlcDDP Cell Lines









Transfection of Barx2 into PEOlcDDP cell line yielded several lines with variable
expression ofBarx2. CB1.3 and CB3.6, the highestpBABE-Barx2 copy number clones
clones, were strongly suppressedfor cell growth compared with control. CB3.7 and
CB2.3 ,clones with lower pBABE-Barx2 copy number clones, was also suppressed
for cell growth compared with controls, but much less than CB and CB.
In summary, compared with cell lines transfected with control pBABE Hygro vector
and parent cell lines, all of the cell lines transfected with Barx2 and demonstrating
strong expression of Barx2 were equally growth suppressed (see Figure 6-13). The
cell lines transfected with Barx2 showing low pBABE-Barx2 copy number clones
were also growth suppressed but a much lesser than those with high pBABE-Barx2
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copy number clones did. The Barx2 transfection revertant clones were not growth
suppressed and behaved like their respective vector-only control transfections and
parental cell lines. These data show that Barx2 gene may play important role in
suppressing ovarian cancer cell line growth.
Figure 6-13 Growth Assay for 4 Ovarian Cell Lines










Vector control 1 and 2 represent independently derived pBABEHygro transfected
control clonal lines for each cell line. Barx2-1 Barx2-2 represents two independently
derived pBABEBARX2 transfected clonal cell lines for each parent cell line. The
growth assay is normalizedfor the control values on day 20, and Barx2 transfections
are proportional to this.
6.3.2 Cell-cycle distribution of ovarian cancer cell lines OAW42 transfected with
Barx2 byflow cytometry
The reasons whereby Barx2 transfection resulted in cell growth inhibition was further
investigated. It was postulated that the suppressive effect may be the consequence of
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either a delay in progression through the cell cycle or as a result of increased
apoptosis (cell death). The results of cell cycle distribution analyses and apoptosis
assays are presented.
Analysis of the cell cycle was performed on two separate occasions for OAW42
parent cell line, Hygromycin control vector transfected clonal derivatives 42H 7.5
and 42H 7.2, and Barx2 transfected clonal derivatives 42B 1.2 and 1.7.
Flow-cytometric cell-cycle analysis was performed using propidium iodide
staining of cells. (Figure 6-14)
FACS analysis demonstrates that transfection of Barx2 into OAW42 caused
clustering in S-phase compared with the parent cell line (see Figure 6-14). This
suggested that the Barx2 transfection was associated with a delay in this part of the
cell cycle.

























FACS cell-cycle analysis of OAW42 (top left) and control vector transfected OAW42
line 42H 7.5 (top right). Compared with these, two Barx2 transfected clonal lines are
shown, 42B 1.2(bottom left) and 42B1.7 (bottom right). There are clearly more cells
in the S-phase population after Barx2 transfection that in controls suggesting delay of
progression through this part of the cycle.
This information is summarized in Table 6-8; the results of statistical analysis for this
data are outlined in Table 6-9.
Table 6- 8 DNA-FACS Analysis of Clones Derived from OAW42
transfected with Barx2 or Hygro control vector
Cell Lines GO +G1 S-Phase G2+M
Mean SD Mean SD Mean SD
OAW42 89.20 2.49 9.77 2.57 1.03 0.15
42H 7.3 85.27 2.03 12.97 2.35 1.73 0.64
42H 7.5 86.60 0.46 11.93 0.70 1.47 0.57
42B 1.2 22.90 9.01 69.00 19.58 8.13 10.77
42B 1.7 22.00 4.54 68.43 12.66 11.57 8.16
Table 6-9 the Results of Statistical Analysis for DNA-FACS
Group F value p value
OAW42 Vs 42H7.3 1.196 0.4554
OAW42 Vs 42H7.5 13.479 0.0691
OAW42 Vs 42B1.2 58.044 0.0169*
OAW42 Vs 42B1.7 24.216 0.0396*
42H 7.3 Vs 42H7.5 11.270 0.0850
42B 1.2 Vs 42 B 1.7 2.392 0.2948
42B 1.2 Vs 42H7.3 69.421 0.0142*
42B 1.2 Vs 42H7.5 782.40 0.0013*
42B 1.7 Vs 42H7.3 29.022 0.0333*
42B 1.7 Vs 42H7.5 327.09 0.0030*
* represent significant difference between two groups.
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6.3.3 Theapoptosis analysisfor Clones Derivedfrom OAW42 transfected with Barx2
Barx2 transfection of OAW42 was also analyzed for apoptosis by the annexin V FACS
assay. The results are summarized in Table 6-10. Figure 6- 15 shows an example of the
annexin V FACS assay for apoptosis in OAW42 pBABE Barx2 transfected clone 42B1.7.
There was no evidence of either increased cell death or apoptosis in this assay to explain
the observed growth suppression phenotype, suggesting that these effects were not
obviously due to non-specific cytotoxicity.
Table 6-10 Annexin V-FACS assay for Clones Derived from OAW42
transfected with Barx2






Figure 6-15 The Annexin V-FACS assay for 42B 1.7 Cell Line
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6.3.4 Cellular attachment assay for Clones Derived from OAW42 transfected with
Barx2 or Hygro control vector
The ability of the cell lines to attach to components of the extra-cellular matrix was tested.
The OAW42 parent cell line, Hygromycin control vector transfected clonal derivatives
42H 7.5 and Barx2 transfected clonal derivatives 42B 1.2, 1.7 were allowed to attach to
tissue culture plastic coated plates with and without collagen IV. (Figure 6-16)
Introduction and expression of Barx2 in OAW42 was significantly associated with
inhibition of attachment to collagen IV coated plastic. No such effect was observed on
plastic alone. Furthermore, the higher expressing Barx2 clone had greater inhibition of
adhesion to collagen IV (40% of control, P<0.001)
Figure 6-16 the Attachment Assay Comparing Control with Clones




































OA W42 celladhesion to uncoated and collagenlVcoated plastic. Barx2 transfect clonal
lines 42B 1.2and42B 1.7 are significantly suppressed for cell adhesion collagen IV
coatedplastic, as compared with OAW42 and vector control lines 7.5. There is no
significent difference in adhesion to non-coatedplastic between the cell lines tested.
6.3.5 Cell migration assay for clones derived from OAW42 transfected with Barx2 or
Hygro control vectors.
In order to determine the affect of Barx2 on cellular migration in response to
components of the extracellular matrix, the under surface of 8 pm pore size Nuclepore
filters was coated with collagen IV. An assessment was made ofmigration of the Barx2
transfected derivative cell lines over 72 hours in response to those extracellular matrix
components using the method outlined in section 2. The results showed that
introduction and expression of Barx2 in OAW42 was significantly (p<0.001)
associated with inhibition of transwell cellular migration to a collagen IV haptotactic
signal. The higher expressing barx2 clone 42B had greater inhibition of cellular
migration. The data is summarized in Figure 6-17
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Figure 6- 17 Transwell Migration Assay for Comparing Control with
Clone Derived from OAW42 Transfected with Barx2
OAW42 haptotactic cell migration to a collagen IV signal. Barx2 transfected clonal
lines 42B 1.2 and 42B 1.7 are significantly suppressed for migration as compared with
OAW42 and vector control line 42H 7.5.
6.3.6 Matrigel Invasion analysis of OAW42 and OVCAR3 following transfection with
Barx2 or Hygro control vector
Two separate experiments were performed and similar results obtained from both.
The initial experiment was carried out by Dr Hani Gabra.
The object of this part of the work was to assess and compare the ability of tumor
cell invasion into matrigel between parent cell lines and Barx2 or Hygro control
vector transfected clonal lines.
Introduction of barx2 into OVCAR3 cell lines produced a highly significant (p<o.ool
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in all cases) and profound inhibition of matrigel invasion to approximately 20 % of
controls. BX3.2 was found to be a Barx2 transfection revertant that had lost the
Barx2 insert, and it was not suppressed for matrigel invasion. (Figure 6-18)
Figure 6-18 Matrigel Invasion Assay for Comparing Control with
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Matrigel invasion of OVCAR3 vector transfected control (EH 1.4) and three Barx2
transfected clonal lines. Barx2 transfected lines BX 1.1, 3.6 and 4.2 are profoundly
suppressed for matrigel invasion. BX 3.2 has lost the Barx2 insert but has retained
hygromycin resistance, and has the same characteristics in this assay as the vector
only control OC3Hygl.4
OAW 42 does not endogenously express Barx2. Transfection of this cell line yielded
several cell lines with variable expression of Barx2. 42B 1.2, the highest Barx2
expressing was significantly suppressed for matrigel invasion compared with controls
(p<0.001 Figure 6-19). 42B 1.7, a clone with lower Barx2 expression than 42B1.2,
239
was also suppressed for matrigel invasion, but to a much less than 42B 1.2 and this
result was not statistically significant. This suggests that the extent of matrigel
invasion-inhibition was dependent on exogenous Barx2 expression level in OAW42.
Figure 6-19 Matrigel Invasion Assay for Comparing Control with





Matrigel invasion of OAW 42 parent and vector transfected control (42H 7.5) and 2
Barx2 transfected clonal lines. Barx2 transfected lines 42B 1.2 and 42B1.7 are
suppressedfor matrigel invasion.
6.3.7 Barx2 andplatinum resistance
As stated previously (section 5), ovarian cancer cell lines derived from ascites before
and following relapse after successful cisplatin chemotherapy for two patients showed
strong downregulation of Barx2 by Northern blotting. PEOlcDDP, a cell line derived
from PEOl by in-vitro cisplatin exposure had about half of the Barx2 expression level
of PEOl relative to actin. These two closely related cell lines were transfected with the
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Barx2 expression construct. Growth inhibition assays were performed to study the
effect of Barx2 expression on cisplatin resistance.
pBABE-Barx2 and control vectors were transfected into PEOl (platinum sensitive)
and PEOlcDDP (platinum resistant) derivative cell lines. The sensitivity of these cell
lines to varying concentrations of cisplatin was then directly compared in inhibition
assays. A total three separate experiments assaying growth inhibition have been
performed. Transfection of Barx2 into PEOlcDDP resulted in highly significant
(p<0.001) growth inhibition at 1.75 and 2.0 uM cisplatin compared with vector
control and untransfected PEOlcDDP. (Figure 6-20) This growth inhibition curve was
essentially super-imposable over the Barx2-transfected, vector-transfected, and
untransfected PEOl (platinum sensitive) growth inhibition curves.
Figure 6- 20 The Growth Inhibition Curve for Cisplatin Sensitity
Comparing in PEOl and PEOlcDDP
0 1 1.25 1.5 1.75 2.0
Cisplatin (niicroM)
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Growth was expressed as a proportional of the no-cisplatin control on day 12 across
a cisplatin concentration range of 0 to 2p,M. Direct comparison of 6 cell lines is made.
PEOl platinum sensitive parent line and representative vector only derivative (PEOl-
Hygl.6) and the Barx2 transfected clone (PEOl-BXl 1.1) show a similar pattern of
cisplatin sensitivity. PEOlcDDP parent line and vector transfected control
(PE01cDDP-Hyg2.2) show a significantly more resistant growth inhibition curve.
The Barx2 transfected clonal derivative PE01cDDP-BX1.3 shows a growth inhibition
curve identical to PEOl and its derivatives, and significantly different from
PEOlcDDP control lines
These data were further analyzed for IC50 in these cell lines. The IC50 for barx2
transfected PEOlcDDP was decreased from 1.75 uM to 1.25 uM cisplatin, the same
range as for PEO1 platinum sensitive parent.




A different way of presenting the same data is shown in Figure 6-21.In this figure
data are presented for PEOl and PEOlcDDP as the fold sensitivity of Barx2
transfected cells relative to the appropriate untransfected control at each cisplatin
concentration. The fold sensitivity of PEOl to cisplatin following Barx2 transfection
remains essentially unchanged over a 1.0 to 2.0uM concentration range. In contrast,
the fold sensitivity of PEOlcDDP to cisplatin following Barx2 is increased over this
range, with a maximum 5-fold increase at 1.5 (J.M cisplatin.
In conclusion, Barx2 transfection predominantly reversed platinum resistance acquired





Ovarian cancer is a disease that affects approximately 1% of European and American
women during their lifetime, and remains the number one cause of mortality from
gynecological malignancies (Landis SH, et al. 1998). Its high mortality is related to its late
presentation. By the time of diagnosis, more than 70% of these cancers will have
disseminated beyond the ovary (Lynch HT, et al. 1998), thereby compromising the patient's
survival. However, we know relatively little about how it develops at the molecular level,
and much work is still required to provide us with a comprehensive grasp of its molecular
pathophysiology. The prospect of fresh conceptual insights from a functional and molecular
genetic approach leading to novel therapeutic strategies is a powerful motivating factor for
any researcher. The study of tumour suppressor genes (TSG) in malignant neoplasia has
been an interesting one in the field of molecular pathophysiology. The study of TSGs has
mainly followed two general strategies; (1) Identifying the possible location where tumour
suppressor genes may reside in the cancer cell genome and (2) determining TSG function in
tumours (Auersperg N, et al. 1998).
The most popular approach for identifying where tumour suppressor genes may reside in
the cancer cell genome is by examination for loss of heterozygosity (LOH). The basis for
these strategies rests in the mechanism by which these recessively acting genes are
inactivated. According to Knudson's two hit hypotheses, inactivation of a tumour
suppressor gene involves two events. The first hit usually involves a mutation in one of the
alleles of the gene while the second hit, which leads to loss of function of the remaining
normal copy of the gene, may occur by a variety of mechanisms including mutation or
deletion (Knudson AG Jr. 1986; Knudson AG Jr, et al. 1995). This latter mechanism
appears to be most common and from it derives the way to determine where an unknown
TSG may reside or if the locus for a known TSG is altered. Polymorphic markers
distributed at high density throughout the genome can be used to distinguish the paternal
and maternal contribution of DNA in normal tissues and tumour from the same individual.
Loss of DNA from one chromosome in tumour cells is associated with failure of the
polymorphic marker to detect the heterozygosity characteristic of the individual's normal
DNA at that locus, hence LOH. When a series of polymorphic markers that cover sites
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throughout the genome are used on a series of tumours and related constitutive DNA, the
frequency of LOH in a given region of the genome can be determined. It is often stated that
a frequency of LOH of approximately 30 % suggests that this region of the genome may
contain a tumour suppressor gene targeted for inactivation by deletion (Godwin AR, et
al.1994; Schultz DC, et al, 1996). Many regions that contain a high frequency of LOH have
been described in epithelial ovarian cancer, indicating that multiple genes may be
inactivated during the initiation or progression of the disease.
Our work is based on previous studies of the role of chromosome 11 disruption in the
development and progression of malignant neoplasm of the human ovarian surface
epithelium.
To investigate new TSG regions, Dr Hani Gabra and colleagues used PCR based
polymorphic microsatellites to define regions of frequent loss of heterozygosity throughout
chromosome 11 especially at 11 q24 in DNA blood/ tumour pairs from patients with
ovarian cancer. The results showed that LOH at 11 q24 was significantly associated with
advanced stage and adverse actuarial survival. Refinement of the 11 q24 region revealed an
8.5 Mb LOH region between D11S934 and D11S1320 retaining the above survival
association (Gabra H, et al. 1996). In order to analyse further the causality of the LOH
observation, microcell mediated chromosome transfer was used to introduce chromosome
11 into ovarian cancer cell line NIH:OVCAR3. The analysis for microcell hybrid clones
(MHCs) showed that chromosome 11 MHCs remained immortalised and demonstrated
significant in-vitro growth inhibition. But this inhibition was not due to cell cycle block or
apoptosis. MHCs were significantly reduced in their ability to invade matrigel in the
transwell invasion assay. MHCs retaining whole chromosome 11 showed significant
reduction in invasiveness compared with MHCs taking up all chromosome 11 as far as
1 lq22. Further analysis of the inhibition of invasiveness associated with the introduction of
chromosome 1 lq revealed that components of this include specific inhibition of attachment
and spreading to laminin coated plastic, and abrogation of the stimulation of tumour cell
migration in response to a collagen IV or fibronectin mediated haptotactic signal. These
studies suggested that the putative TSG from this region act as a suppressor of ovarian
cancer progression.
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Since then, investigation has focused on the distal 1 lq region, and candidate tumour
suppressor genes within this region were investigated. The Barx2 gene is one such
candidate. (Hjalt T, et al.1999; Krasner A, et al. 2000). The Human Barx2 gene encodes a
254 amino-acid homeodomain transcription factor (Krasner A, et al. 2000) homologous to
the Drosophila Bar class of homeobox-domain containing proteins.
The function of the Barx2 gene is still unclear, but some lines of evidence have revealed the
role of the barx2 .1) It has a developmental transcription profile at the site of epithelio-
mesenchymal transition and similarity to other homeodomain regulators of mesodermal cell
fate (Jones FS, et al. 1997; Gawantka V, et al. 1995). 2) Barx2 plays a bifunctional role in
regulation of specific cell adhesion molecules (CAMs) (Edelman D, et al. 2000). It has been
demonstrated that epithelial tumour cells lose cell-cell and cell-matrix contact in the later
stages of tumorigenesis, in association with down-regulation of cell adhesion molecules
(Takeichi M. 1995). 3) Barx2 is also identified as a regulatory element in the ras/raf
pathway (Krasner A, et al. 2000). Therefore, these findings suggest that the Barx2 gene
may function as a candidate tumour suppressor gene in ovarian cancer.
The objective of my work was to investigate whether or not the Barx2 gene acts as tumour
suppressor gene in ovarian cancer and if so, its mechanisms of inactivation and action.
7.2 Loss of Heterozygosity at Chromosome 11 q between D11S1894 to
D11S1390 Region in Colorectal Cancer
Three independent lines of analysis suggested that a putative tumour suppressor gene was
located at chromosome Ilq22-q24 and could be involved in the tumorigenesis of several
solid tumours of diverse cell types, such as tumours of the breast (Carter SL, et al. 1994;
Tomlinson IP, et al. 1996), stomach (Baffa R, et al. 1996) and so on. The involvement of
this chromosomal region in the tumorigenesis of colorectal cancer is still unclear, with
cytogenetic (Konstantinova LN. 1991; Keldysh PL, et al. 1993) and some molecular studies
(Tomlinson IP and Bodmer WF, et al.1996) indicating losses in this region but with other
molecular studies reporting no significant losses (Koreth J, et al. 1997). Previous LOH data
from our laboratory suggested that disruption of chromosome llq24 frequently occurs in
ovarian cancer and colorectal cancer, and is associated with poor prognosis in epithelial
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ovarian cancer patients (Gabra H, et al; Connolly KC, et al. 1999). It is worth noting that
these studies employed four or fewer loci in this region, an insufficient number to establish
clearly the regions of chromosome 11 q deletion in colorectal carcinogenesis but the two
studies did suggest identical regions.
In order to confirm these results, to narrow this region (4.5Mb) further by using more
polymorphic microsatellite markers, and to identify whether there is relationship between
loss of this region in tumour and the localisation of Barx2 gene, we performed a
comprehensive genetic analysis of chromosome llq24 in 39 blood/tumour pairs with
colorectal cancer using 14 highly polymorphic microsatellite markers across the 4.5 Mb
region in chromosome 11 q24.
This study describes a detailed deletion mapping exercise of the chromosome 1 lq24 region
in colorectal carcinoma. The region of LOH on chromosome llq24 has been refined
further. From 39 cases of colorectal cancer that could be analysed, 28 cases (71.18 %) had
evidence of LOH involving at least one locus in this region. 10 cases (25.6%) had LOH at
all markers, 18 cases (46.2%) had partial LOH and 11 cases (28.2%) showed no evidence
of LOH in this region. These results are lower than but consistent with previous findings
(44/50 cases, 88% of LOH at microsatellite marker between D11S1351 to D11S969)
(Connolly, et al.1999). The highest LOH frequencies were observed at D1 IS 1894
(58.33%), at D11S874 (50.8 %) and at D1 IS 1320 (50 %). Previous microsatellite analyses
of the chromosomal region llq24 -q25 in colorectal cancer utilising only four loci have
demonstrated that there was a higher frequency of LOH in this region. Connolly et al
(1999) reported high frequencies of LOH of 70% at D11S912, 68% at D1 IS 1320 and 39.1
% at D11S969. Our finding of high frequencies of LOH provides further evidence that the
chromosomeal region 1 lq24 is indeed lost during colorectal cancer.
A study by Korth et al. (1997) concluded that distal loss on chromosome llq was not
frequent in colorectal cancer, in contradistinction to a parallel series of breast cancer cases
reported in the same study. In particular, the telomeric marker D11S969 was subject to a
low LOH rate (15%; 3 of 20). This variation in the frequencies of LOH between studies of
the same tumour type and using the same microsatellite marker may be due to the different
cut-off criteria used for the assessment of LOH or due to methodological differences.
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Koreth et al used r>0.5 as cut-off for the r-value and used y32P-end-labeled PCR
autoradiography to detect LOH, whereas r< 0.7 was used as the cut-off for automated laser
fluorescence (ALF)-PCR in this study. Our study, clearly demonstrated a region of frequent
LOH lying just centromeric to D11S969 in colorectal cancer using >0.7 r value cut-off;
however, D11S969 was lost at a much higher rate (41.67%) in this study. It is also
consistent with the previous finding of Connolly (39 %) using the same cut-off criteria
(Connolly, et al.1999). We therefore re-analysed our data using the >0.5 r value cut-off
used by Koreth et al (1997) and found that the LOH rate at D11S969 dropped to 25 %. It is
therefore apparent that wide discrepancies in LOH rate can be generated by differences in
well-established methodologies.
In this colorectal study, we found no associations with clinicopathological factors, although
a trend towards significance was noted between LOH at D11S4131 and differentiation
grade (p=0.0561). These data are consistent with the findings of Keldysh et al (1993) as
well as of Connolly et al (1999). which did not associate LOH on 1 lq with adverse
clinicopathological features. Evidence has been published that the 1 lq23.3-24.2 region may
contain a late-acting suppressor gene that is prognostically important for ovarian cancer
(Gabra H, et al. 1996; Launonen V, et al. 1998). However, this evidence is not unequivocal
because another ovarian cancer study (Davis M, et al. 1996) found a relatively high rate of
LOH in this region in early stage tumours, suggesting that LOH in this region may
represent an early rather than a late event. The findings in our colorectal cancer study
appear to concur with latter view.
The centromeric deletion unit described by Connolly et al was frequently subject to LOH
but was much larger (4.5Mb) (Connolly KC, et al. 1999). Compared with this study (see
Figure 7-1), three shortest region of overlap (SRO) was found to correspond to three
consensus regions of deletion/allele imbalance at D11S912 to D114150, at GAT72A01 to
D11S4131 and at D1 IS 1320 to D11S4085. These three minimal region not only overlapped
completely with others that have been defined previously in colorectal and ovarian cancer
(Gabra H, et al. 1996; Davis M, et al. 1996; Launomen V, et al. 1998; Launomen V, et al.
2000), but also further narrowed this region from 4.5 Mb to approximately less than 200Kb
between D11S912 and D11S4150, 200kb between GATA72A01 and D11S4131 and 2Mb
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D11S1320 and D11S4085. This study has therefore more precisely defined the regions of
chromosome 1 lq likely to contain tumour suppressor genes.
Two papers by launonen et al (1998 and 2000) described regions of LOH on chromosome
1 lq which partially overlap the three minimal region described here. However, Launonen
did not analyse any markers which lie more distally on 1 lq, and therefore the regions of
LOH he describes may extend further distally and fully encompass the three minimal
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Figure 7-1 Consensus deletion pattern for llq24 between the microsatellite marker
D11S1894 and D11S1309fromstudies ofdifferent tumour types. Numbers on left, ordering
of polymorphic microsatellites is from publications shown and the Genome Database.
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Quoted publications in top. Black vertical bars regions of deletion published previously.
Black shadow vertical bars, regions of deletion defined by this study, yellow open boxes,
consensus regions ofdeletion.
This study not only confirmed the previous studies but also has already contributed to the
cloning effort by reducing further the minimum size of the most telomeric region. The
accumulating evidence for frequent LOH in the distal deletion unit in many tumour types
suggests that the proposed tumour-suppressor gene from this region may be fundamental to
the process of neoplasia.
To date, although some genes have been identified in this region such as PIG8 (p53-target
gene)(Gu Z, et al.2000), APLP2 (encoding a human sperm membrane protein) (Leach R, et
al. 1999), KCNJ1 (encoding various isoforms of the human poassium channel) (Bock JH, et
al. 1997), SNC19 (Zhang Y, et al. 1998) and Barx2 gene, they have not yet linked directly
to carcinogenesis.
The Barx2 gene is located at chromosome llq between marker D11S912 to D11S1320.
Our LOH data showed that 10 cases (25.6%) had LOH at all loci, 18 cases (46.2%) had
partial deletion within this region. Combined with previous LOH data (Gabra H, et al.
1996; Davis M, et al. 1996; Launomen V, et al. 1998; Launomen V, et al. 2000) in same
region for ovarian cancer, the data from this study suggest that the Barx2 gene was a
promising putative tumour suppressor gene involved especially in ovarian cancer
progression.
7.3 Alteration of Expression of Barx2 in Ovarian Cancer
The human Barx2 gene, a homeobox gene, has been identified as a transcription factors
(Jones FS, et al.1997). In my analysis by RT-PCR, the Barx2 gene was strongly expressed
in 10 cases of normal ovarian epithelium samples. This is consistent with the previous
study that Barx2 is expressed at the sites of epithelio-mesenchymal interaction during
murine development (Jones FS, et al.1997). The multi-tissue northern blot analysis of adult
human tissue (Clontech) also showed that Barx2 gene was expressed in the normal prostate,
testis and colon, with a band of 1.9-2.2 kb, but very weak expressed in ovary (Sellar GC, et
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al. unpublished data). This paradox is because ovarian surface epithelium is very small
proportion of the whole ovary. The Barx2 gene therefore has normal physiological
functions in ovarian epithelium. Compared with normal ovarian epithelium, the expression
of Barx2 Fl/Rl, F2/R2 and F3/R3 were demonstrated in 52.0%, 60.6% and 68.7% of
ovarian cancer cases respectively. Although there were no statistically significant
association, the expression level of Barx2 in early clinical stage (I - II) seemed higher than
that in late clinical stage (Ill-IV)patients with ovarian cancer. Analysis of relationship
between Barx2 expression level and survival of ovarian cancer patients also showed that the
expression of Barx2 Fl/Rl was significantly associated with survival of ovarian cancer
patients (p = 0.0048). These data suggested that the Barx2 gene could be linked to ovarian
carcinogenesis. The Barx2 gene has been identified as a transcription factor that mediates
ras/raf dependent transcription of the calcitonin gene via a ras/raf responsive transcriptional
element within the calcitonin gene promoter (Krasner A, et al. 2000). Clinically, down-
regulated expression of the calcitonin gene correlates with the poor differentiation of
thyroid carcinoma cells and also with adverse patient survival (Ball, DW. 1996). Therefore,
loss of the Barx2 gene expression may be involved in tumour progression.
The expression of Barx2 F1/R3 was found to be significantly lower for endometrioid (EM)
and clear cell (CC) variants of ovarian cancer comparied with other histological subtypes
(p=0.03). Mean Barx2/actin ratio was 17.5 for endometrioid and clear cell ovarian cancer
but mean Barx2/actin ratio was 46.2 for serous and mixed mesodermal tumour histologic
types. EM/CC histological subtypes are regarded as being derived from a common cell
type, and are associated with endometriosis. Although epithelial ovarian cancer is generally
a chemosensitive disease at presentation, endometrioid ovarian cancer has been shown in a
single large study to be significantly associated with platinum chemotherapy non-response
(Voest EE, et al. 1989). Clear cell carcinoma has also been associated with poor response to
platinum chemotherapy and adverse patient survival. In a series of patients with clear cell
ovarian carcinoma, the response rate to platinum chemotherapy was only 11% compared
with 70% in matched group of serious ovarian cancer (Behbakht K, et al. 1998; Goff BA, et
al. 1996; Recio FO, et al. 1996; Sugiyama T, et al. 2000).
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Northern Blot analysis revealed strong expression of a broad 1.9-2.2Kb Barx2 band in the
ovarian cancer cell lines PEOl, PE014 and OVCAR3, but downregulation/absence in most
other ovarian cancer cell lines. It is interesting that PEOl and PEOl4 represent platinum
sensitive ovarian cancer lines derived from two patients early in the course of their disease
and show abundant Barx2 expression. PE04/PE06 and PE023 are platium resistant cell
lines derived from the same two patients respectively following relapse after cisplatin
chemotherapy. PEOlcDDP was devived from PEOl in-vitro cisplatin exposure.
Comparing the expression of Barx2 gene in PEOl with its derivative cell lines, PEOl
cDDP, PE04 and PE06, have only 57.7%, 14.6% and 9.5% of the Barx2 expression level
of PEOl relative to actin respectively. These finding raised the possibility that Barx2 plays




Figure 7-2A model incorporating cisplatin resistance and expression the Barx2 in the
PEOl ovarian cancer series
7.4 RNA Isoforms of Barx2 Expression in Ovarian Cancer
RT-PCR and Northern blotting suggested that there were two isoforms of Barx2 expression
in the ovarian cancer cell lines, an upper broad band and a narrow lower band. Removal of
the polyA tails from the transcript population by RnaseH digestion resolved this broad band
into three distinct products, suggesting at least three Barx2 isoforms. Sequencing of RT-
PCR products identified two transcript forms: full length, and a minus exon 2 variant. The
two Barx2 transcript isoforms identified by Northern blotting are estimated to differ by
approximately 300bp. As this estimated difference approximates to the size of exon2. It can
be speculated that the lower transcript isoform corresponds to the exon 2 minus variant
identifiably sequencing of PCR-generated transcript. The shorter isform has different
relative abundance in different cell lines, but in general is quite abundant in both northern
blot and RT-PCR analysis. Translation of the variant transcript isoforms resulted in a
frameshift, with the result that a premature termination codon is brought into frame
downstream of the splice junction. Translation of these isoforms created by using the exon-
intron boundaries reported by Krasner et al (Krasner A, et al. 2000) verified these findings.
These proteins would therefore be potentially transcriptionally functionless, but retain the
leucine zipper and could therefore bind to the cyclic AMP response element (CRE)-binding
protein (CREB) family and differently regulate its function without homeodomain DNA
binding activity. The function of these isoforms in ovarian cancer is unknown. Multi-tissue
northern blot analysis of adult human tissue (Clontech) also showed that there were two
isoforms of Barx2 expression in some normal adult human tissue. Therefore, these isforms
are not specific for ovarian cancer
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7.5 Barx2 Is Not Inactivated by Somatic Mutation in Ovarian Cancer
Downregulation/absence of Barx2 gene expression could be caused by alteration of the
structure of the gene. To explore this possibility, Southern blot and Pulsed-Field Gel
Electrophoresis were first used to analyse whether structural alteration of Barx2 had
occurred. Barx2 gene was not rearranged or deleted in ovarian cancer cell lines.
However, tumours may arise through the accumulation of somatic mutation or through the
inheritance of a mutation through the germ line, followed by the acquisition of additional
somatic mutations (Bishop JM. 1991). While alterations in gene expression also contribute
to the malignant phenotype, the sequential mutation of cancer-related genes leading to
outgrowth of a clonal population of cells is an important determinant of whether a cancer
develops (Tashiro H, et al.1992; Vogelstein B and Kinzler KW. 1993; Weinberg RA.
1989). Although some sequence alterations of Barx2 exon2 were identified in few cancer
cell lines, we were unable to demonstrate evidence of somatic inactivating mutations of
Barx2 in ovarian cancer.
7.6 Barx2 Is Not Somatically Methylated in Ovarian Cancer
Numerous studies have confirmed that dysregulation of the DNA methylation machinery is
a feature of many different types of neoplasms, manifest by general genomic
hypomethylation, as well as regional hypermethylation and increased expression of a 5-
methyl transferase (5-MT) encoding gene (Baylin SB, et al. 1991; Kay PH, et al. 1997).
Methylation may induce silencing of tumour suppressor genes such as Rb (Simpson DJ, et
al. 2000) and pl6 (Merlo A, et al. 1995), which are usually hypomethylated. Such genes are
critical in control of the cell cycle and cellular differentiation ( Kay PH, et al. 1997).
Methylation southern blotting and methylation-specific PCR were used to detect whether
there was methylation of the Barx2 gene in ovarian cancer. Although southern blot analysis
showed that Barx2 5'CpG island was methylated in some cancer cell line and evidence of
progressive methylation was observed in cell lines downregulated for Barx2, methylation-
specific PCR, a novel and highly sensitive technology for detection of genes methylation
(Herman JG, et al. 1996), did not show any evidence for methylation in 80 epithelial
ovarian normal/tumour pairs and 38 matched ovarian cancer biopsies prior to and following
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relapse after cisplatin chemotherapy as well as cancer cell lines, expect for Hela cell line.
Therefore, the Barx2 gene is not methylated in ovarian cancer. The Southern Blot result
was probably caused by an artefact of inadequate digestion with restriction enzymes in
DNA.
Since we were unable to detect evidence of somatic methylation in the CpG island or
inactivating mutations in the coding region of the Barx2 gene in ovarian cancer, we
therefore reasoned that the existence of promoter mutations or alterations in trans acting
factors are likely to be responsible for the downregulation/absence of Barx2 expression that
we observed. Further investigation will be necessary to confirm this hypothesis. The use of
reporter gene constructs would make it possible to elucidate which of these mechanisms are
responsible. Reporter gene constructs containing the luciferase gene and varying lengths of
the 5' Barx2 flanking sequence could be constructed. Transfection of a construct containing
the full-length 5' sequence would be performed initially into a cell line that does not
express Barx2. Demonstration of the presence or absence of luminescence in a cell that
does not express Barx2 would identify whether or not the necessary trans acting factors
were present to stimulate gene transcription. The absence of luminescence would suggest
the presence of dysregulated trans acting factors. Presence of luminescence would suggest
that there could be a mutation within the promoter and sequencing would identify this.
Transfection of constructs containing shorter lengths of 5' sequence would allow
identification of the minimal critical region that is required for gene transcription (see












Figure 7-3 A model for reporter gene constructs to elucidate promoter mutation or
alteration in trans acting factors.
Green box = 5'Barx2 flanking sequence. Luc = luciferase gene.
Green ellipse = transactivation factor.
Blue ellipse = dysregulated or mutated transactivationfactor
Reporter gene constructs expressing the luciferase gene under the control of the Barx2
promoter, a) Transactivating factorsmay be required to bind to the Barx2 promoter to
cause transcription, b) Mutations within the Barx2 promoter may disrupt this binding and
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result in no transcription, c) Similarly, dysregulation, or mutation, of the transactivating
factors may also lead to no transcription.
7.7 The Barx2 Gene Acts as Suppressor of Ovarian Cell Line Growth in
vitro
In order to understand the role of the Barx2 gene in ovarian cancer, gene transfection and
functional analysis were performed in this study.
The OVCAR3 cell line was first chosen for transfection with Barx2 gene because condition
of transfection for this cell line was well-established in our lab. OAW42 and A2780 are
non-expressors of Barx2. They were also suitable recipients for transfecting with Barx2.
Also, data above has shown that falling expression of Barx2 was associated with disease
progression and cisplatin-resistance in PEOl series. Therefore, the PEOl series were also
selected for to transfection with Barx2 construct. In molecular analysis of the clonal lines
derived from parent cell lines transfected with the Barx2 gene, the expression of Barx2 full-
length sequence in Barx2 transfected clonal derivatives OAW42BX 1.2, 1.3 and 1.7 was
determined by Nothern blot and RT-PCR. Because Barx2 full length sequence is expressed
in PEOl and PEOl cDDP, It is difficult to distinguish the difference between expression of
Barx2 transfected insert and expression of Barx2 originally in cell lines. However, the
Barx2 Fl/Rl expression was negative in PEOl cDDP. Barx2 Fl/Rl RT-PCR was used to
detect whether Barx2 Fl/Rl is expressed in Barx2 transfected clonal derivatives PEOl
cDDPBX series.
Growth assays for 4 Barx2 transfected clonal cell lines compared with each of the parent
cell lines and Hygromycin transfected control cjlonal cell lines showed growth inhibition in-
vitro for these Barx2 transfected clonal cell lines. This inhibition was independent of the
cell lines' endogenous Barx2 expression level. For example, in OVCAR3 series, BX 3.2
was found to be a Barx2 transfection revertant that had lost the Barx2 insert and it was
compared with Hygromycin transfected series derived from control vector transfected
OVCAR3, there was no significant difference in cell growth. Transfection of OVCAR3
with Barx2 also yielded several lines with variable expression of Barx2 BX4.2 and BX3.6,
the highest expressed clones, were strongly suppressed for cell growth compared with
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controls (p<0.01). BX3.4, a clone with lower Barx2 expression, was also suppressed for
cell growth compared with controls, but much less than the highest Barx2 expressed clones.
This suggested that the extent of cell growth-inhibition was related to the exogenous Barx2
expression level in ovarian cancer cell line. Further investigation of cell cycle distribution
and apoptosis by FACS- analysis for Barx2 transfected clonal derivatives OAW42BX
series revealed that transfection of Barx2 into OAW42 appeared to cause clustering in S-
phase. There was no evidence of either increased cell death or apoptosis in this assay to
explain the observed phenotypes, suggesting that although the Barx2 gene acts as
suppressor of ovarian cell line growth, these effects were not obviously due to non-specific
cytotoxicity.
7.8 Barx2 inhibits invasion, migration, adhesion of ovarian cancer
Cell lines invitro
In this study, ovarian cancer cell lines OVCAR3 and OAW42 transfected with vector
controls and Barx2 construct were compared in the matrigel invasion assay. Introduction of
Barx2 into OVCAR3 and OAW42 produced a highly significant (p<0.001) and profound
inhibition of matrigel invasion and the extent of matrigel invasion-inhibition depends on
exogenous Barx2 expression level in these clonal cell lines.
Two Barx2-transfected clones were directly compared with two vector-only controls for
cellular migration and cellular adhesion functional assays. Introduction and expression of
Barx2 in OAW42 was significantly (pcO.OOl) associated with inhibition of transwell
cellular migration to a collagen IV haptotactic signal. Again, the higher expressing Barx2
clone had greater inhibition of cellular migration. Introduction of Barx2 in OAW42 was
also significantly associated with inhibition of attachment to collagen IV coated plastic. No
such effect was observed on plastic alone. Furthermore, the higher expressing Barx2 clone
had greater inhibition of adhesion to collagen IV (40 % of control, p<0.001). These data
suggest that the function of the Barx2 may be an inhibitor of invasion, migration, adhesion
and, by analogy peritoneal dissemination of ovarian cancer. These findings are consistent
with recent thinking regarding molecular mechanisms of ovarian cancer progression.
Firstly, LOH studies have demonstrated that chromosome llq24 deletion region within
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which Barx2 is located is associated with disease progression in ovarian cancer. The
frequency of LOH in late stages is higher than it in early stages of ovarian cancer,
combining with locoregional dissemination and disease progression (Gabra H, et al. 1996;
Launonen V, et al. 2000). Secondly, previous studies by Dr Hani Gabra in our lab
demonstrated that introducing chromosome 11 containing the q24 region into an ovarian
cancer cell line (OVCAR3) reduced the ability of cancer cell line in to invade matrigel,
cellular migration and attachment compared with a micocell hybrid containing chromosome
11 without q22-ter. Thirdly, contiguous YACs overlapping most of the chromosome 1 lq25
deleted region were used for transfection into murine fibrosarcoma cell and caused
significant suppression of tumorigenicity compared to the control (Koreth J, et al. 1999).
The Barx2 gene has been identified as regulator of specific cell adhesion molecules
(CAMs) (Edelman D, et al. 2000). In sheep, Barx2 is expressed in the epithelial component
of the developing follicle and in the outer root sheath of the adult follicle in a pattern that is
similar to E-cadherin. This suggests that Barx2 may have a general function in controlling
adhesive processes in keratinising epithelia (Sander G, et al.2000). Alteration of normal cell
to cell adhesion is an important event in the development of invasive and metastatic
disease. The role of CAMs in epithelial-mesenchymal transition is well documented in
cancer progression. They have demonstrated their utility as prognostic markers in a variety
of neoplasms. Dysfunction of cadherins has a major impact in the progression of epithelial
tumours (Shiozaki H, et al. 1991). Loss or abnormal expression of cadherins in tumours can
lead to tumour invasion and disease progression, as demonstrated for E-cadherin expression
in prostate (Umbas R, et al. 1994), stomach (Shimoyama Y, et al. 1991), bladder (Bringuier
PP, et al.1993), breast (Rasbridge SA, et al. 1993), and cervical cancer (Vessey CJ, et al.
1995). Similar results have been reported for P-cadherin, for example in breast cancer
(Rasbridge SA, et al. 1993), gingival carcinomas (Sakaki T, et al. 1994), and gastric
neoplasia (Shimoyama Y, et al. 1991). Furthermore, treatment of madin darby canine
kidney cells with an antibody against the extracellular domain of E-cadherin increases the
invasiveness of these cells in-vitro (Behrens J, et al. 1989).
It was recently demonstrated that Barx2 interacts with two leucine zipper containing
proteins of the CREB family of transcripition factors, CREB1 and ATF2 (Edelman SH, et
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al. 2000). CREB and its associated proteins have been proposed to act as survival factors
for human melanoma cells. Transfection of a dominant negative CREB (KCREB) into
melanoma cells inhibits the invasiveness and tumorigenic and metastatic potential of these
cells (Jean D, et al.1998). This is a similar phenotype to that observed with transfection of
Barx2 into ovarian cancer cell lines.
More recently, a study by Dr Grant C. Sellar in our lab demonstrated that cadherin-6 (K-
cadherin, CDH6) is a likely target of the human Barx2 gene. Cadherin-6 may function to
maintain epithelial-epithelial cell interactions (Stewart DB, et al. 2000). In formation of the
adherens junction complex, E-cadherin interacts with and stabilises (3-catenin to establish
cell adhesion, a-catenin also binds to (3-catenin, connecting cell membrane to the actin
cyto-skeleton. However E-cadherin by sequestering (3-catenin from its intracellular free
pool antagonises the Wnt signalling pathway (Orsulic S, et al. 1999). In the madin derby
canine kidney (MDCK) system, where E-cadherin is identified as the major cadherin,
cadherin-6 was identified by microsequencing as a 130kd complex associating with (3- and
a-catenin. This complex accumulated with cell-cell contact. Cadherin-6 was post-
translationally downregulated in the presence of activated mutant (3-catenin that does not
regulate cadherin levels in MDCK cells. This was achieved by a non-ubiquitinating
proteolytic degradation pathway. Cadherin-6 downregulated cells were flatter, formed less
compacted colonies, and were more migratory (Stewart DB, et al. 2000), which is
consistent with the phenotypes that we have observed in this study. Although the
involvement of cadherin-6 in the development or progression of ovarian cancer has not
previously been documented, absent expression of cadherin-6 was demonstrated in renal
cancers of different histological type and tumour grade with downregulation of expression
in a significant subset of renal cell carcinomas consistent with an involvement of this cell
adhesion molecule in the progression of renal cell cancer. Importantly, absent expression of
CDH6 in renal cancer was associated with poor prognosis (Paul R, et al. 1997; Shimazui T,
et al. 1998).
From these data Barx2 appears to act as inhibitor of invasion and dissemination of ovarian
cancer, and although no structural alteration of Barx2 was observed, we can hypothesise
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that the Barx2 may mediate its role as a suppressor via transcriptional regulation of specific
target cell adhesion molecules such as cadherin-6 (see Figure 7-2).




Figure 7-2;A putative model incorporating invasion and dissemination of cancer cells and
downregulation of the Barx2 gene in ovarian cancer cell lines. Downregulation of Barx2
may be targeted toCDH6and would act as a regulator.
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Disruption of CDH6 may directly affect invasion and dissemination of cancer cell. CDH6
may be bound with (3-and a-catenin. This complex accumulates with cell-cell contact, and
would indirectly act with E-cadherin as a regulator (Stewart DB, et 2000). E-cadherin
not only plays a direct role in suppressing invasion and dissemination of cancer cells but
also plays a role as a modifier of the Wnt signalling pathway. Wnt signalling is involved in
a large number of developmental processes, including tumorigenesis. a) activation of the
Wnt receptor prevents (3-cateninbeing targeted for degradation by glycogen synthase
kinase 3 (GSK-3) and the adenomatous polyposis coli (APC) protein, b) /3-catenin can then
form complexes with the lymphoid enhancer factor (LEF) and T-cell factor (TCF) families
of transcription factors, c) initiate the transcription of genes involved in cell proliferation,
and d)because E-cadherin sequesters /3-catenin into the adhesion complex, dowregulation
of E-cadherin is likely to result in increased levels offree /3-catenin and transcription
the targets of Wnt signalling (Guilford P. 1999).
7.9 The Barx2 Transfection Predominantly Reversed Platinum
Resistance Acquired in PEOl cDDP
As was demonstrated earlier (Figure 4-18 and Figure 4-15), downregulation of Barx2
expression is associated with platinum resistance in ovarian cancer cell lines and
endometrioid/clear cell primary ovarian cancers that have been shown to have a poor
response rate to platinum chemotherapy. These findings raised the possibility that Barx2
plays a role in the development of resistance to platium chemotherapy. In order to confirm
further this possibility, two closely related cell lines were transfected with the pBABE
Barx2 expression construct. The growth inhibition and clonogenicity assays were
performed to study the effect of Barx2 expression on cisplatin resistance. These two closely
related cell lines are PEOl, platinum sensitive and strongly Barx2 expressing cell line, and
PEOlcDDP, a cell line derived from PEOl by in-vitro cisplatin exposure with 57.7%
expression level of Barx2 compared with PEOl. The sensitivity Barx2-transfected, vector-
transfected and non-transfected PEOl cDDP was directly compared using varying
concentrations of cisplatin in growth inhibition assays. Transfection of Barx2 in
PEOlcDDP resulted in highly significant increase (p<0.001) in growth inhibition at 1.75
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pM and 2.0 pM cisplatin compared with vector control and untransfected PEOlcDDP.
This growth inhibition curve was essentially super-imposable over the Barx2-transfected,
vector-transfected, and non-transfected PEOlgrowth inhibition curves. IC50 for Barx2-
transfected PEOlcDDP was reduced from 1.75 pM to 1-1.25 pM (the range for PEOl
platinum sensitive parent). No significant difference was observed between the intrinsically
more platinum sensitive PEOl cell line and its Barx2- or vector-transfected derivatives (see
Figure 7-4). We conclude therefore, that in this model system, Barx2 transfection
predominantly reversed platinum resistance acquired in PEOl cDDP without enhancing the
intrinsic platinum sensitivity of PEOl in this invitro model.
Cisplatin (microM)
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Figure 7.4The Growth Inhibition Curve for Cisplatin Sensitive Testing in PE01 and
PEOlcDDP
Normalised growth inhibition curve on day 12 across cisplatin concentration range.
Direct comparison of 6 cell lines derivative is made. PE01 platinum sensitive parent line
and representative vector only derivative (PEOl-Hygl.6) and Barx2 transfected (PE01-
BX11.1) clones show a similarpattern ofcisplatin sensitivity. PEOlcDDP parent line and
vector transfected control (PE01cDDP-Hyg2.2)show a significantly more resistant
growth inhibition curve. The Barx2 transfected clonal derivative PE01cDDP-BX1.3
shows a growth inhibition curve identical to PE01 and its derivatives, and significantly
differentfrom PEOlcDDP control lines.
To further explore the mechanism of platinum resistance reversal, clonogenic assays were
performed by Dr Karen P. Watt in our lab to determine if the observed growth inhibition
was due to loss of clonogenic cells (i.e. cell death) or merely slower growth rates. These
assays demonstrated reduced clonogenic survival of Barx2 transfected cells compared to
controls on exposure to cisplatin and confirmed further that the Barx2 gene plays a role in
determining sensitivity to cisplatin (Watt KP, et al. unpublished data).
Although the mechanisms by which the Barx2 gene exerts these effects are at present
unclear, we can speculate as to the mechanism by which Barx2 may mediate this
sensitivity to cyotoxic agents.
Multiple mechanisms have been proposed for cellular resistance to cisplatin;
a) Increased inactivation by detoxification enzymes such as glutathione-S-transferases
(GST), or direct binding to nonprotein thiols such as glutatione (GSH). A wide variety of
detoxification pathways exist that enable a cell to inactivate cytotoxic drugs. The
mechanisms that have received the most attention in mediating drug resistance in ovarian
cancer include increased levels of GSH, GSTs transferases, and metallothioneins.
Spontaneous conjugation of GSH with cisplatin has been shown in vitro (IshikawaT, et al.
1993) and increased levels of GSH have been found to be associated with resistance to
platinum (Britten RA, et al.1991; Godwin A, et al. 1992; Hosking LK, et al.1990). The
GSTs, a multigene family which catalyses the conjugation of GSH with electrophilic drug,
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have been implicated in resistance to alkylating agents , anthracyclines, and platinum
(Meijer C, et al. 1990; Black SM, et al. 1990).
b) Decreased expression or alteration of a gene or its product may enable a cell to
escape the cytotoxic effect of certain chemotherapy. Decreased expression or mutation of
the topoisomerase I and topoisomerase II genes has been implicated in resistance to
platinum in derived drug resistant models in vitro (Eng WK, et al. 1990; Wang LF, et al.
1997; Hsing Y, et al. 1996).
c) Increased DNA repair activity. Tumour cells may be able to develop DNA repair
mechanisms that are more efficient than normal, counteracting the genotoxic effects of
cytotoxic chemotherapy, and hence contributing to resistance to DNA damaging drugs.
Increased repair of platinum-DNA adducts have been shown to be associated with cisplatin
resistance in human ovarian cancer cell lines (Parker R, et al. 1991), and evidence for
increased repair of cisplatin interstrand crosslinks in specific genes and nongene regions in
cisplatin-resistant cells also have been demonstrated (Johnson S, et al. 1994).
The role of either cell adhesion molecules or transcription factors involved in this process
of platinum-resistance is poorly defined. It has been shown, however, that small cell lung
cancer cell lines can be protected from chemotherapy-induced apoptosis by interaction
with the extra-cellular matrix (ECM) and its components (Fridman R, et al. 1990).
Recently, it has been demonstrated that adhesion to extracellular matrix protects cancer cell
line from chemotherapy-induced apoptosis by (31 integrin-mediated adhesive process
(Sethi T, et al. 1999). In a similar vein, maintenance of cadherin-6 may be associated not
only with the maintenance of normal tissue integrity but may also play a role in the
sensitivity to cytotoxic agents. It has been recently demonstrated that the expression of E-
cadherin reduced bcl2 expression and increased sensitivity to etoposide induced apoptosis
(Sasaki CY, et al.2000). In this study, we not only found that Barx2 transfection into
ovarian cancer cells resulted in suppressed adhesion to collagen IV but also demonstrated
that cadherin-6 was a likely target of the Barx2 gene. Therefore, the Barx2 may mediate
increased sensitivity to cisplatin through inhibition of adhesion to component of ECM,
perhaps by regulation of cadherin-6. In contrast, we did not observe Barx2-mediated
enhanced apoptosis in response to cisplatin. This difference may reflect contextual
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differences between our system and that reported by other investigator (Xie S, et al. 1997)
although, in a similar analysis of CREB2 knockout in melanoma cells, there was a
suggestion that CREB2 abrogation sensitised the cells to chemotherapy (Ronai Z, et al.
1998).
As a general principle, it may be that interaction of cancer cells with the extra-cellular
matrix or with other cells induces resistance to cytotoxic agents (Kerbel RS, et al. 1994; St
Croix B and Kerbel RS. 1997; Green SK, et al. 1999). For ovarian cancer, there is also
variation in intrinsic primary platinum sensitivity that not only reflects inter-individual
pharmacogentic and pharmacodynamic differences, but also histology specific differences.
It may be that, additionally, Barx2 mediates cisplatin sensitivity via regulation of cell
adhesion molecules. Furthermore, the finding of Barx2 downregulation after platium
therapy raises an interesting hypothesis that the embryotoxic effects of cisplatin (Kopf-
Maier P, et al.1985) might be specifically mediated by disruption of homeobox gene
expression. Alterations in the expression of specific HOX genes have been reported in
human embryonal carcinoma cells following exposure to the anti-epileptic drug valproate,
and this mechanism may underlie the teratogenic effects of the anti-epileptic drug
valproate(Faiella A, et al. 2000).
7.10 In summary
LOH analysis presented within this thesis has confirmed the previous studies of LOH at
chromosome 1 lq between D1 IS 1894 and D1 IS 1309 in colorectal and ovarian cancer and
also has reduced further the minimum size of telomeric region from 4.5 Mb to 200kb and
2Mb. Three distinct LOH regions were detected, between D11S912 and D11S4150,
GAT72A01 and D11S4131, and D11S1320 and D11S4085, suggesting possible sites for
tumour suppressor genes. Therefore, it provides complementary evidence for the ongoing
effort to identify the genes involved in these minimal regions, which include some known
genes although they do not represent logical candidate TSG based on their known
functions.
The Barx2 gene, a homeobox transcription factors located at chromosome 1 lq25 between
the marker D11S912 and D11S1320, was investigated in this study. We present evidence
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from in vitro expression studies that, following transfection, human Barx2 inhibits matrigel
invasion in the ovarian cancer cell lines OAW42 and OVCAR3. OAW42, a Barx2 non-
expressing cell line, following transfection, was also inhibited for migration in response to
a collagen IV signal and adhesion to collagen IV. In two sequential cell line series derived
from patients with ovarian cancer pre- and post-platinum chemotherapy, Barx2 was
downregulated in ovarian cancer cells collected after relapse. Transfection of the Barx2
gene into a platinum resistant cell line, PEOl cDDP derived from PEOl by in-vitro
cisplatin exposure and downregulated expression of Barx2, showed that Barx2 reversed
cisplatin resistance. We also show that Barx2 expression levels are lower in clear
cell/endometrioid ovarian adenocarcinoma histological variants that are less likely to
respond to cisplatin. Taken together, our data suggested that the Barx2 gene is a candidate
suppressor of tumour progression, a modulator of cisplatin resistance in ovarian cancer.
Furthermore, this represents the first report of Barx2 gene expression associated with
modulation of cytotoxic drug sensitivity.
Further investigation of Barx2 is necessary for the understanding a mechanism as TSG.
The use of reporter gene constructs would make it possible to elucidate whether
downregulation/absence of Barx2 expression could be caused by the existence of promoter
mutations or alterations in trans acting factors. In addition, although Barx2 has been
involved in interacting with CAMs such as CDH6, which have been demonstrated to have
associated with invasion, dissemination and drug resistance of cancer cells, the relationship
between both is unclear. So further study of the relationship between Barx2 and CAMs
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